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Abstract 
Biologically active small molecules are typically discovered in design-
synthesis-purify-test cycles. These workflows are underpinned by a 
remarkably narrow toolkit of robust and reliable chemical transformations and 
place equal resources on all molecules regardless of their biological function. 
Activity-directed synthesis harnesses the potential of chemical reactions that 
can form more than one possible product and allows resources to be focussed 
on small molecules with biological activity. The discovery of small molecules 
through activity-directed synthesis emerge in parallel to their associated 
synthetic routes. A feedback mechanism can serve to optimise the range of 
bioactive products, analogous to the emergence of natural products through 
the evolution of biosynthetic pathways found in nature.  
The implementation of fragments as substrates in activity-directed synthesis 
has the potential to enable their optimisation into lead-like compounds without 
the target molecule being predefined, contrasting starkly to typical structure-
guided fragment-to-lead studies. A range of C-H functionalisation chemistry 
was configured in microscale parallel reaction array format, for its 
implementation as a fragment elaboration strategy in activity-directed 
synthesis. This chemistry, along with the previously established metal-
catalysed carbenoid chemistry, was assessed for its potential to elaborate 
Hsp90 fragments. To ensure a streamlined workflow for activity-directed 
synthesis a series of protocols, for scavenging of metal catalysts and 
electrophiles and removal of fragment protecting groups, was established for 
use in parallel reaction array format. 
To enable the elaboration of Hsp90 fragments with the chosen chemistries in 
activity-directed synthesis, a set of fragments designed for biological activity 
against Hsp90 was prepared. The fragments were screened in the established 
high-throughput assay and led to the discovery of analogues of Hsp90 
fragments with previously unreported activity. The use of the high-throughput 
assay and LC-MS enabled the biological activity and success rate of the crude 
reaction mixtures from the arrays to be rapidly assessed. The study 
highlighted the poor functional group tolerance of modern chemical 
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methodologies and the need for robust and reliable chemical transformations 
in medicinal chemistry workflows.  
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Chapter 1. 
Chemical Approaches to Enable the Exploration of Chemical 
Space 
Biologically active small molecules are of immense value in medicinal 
chemistry and chemical biology.1,2 They rank highly in the top FDA approved 
prescription drugs3 and can enable fundamental biomedical research.4 
However, the discovery of bioactive small molecules is extremely challenging. 
Bioactive small molecules are typically discovered in design-synthesis-purify-
test workflows, which are underpinned by a narrow toolkit of chemical 
transformations. This has led to a lack of productivity in the pharmaceutical 
industry,5 encouraging the development and uptake of new molecular 
discovery practices.  
Herein, an overview of current and emerging approaches for molecular 
discovery is given, followed by the recent revolution in automated high-
throughput microscale experimentation for increasing productivity within the 
pharmaceutical industry. Function-driven approaches, which have the 
potential to disrupt practices within current discovery workflows, are 
discussed, followed by an outline of the proposed project – Activity-Directed 
Fragment-Based Ligand Discovery.  
1.1   Bioactive Small Molecule Discovery 
1.1.1  The Pharmaceutical Industry 
The ability to treat disease is largely driven by biologically active small 
molecules, with nine of the top ten prescribed drugs in the US in 2014 being 
small molecules.3 However, the discovery of bioactive small molecules 
remains an enduring challenge in both medicinal chemistry and chemical 
biology. The  discovery process, and associated costs, have come under 
greater scrutiny in recent years5 and despite increased investment, the rate of 
drug discovery has remained roughly constant for the last 60 years.6 
Estimates for bringing a new molecular entity (NME) to market, when 
accounting for costs incurred in failed drug campaigns, lie at ca. $2 billion.5 
This enormous cost can be attributed to two key areas of the drug discovery 
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pipeline. Firstly, the pre-clinal (lead discovery) phase accounts for a third 
(32%) of all associated costs in drug discovery, as a large number of 
programmes fail to lead to marketed drugs. Secondly, attrition rates in clinical 
trials are extremely high, with rates of attrition in phases II and III being 
estimated at 66% and 30% respectively.5 As a result, marketed drugs have to 
carry the costs of failed drug campaigns to recoup the huge investments in 
research and development. These enormous costs and high attrition rates are 
evidence that more high-quality, cost-effective candidates, that are able to 
evade attrition in clinical trials, are needed. Indeed, increasing productivity has 
been identified as the pharmaceutical industry’s grand challenge.5 
 
1.1.2  Exploration of Biologically Relevant Chemical Space 
The discovery of high-quality chemical probes is paramount for 
understanding the fundamental biology of a protein, however, the historical 
exploration of protein biology has been highly uneven.4 To enable the 
underpinning biology of new and challenging targets, e.g. protein-protein 
interactions, to be understood, new classes of small molecules will likely be 
required.7 Chemical space is the total number of possible compounds that 
confirm to a given set of conditions (e.g. <500 Da and number of heavy 
atoms). Chemical space is multidimensional and is defined by multiple 
descriptors such as charge, surface area and number of hydrogen bond 
donor/acceptors, not simply the three dimensional space that the compound 
fills. The ability to explore biologically relevant chemical space (often 
described by Lipinksi’s ‘Rule of 5’8) in search of novel bioactive small 
molecules is arguably the medicinal chemists greatest challenge. Chemical 
space is vast and based on extrapolation from an enumerated library of 
molecules with up to 17 heavy atoms (GDB17), there are 1033 possible 
molecules with up to 36 heavy atoms.9 The historical exploration of chemical 
space by chemists has been highly uneven and unsystematic, highlighted by 
the fact that half of the small molecules in the CAS registry are based on just 
0.25% of the known molecular frameworks.10 This has resulted in  a lack of 
scaffold diversity in medicinal chemistry space11 and drugs.12 This 
unsystematic approach to chemical space exploration can be attributed to the 
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workflows, and their underpinning chemistries, employed during drug 
discovery. 
Early-stage drug discovery is initiated by a variety of strategies. A review 
of clinical candidates published in the Journal for Medicinal Chemistry (in 2016 
and 2017)13 concluded the most common lead generation strategies, amongst 
others, were; known starting points derived from previous campaigns (44%), 
high-throughput screening (HTS) of compound libraries (29%) and structure-
based drug design (14%). HTS of large compounds libraries is routine in drug 
discovery and generates series of hit compounds against a specific biological 
target.14 Hit compounds provide starting points for drug discovery and the 
development of detailed structure-activity relationships (SAR) can facilitate 
lead discovery and optimisation. The potency, selectivity and physiochemical 
properties of the compounds are improved through iterative design-synthesis-
purification-test cycles (Figure 1.1).15 This empirical approach of design, 
synthesis and testing usually all takes place in isolation from assessment of 
function, meaning that equal resources and time are spent on all molecules 
regardless of biological function.16,17 
 
 
Figure 1.1 Overview of current workflows in bioactive small molecule discovery 
 
Medicinal chemists have relied on a remarkably narrow toolkit of robust 
and reliable chemical transformations in drug discovery workflows,18–22 which 
has contributed to the lack of structural diversity and uneven exploration of 
chemical space. Medicinal chemists reliance on a limited suite of chemical 
reactions, such as amide formations, Suzuki-Miyaura and SNAr reactions, has 
resulted in densely populated areas of chemical space with structurally similar 
compounds.20 These reaction types typically contribute to the increased 
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exploration of more lipophilic and flat (sp2-rich) compounds,23,24 which typically 
have higher attrition rates compared with more sp3-rich compounds.25 For 
compounds to have desirable molecular properties for successful drug 
discovery,8,26 libraries need to be prepared from highly functionalised and 
polar substrates.26,27 Given that such substrates systematically fail synthesis 
and can prove challenging for purification, compound libraries can suffer from 
‘logP drift’, resulting in compounds moving away from their intended molecular 
properties.27 The pharmaceutical industry has highlighted the need to explore 
a wider range of reaction classes,18,28 for example, photoredox catalysis to 
enable C(sp3)-H functionalisation29,30 for fragment optimisation studies 31 and 
indeed, the range of reactions published in US patents over the last 40 years 
has gradually been increasing.24  
To address some of the challenges of chemical space exploration, there 
has been an increased focus on strategies that enable the efficient 
development of more diverse compound libraries, containing scaffolds that 
have the potential to explore previously untouched areas of chemical space. 
More structurally diverse compound libraries are believed to increase the odds 
of addressing a broad range of biological targets. Diversity-Oriented Synthesis 
(DOS) is the divergent construction of distinctive scaffolds using minimal 
synthetic steps,32 which has been applied in the creation of fragment,33 small 
molecule,34 peptide35 and macrocylic36 libraries (Figure 1.2). An analogous 
approach, Lead-Oriented Synthesis (LOS), relies on a similar divergent 
approach for compound library preparation, but places greater emphasis on 
the molecular properties of the compounds,37 by focussing attention on 
compounds which lie within lead-like chemical space (Figure 1.2). Lead 
compounds can act as stronger starting points in drug-discovery, as ligand 
optimisation ensures final compound libraries maintain their desired molecular 
properties. While DOS/LOS libraries can enable underexplored areas of 
chemical space to be studied, there are no guarantees library compounds will 
lead to the identification of biological activity during the screening phase.  
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Figure 1.2 Overview of the synthetic strategy utilised in Diversity- and Lead-Oriented 
Synthesis. Colours represent pair-wise cyclisation strategies to generate diverse molecular 
scaffolds.38 
 
Alternative high-throughput technologies have emerged as potential 
sources for novel compound collections, such as Dynamic Combinatorial 
Chemistry (DCC), which is the preparation of compound libraries synthesised 
from building blocks based on their affinity for a protein,39 and DNA-encoded 
libraries (DEL) which enables the deeper sampling of chemical space by four 
or five times compared to traditional high-throughput screening methods 
(Figure 1.3).40 However, both approaches suffer from a limited range of 
chemistries applicable to their respective technologies, most notably DCC, 
which relies on reversible chemistry that must be suitable for protein stability, 
limiting the potential diversity of products possible. While these strategies can 
help address the lack of scaffold diversity in screening libraries (typical library 
size 106), they fail to address the issue of how to most efficiently sample 
biologically relevant chemical space (1033 compounds with 36 heavy atoms). 
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Figure 1.3 Overview of the preparation of DNA-Encoded Libraries. BB – Building Blocks.  
 
1.1.3  Fragment-Based Drug Discovery 
Fragment-based drug discovery (FBDD) has become a widely adopted 
strategy in the pharmaceutical industry (5% of leads come from fragment 
screens),32,41,42 as a means of efficiently sampling biologically relevant 
chemical space. This is because the size of chemical space increases 
exponentially with molecular size, and so there are only ~107 possible 
fragment-sized compounds.41,43 There have been several metrics proposed 
for capturing fragment space, for example, Astex restrict fragment libraries to 
compounds with molecular weight 140-230 g mol-1, 10-16 non-hydrogen 
atoms and clogP: 0.0 to 2.0.44 Fragments typically have lower complexity, 
compared to traditional screening libraries, and are more likely to form 
favourable interactions with a biological target.45 FBDD typically undergoes 
(1) fragment library design, (2) screening of the fragment library and (3) 
fragment elaboration and optimisation.46 
Fragments tend to have lower affinities (0.1 – 10 mM) towards biological 
targets, compared to traditional screening compounds, but it is believed the 
interactions between the fragment and the target tend to be of higher quality 
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i.e. have high ligand efficiency (see below).47 Fragment binding reveals 
protein hot-spots which drive high affinity ligand binding.48 However, detecting 
weaker fragment-protein interactions can be challenging and so biophysical 
screening techniques such as X-ray crystallography, NMR, ITC and SPR are 
routinely used in fragment screens, which detect binding rather than 
inhibition.46,48 It is the specificity of the binding interactions and the potential 
to build or grow off the hit that needs to be considered when analysing a 
fragment hit. 
Once a fragment hit has been identified, validated and binding mode 
established, the fragment undergoes cycles of elaboration to develop the hit 
into a lead.49 Fragment linking involves connecting multiple fragments 
together that bind at adjacent sites in the target (Figure 1.4).46 When a 
fragment’s binding mode has been identified, it has revealed its preferred 
orientation to the target. Maintaining each fragments binding mode and 
ensuring the linker itself makes favourable interactions within the binding site 
can be extremely challenging.46 Fragment growing is seen as a more tractable 
approach in FBDD which involves growing a fragment synthetically along one 
or many vectors to establish new interactions with the target (Figure 1.4). 
Structural information is often key for developing a successful fragment.46 
 
 
Figure 1.4 Overview of fragment elaboration. a) Fragment linking of two fragments hits 
bound in adjacent sites of protein binding pocket. b) Fragment growth by synthetically 
elaborating along one (or many) vector(s) of the fragment into adjacent binding sites. 46,49 
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At each stage of the design, synthesis, testing and evaluation in the 
fragment growth cycle, ligand efficiency (LE) can be used to assess the 
success of the newly evolved fragment.48,50 Ligand efficiency is defined as the 
free energy of binding of the ligand, divided by the number of heavy atoms in 
the ligand (or average binding per heavy atom), which can be used to assess 
whether the additional molecular mass has contributed significantly to 
fragment-protein binding.50 Ultimately the choice of fragments to pursue will 
be selected based on the potency, ligand efficiency, synthetic tractability and 
more general medicinal chemistry considerations.   
The value of FBDD has been realised with two drugs discovered in 
fragment programmes now marketed, Vemurafenib51 and Venetoclax52, as 
well as numerous clinical candidates (Figure 1.5)41,42. However, there are still 
some challenges that must be overcome if FBDD is to fulfil its promised 
potential. FBDD relies on knowledge of the fragments binding mode to the 
target and often requires the development of synthetic routes at each stage of 
the fragment elaboration cycle. These fragment elaboration cycles can be 
extremely iterative and hence both money and time-consuming. One attractive 
concept in FBDD is the opportunity to synthetically grow the fragment in three-
dimensions, i.e. accessibility to all vectors of the fragment, allowing for the 
broader exploration of chemical space.44 The development of methodologies 
that allow for synthetic growth along multiple vectors, such as C-H bond 
functionalisation at sp2- and sp3-centres, that incorporate protentional 
problematic polar binding groups in synthetic methodologies,53 can only 
enhance the potential of FBDD.31  
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Figure 1.5 The two current marketed drugs, a) Vemurafenib and b) Venetoclax, that have 
been discovered from fragment-based drug discovery programmes.51,52  
 
1.1.4  Automation in Drug-Discovery to Enable High-Throughput 
Experimentation 
Automation has played a key role in the pharmaceutical industry for 
many years,54 most notably in the high-throughput screening of compound 
libraries to generate hit compounds.14 More recently there has been a marked 
increase in the use of automation and high-throughput experimentation in drug 
discovery workflows. Automation of chemical synthesis has been aided by 
technological advancements,55 and has been applied, for instance, in the 
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synthesis of an array of small molecules using a single automated process.56  
N-methyliminodiacetic acid (MIDA) boronate building blocks (protected to 
enable greater stability and prevent polymerisation) were iteratively coupled 
in a linear fashion, using a technology which incorporated coupling, 
deprotection and purification modules to give a library of diverse small 
molecules. The linear compounds were cyclised to give a range sp3-rich 
macro- and polycyclic natural product and natural product-like cores (Figure 
1.6).56  
 
Figure 1.6 Overview of the automated synthesis of an array of small molecules using MIDA 
boronate building blocks. a) Automated linear synthesis and cyclisation of Citreofuran b) 
Exemplar sp3-rich macro- and polycyclic natural products and natural product-like cores. 
D: Deprotection of protected boronate building block, C: Couple and P: Purification.  
 
Given that target molecules in medicinal chemistry need to be prepared 
from polar and highly functionalised substrates, they tend to perform poorly in 
chemical reactions and often require bespoke reaction conditions for each 
specific combination of substrates.19,26,57 Automated high-throughput 
experimentation has enabled the rapid exploration of multiple reaction 
parameters, to optimise conditions for specific reaction classes, using only 
small amounts of material.57,58 A range of palladium catalysed coupling 
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reactions (C-C, C-N and C-O cross couplings) was, on nanomole scale, 
optimised in batch57 and flow-based58 systems, by exploring discrete 
(catalysts and bases) and continuous (reagent stoichiometry and catalyst 
loading) parameters. The optimisation study enabled a broader scope of 
substrates to be used, enabling a greater number of compounds to be 
successfully prepared, thus increasing the value of the specific reaction class. 
Automated high-throughput experimentation has also enabled the discovery 
of novel reaction classes e.g. in the nickel catalysed variant of alkyne 
diarylation.59  
The automation of these processes has almost always been performed 
on isolated stages of discovery workflows,60 as ensuring all stages of the 
discovery workflows for full integration, have a high- and matched-throughput 
is challenging. The major bottleneck in integrating stages of discovery 
workflows is almost always purification, due to widely adopted purification 
technologies (e.g. mass-directed HPLC, which is performed in series), in the 
industry.60 However, there are reported examples in which automated 
synthesis and biological evaluation have been integrated.61–68 One approach, 
‘nanoscale synthesis and affinity ranking’,68 integrated reaction optimisation, 
library synthesis and affinity ranking of library compounds in the discovery of 
serine/threonine-protein kinase (CHK1) inhibitors (Figure 1.7).  
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Figure 1.7 Overview of nanoscale synthesis and affinity ranking. a) The integrated 
workflow in which reaction conditions were assessed, a library of 345/384 compounds 
synthesised, mixtures  pooled and the library products assessed and ranked against CHK1 
using affinity-selection mass spectrometry. b) Exemplar CHK1 inhibitors discovered from 
nanoscale synthesis and affinity ranking studies.60,68 
 
Palladium-catalysed cross couplings, C-C, C-O, C-S and C-N, were 
exploited in the preparation of a small compound library. Four sets of reaction 
conditions were identified for each class of nucleophile (thiols, alkynes, 
boronates, alcohols, amides, amines and sulphonamides) for reaction with 
bromothiazole 1 to enable the synthesis of 384 target compounds. Of the 384 
target compounds, 345 were successfully synthesised (compared to 158 
under the single best reaction conditions) on a 100 nmol scale (Figure 1.7). 
Reaction mixtures (12-24) were pooled together and incubated with the target 
protein, CHK1, at range of protein concentrations. The mixtures were eluted 
through a size-exclusion column to remove unbound compounds, and the 
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identity of the bound compounds identified by HRMS (Figure 1.7a). By 
incubating compounds along a concentration gradient of the target protein, 
ligands were ranked based on their affinity to CHK1. A range of CHK1 
inhibitors, 2a-c, was discovered following successful scale up, product 
identification and biological activity confirmation (Figure 1.7b).  
The ability to initially assess the biological function of crude reaction 
mixtures can eliminate purification bottlenecks in integrated discovery 
workflows. Indeed, the direct screening of crude reaction mixtures has been 
performed in the ‘off-rate’ screening, by SPR, of unpurified reaction products, 
containing designed test compounds, in the fragment-to-hit phase of FBDD.69 
The rapid assessment of crude reaction products performed in high-
throughput microscale reaction arrays, that incorporate previously 
underutilised reaction classes, could disrupt current practices within the 
pharmaceutical industry, enabling the increase in productivity and in chemical 
and biological innovation.  
1.2.  Function-Driven Approaches to Bioactive Small 
Molecule Discovery 
1.2.1  Emergence of Natural Products through Biosynthetic 
Pathway Evolution 
Natural products have been a huge inspiration in drug discovery 
programmes, inspiring around third of FDA approved drugs between 1980 and 
2010.70 Atorvastatin is a microbial natural product used for the treatment of 
hypocholesterolemia, and has inspired a range of other statin drugs, e.g. 
Lovastatin.70 Natural products provide a source of biologically-relevant 
chemical diversity, with a broad range of pharmacophores and inherently 
higher fraction of sp3-hybrisided carbons, compared to synthetic 
compounds.71 Natural product emergence through biosynthetic pathways72,73 
is remarkably different to the discovery of synthetic bioactive small molecules. 
Natural products arise based on their benefit to the host organism. Nucleic 
acids are transcribed and translated to produce biosynthetic enzymes, which 
use simple bioavailable molecules (primary metabolites) as building blocks for 
natural product synthesis. Evolutionary pressure provides a feedback loop 
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that serves to optimise the range of natural products produced. As a result, 
bioactive products emerge in parallel to their biosynthetic routes (Figure 1.8). 
Two function-driven approaches for bioactive small molecule discovery, 
Synthetic Fermentation74 and Activity-Directed Synthesis16,17, have some 
parallels to the emergence of natural products.  
a)  
 
 
Figure 1.8 a) Evolution of biosynthetic pathways found in nature. b) Exemplar natural 
products that arise through biosynthetic pathways.75,76 Rubrofusarin and Alternariol-9-
methyl ether have been reported as having antimicrobial effects.  
 
1.2.2  Synthetic Fermentation 
Synthetic fermentation is a function-driven bioactive small molecule 
discovery approach that enabled the discovery of bioactive β-peptide 
inhibitors of HCV NS3/4A protease.74 Products were prepared by reacting 
simple building blocks in arrays of plate-based reactions termed ‘cultures’. 
Aqueous-tolerant amide-forming ligations were exploited, by reaction of -
keto acid initiators (I) with isoxazolidine elongation monomers (M) to yield -
keto acid oligomers, which upon reaction with terminator (T) building blocks 
stopped the elongation process (Figure 1.9a). The sequences, structures and 
compositions of the products could be modified by altering the building blocks 
and conditions used. Thousands of compounds were readily prepared by 
combining suitable building blocks in aqueous solution and screened directly, 
without purification, in the biological assay. Each well contained several major 
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products, which could be identified from the building blocks used. Active 
compounds were then identified using combinatorial deconvolution strategies. 
 
 
Figure 1.9 Overview of synthetic fermentation a) Representative initiator (I), elongation 
monomer (M) and terminator (T) building blocks. b) Discovery of a hepatitis C virus N53/4A 
protease inhibitor 3, (IC50 = 1 μM).74  
 
Three rounds of reactions were performed and after each round, analysis and 
identification of active mixtures was performed to reveal how effective 
moieties had performed. Poorly performing moieties were eliminated in 
subsequent rounds and only functional building blocks were taken forward for 
further study, ensuring subsequent rounds focussed only on producing 
bioactive mixtures. The approach resulted in the discovery of a hepatitis C 
virus N53/4A protease inhibitor 3 (IC50: 1 μM), that was readily identified and 
characterised from around 6000 unnatural peptides that were synthesised 
from just 23 building blocks (Figure 1.9b). However, the necessity for aqueous 
chemistry limits the range of compatible chemical transformations, greatly 
reducing the diverse range of products possible. 
 
1.2.3  Activity-Directed Synthesis 
Activity-directed synthesis (ADS) is the function-driven discovery of 
bioactive small molecules, in which the target molecule is not predefined at 
the outset of the discovery phase.16,17 Reactions with many possible outcomes 
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are deliberately chosen, which can be steered by the specific reaction 
conditions used. Arrays of microscale reactions are performed, in which the 
components (substrates, catalysts, solvents etc.) are varied. Following 
reaction completion, the crude mixtures are scavenged, evaporated, and 
screened, without purification, for biological activity. Reactions that yield active 
products inform the design of subsequent reaction arrays, by varying the 
components of those reactions. Finally, after multiple rounds of ADS, 
promising reaction mixtures are scaled-up to enable purification, structural 
elucidation and characterisation of the responsible bioactive small molecules 
(Figure 1.10). Unlike conventional medicinal chemistry workflows, ADS 
enables resources to be focussed solely on small molecules with biological 
function. The approach is iterative, and enables the function-driven discovery 
of biologically active small molecules in parallel with their associated synthetic 
routes. 
 
 
Figure 1.10 Overview of the workflow in Activity-Directed Synthesis: Reaction arrays are 
performed, scavenged and screened for biological activity. Subsequent reactions arrays 
are designed by varying the components of active product mixtures. The most promising 
reactions are scaled-up to identify the bioactive small molecules.16,17  
 
ADS has been demonstrated as a powerful small molecule discovery 
approach, in a series on intra-16 and intermolecular17 studies, that enabled the 
efficient discovery of novel ligands with submicromolar activity against the 
androgen receptor. Metal-catalysed carbenoid chemistry, exploiting a range 
of -diazoamide compounds, was chosen as many possible reaction modes 
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are possible, including intermolecular C-H, N-H and O-H insertions, 
cyclopropanations, ylide formation/cycloaddition as well as intramolecular 
variations that yield varying ring sizes, enabling the possible evaluation of a 
wide-range of chemotypes.77–79  
The initial intramolecular study of ADS employed a range -diazoamides  
4-19, bearing a known (4-cyano 3-trifluromethyl phenyl) binding group of the 
androgen receptor (Figure 1.11). Reaction arrays were performed in which the 
diazo substrate, catalyst and solvent were varied.  
 
 
 
R’ R 
 Ac H 
Round 1 Diazoamides for 
Intramolecular series 
nPr 
CH2Ph 
(CH2)2Ph 
(CH2)2CH=CH2 
(CH2)2iPr 
CH2CONMe(CH2)2CH=CH2 
4 
6 
8 
10 
12 
14 
5 
7 
9 
11 
13 
15 
Round 2 Diazoamides for 
Intramolecular series 
nPr 
CH2Ph 
(CH2)2Ph 
(CH2)2CH=CH2 
CH2CONMe(CH2)2CH=CH2 
4 
6 
- 
10 
14 
- 
- 
9 
- 
15 
Round 3 Diazoamides for 
Intramolecular series 
nPr 
CH2Ph 
(CH2)2OMe 
4-pyridylmethyl 
(CH2)2CN 
Propargyl 
4 
6 
16 
17 
18 
19 
- 
- 
- 
- 
- 
- 
Diazoamides for 
Intermolecular series 
Me 
Cyclopropyl 
20 
22 
21 
23 
Figure 1.11 -Diazoamides, with many possible intra/intermolecular reaction modes, that 
were utilised in activity-directed synthesis. 4-19 were used for intramolecular reactions and 
20-23 for intermolecular reactions in the discovery of androgen receptor agonists. 
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In the first array 36 reactions were explored, in which twelve diazoamides 
4-15 and three catalysts in dichloromethane were varied. After 48 h, reactions 
were scavenged for metal catalysts, evaporated and screened (total product 
concentration: 10 M) directly, without purification, for agonism of the 
androgen receptor. Of the 36 reactions, substrates 4, 6, 9 and 10 yielded 
product mixtures with biological activity, which were used to inform the design 
of the second array. The four most promising substrates 4, 6, 9 and 10, along 
with two control substrates, 14 and 15 were explored with an expanded range 
of eight catalysts and four solvents. Following scavenging and evaporation, 
the product mixtures were screened (total product concentration: 1 M) for 
activity. Only substrates 4 and 6, with specific combinations of catalysts and 
solvents, yielded product mixtures with biological activity, suggesting the 
reaction conditions are critical in steering substrates towards bioactive 
products.  
A final array exploited substrates 4 and 6 and built on promising 
combinations of catalyst and solvent. Four additional structurally-related 
substrates 16-19, were also included and reacted combinatorially with six 
rhodium carboxylate catalysts and three different solvents. The reaction 
mixtures were screened (total product concentration: 100 nM) for activity.  
Reactions of three of the substrates, 4, 6 and 18, yielded the most active 
product mixtures.  
Ten reactions involving the three substrates 4, 6 and 18, were selected 
for scale-up (50-fold increase) based on their biological activity from round 
three.  From the ten reactions, three distinct products were discovered.  Diazo 
substrates 6 and 18 underwent intramolecular C−H insertion to yield the -
lactams 24 and 25 respectively and diazo substrate 4 also underwent 
intramolecular C−H insertion to yield -lactam 26 (Scheme 1.1). The three 
isolated products were all sub-micromolar modulators of the androgen 
receptor, with none of the chemotypes previously reported with activity against 
the androgen receptor. Remarkably, of the 336 reaction performed, ten were 
only ever scaled up and only three products, which were biologically active, 
needed to be purified, highlighting the efficiency of ADS.  
Following the intramolecular study, the use of intermolecular reactions in 
activity-directed synthesis was explored. Intermolecular reactions allowed 
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fewer fragments, loaded with the core-binding moieties, to be synthesised, 
which can undergo reactions with huge numbers of commercially available co-
substrates. In this case just four diazo substrates 20-23, each armed with the 
4-cyano 3-trifluoromethyl phenyl group, were prepared (Figure 1.11). 
 
Scheme 1.1 Reactions selected for scale-up from ADS, which enabled the discovery of 
three novel submicromolar agonists, with previously unreported activity, of the androgen 
receptor.   
Arrays were performed in which the diazos 20-23, commercially 
available co-substrates which possess multiple possible reaction modes, 
catalysts and solvents were varied. Following reaction completion and 
scavenging, reactions mixtures were screened without purification for 
agonism of the androgen receptor. A total of three rounds of ADS was 
performed and reactions with promising biological activity from all three 
rounds were chosen for scale up (50-fold larger scale), to enable the 
identification of the products responsible for biological activity.  
Over the three rounds, products were identified from alternative patterns 
of reactivity. Rounds one and two yielded active products formed from 
intermolecular C-H insertions and cyclopropanations. However, products from 
round three emerged from new patterns of reactivity, highlighting the value in 
exploiting reactions with many possible outcomes. The dihydropyran 27 and 
the benzopyran 29 (Scheme 1.2) were chosen on the basis of their similarity 
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to promising co-substrates from round two and were expected to undergo 
similar cyclopropanation reactions. However, the bioactive molecules 28 and 
30 were produced as a result of different modes of reactivity (Scheme 1.2). 
Amide 28 was the product of an enantioselective O-H insertion reaction, the 
first reported example of its kind. Interestingly, the enantioselective reaction 
was inferred in the activity data in round three. Reaction of diazo substrate 20 
with dihydropyran 27 resulted in an active product with Rh2(R-DOSP)4, but 
there was no observed activity using same substrates and the enantiomeric 
catalyst Rh2(S-DOSP)4. Finally, oxazole 30 was formed by reaction of diazo 
substrate 20 with the nitrile group in co-substrate 29.  
 
 
Scheme 1.2 Biologically active products discovered from ADS with intermolecular metal-
catalysed carbenoid reactions.  
 
 Function-driven approaches have the potential to address bottlenecks 
in discovery workflows and ensure resources are focussed solely on 
biologically small molecules. However, to maximise the impact of such 
discovery workflows, the range of applicable chemistries would need to be 
expanded in order to allow a broad range of chemotypes to be discovered.  
1.3  Summary 
The historical uneven exploration of chemical space can largely be 
attributed to the narrow toolkit of reactions employed during drug discovery 
workflows, which has resulted in densely populated areas of chemical space. 
This often results in compound libraries with undesirable molecular properties 
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for successful drug discovery. The pharmaceutical industry has recognised 
the need for the development of robust synthetic strategies that incorporate 
the use of highly functionalised substrates in compound library preparation. 
This has resulted in the development and uptake of technologies that enable 
automated high-throughput experimentation for reaction optimisation, reaction 
discovery and compound library preparation. To fully automate and integrate 
all stages of drug discovery workflows, purification bottlenecks, which are 
performed in series, need to be addressed. Function-driven approaches, such 
as activity-directed synthesis, allow direct evaluation of crude reaction 
mixtures and have the potential to disrupt current practices within discovery 
workflows. To maximise the impact of activity-directed synthesis, the range of 
applicable chemistries must be expanded to enable diverse regions of 
chemical space to be explored.  
 
1.4  Project Outline: Activity-Directed Fragment-Based 
Ligand Discovery 
Activity-directed synthesis has been demonstrated as powerful approach  
for bioactive small molecule discovery. Intermolecular reactions in activity-
directed synthesis have potentially greater impact in the search for bioactive 
small molecules, as fewer fragments loaded with core-binding moieties need 
to be synthesised, which can undergo reaction with huge numbers of 
commercially available co-substrates.  
Elaboration of fragments in conventional FBDD workflows is greatly 
assisted by knowledge of a fragments binding mode to its biological target and 
often requires the development of synthetic routes at each stage of the 
fragment elaboration cycle. In stark contrast, activity-directed synthesis has 
the potential to enable fragment-to-lead optimisation studies to be performed 
without predefining the target molecule. However, a limitation in employing a 
fragment loaded with a diazotised-carbon, for metal-catalysed carbenoid 
chemistry, is that reaction is only possible on the carbon loaded with the diazo. 
This reduces the number of accessible vectors for fragment elaboration, 
limiting the potential to explore broad swathes of biologically-relevant 
chemical space.  
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For activity-directed synthesis to be employed for fragment elaboration, 
new chemistry must be utilised which enables synthetic elaboration at multiple 
reaction sites of the fragment. It was proposed that metal-catalysed C-H 
functionalisation has the potential to elaborate along one or many C-H 
vector(s) of a fragment to produce a range of regioisomers for biological 
evaluation. 
 It was proposed that the establishment of C-H functionalisation 
chemistry for activity-directed synthesis in the discovery of novel bioactive 
small molecules would enable the establishment of a multistep discovery 
platform. The platform would enable the function-driven discovery of novel 
bioactive small molecules, at each stage of the discovery phase, without any 
bioactive molecule being designed at the outset. The establishment of multiple 
chemistries in activity-directed synthesis would then allow extrapolation of the 
platform to a range of biological targets. For example the previously 
established intramolecular metal-catalysed carbenoind chemistry could be 
employed for the function-driven discveory of novel fragments for a specific 
biological target. Scale up and isolation of the active fragments, could then be 
utilised as fragments for fragment elaboration with C-H functioanlsiation 
chemistry to improve the activity of the fragments (Figure 1.12).  
 
Figure 1.12 Proposed multistep discovery platfrom that could be established with multiple 
synthetic strategies.  
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A series of project objectives was outlined to evaluate the function-driven 
elaboration of fragments in activity-directed synthesis, which can ultimately be 
incpororated into a multistep function-driven platform. Hsp90 was chosen as 
the biological target to exemplify the fragment elaboration strategy with 
activity-directed synthesis.  
Objective 1: Configure a range of C-H functionalisation reactions for 
application in plate-based microscale arrays (Section 1.4.1).  
Objective 2: Establish a high-throughput assay and design, prepare and 
identify a series of Hsp90 fragment hits (Section 1.4.2).  
Objective 3: Evaluate the value of C-H functionalisation and metal-catalysed 
carbenoid chemistry in the structure-blind elaboration of Hsp90 fragments 
(Section 1.4.3).  
 
1.4.1  Objective 1: Configuration of C-H Functionalisation for 
Activity-Directed Synthesis 
C-H functionalisation has the potential to synthetically grow along many 
C-H vectors of a fragment, allowing for the exploration of diverse chemical 
space. To evaluate C-H functionalisation for activity-directed synthesis, it was 
proposed that a range of C-H functionalisation literature reactions would be 
chosen, based on their mild reaction conditions (room temperature and 
air/moisture stable), reproduced in flask and the products isolated and 
characterised. To demonstrate the chosen reactions were amenable for plate-
based reactions it was proposed that replication of the reactions, on 
microscale, in plate-based formats and comparison of the crude reaction LC-
MS traces of flask and plate formats, would be performed to determine 
reaction reproducibility (Chapter 2.2). To broaden the range of chemistry, it 
was proposed that analysis of heating technology for parallel microscale 
arrays would be conducted by analysis of flask and plate-based reactions.  
Given C-H functionalisations rely on a broad range of metal catalysts to 
activate C-H bonds, it was proposed a series of scavenging studies would be 
performed to ensure residual reaction components, such as metal catalysts 
and strong electrophiles, can be scavenged to prevent interference in the 
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biological assay. Ideally a range of C-H functionalisation reactions would be 
configured for parallel reaction arrays at room and elevated temperatures and 
an operationally simple workflow for scavenging metal catalysts and Michael 
acceptors be established.  
 
1.4.2  Objective 2: Configuration of High-throughput Assay and 
Fragment Chemical Matter for Heat shock protein 90 
The chosen biological target for evaluation of C-H functionalisation for 
fragment elaboration is Hsp90 (Heat shock protein 90), as it has been widely 
studied in various fragment-based drug discovery programmes and there are 
many reported fragments that looked well-suited to elaboration using C-H 
functionalisation chemistry (multiple directing groups).  
It was proposed that a range of Hsp90 fragments, inspired by known 
ligands, that possess at least one potential directing group for C-H 
functionalisation, would be prepared and their biological activity assessed  by 
generating dose response curves. For the biological assessment of the 
prepared fragments and screening of crude reaction mixtures, a high-
throughput robust assay was required. The proposed assay for the project 
was a reported biochemical fluorescence anisotropy assay,80 which required 
the expression of the protein, synthesis of the tracer and establishment of the 
control experiments.  
It was proposed the assay would aid the selection of fragments to 
implement in the reaction arrays as well as ensuring the reaction array 
components do not interfere in the assay. Ideally a robust assay would be 
established which was suitable for identifying a series of Hsp90 fragment hits, 
that would serve as substrates for ADS, and enable biologically active reaction 
mixtures from ADS to be identified. It was envisaged the biologically active 
reaction mixtures would be a result of ligand-efficient synthetically elaborated 
fragments.  
1.4.3  Objective 3: Implementation of Reaction Arrays 
It was proposed the configuration of the chemistry and scavenging 
protocols in parallel plate-based format and establishment of the high-
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throughput assay for assessing crude reaction mixtures would ensure a 
practical workflow for implementing the reaction arrays. It was proposed a 
range of reaction arrays based on different chemistry and elaboration 
strategies, C-H functionalisation and metal-catalysed chemistry, would be 
performed. Reactions would be performed by varying, fragment, substrate and 
catalyst combinations and crude reaction mixtures screened at low 
micromolar concentrations against Hsp90 for biological activity (Figure 1.13). 
The arrays would enable the value of each of the elaboration chemistries to 
be determined against Hsp90. 
 
Figure 1.13 Project overview: Example Hsp90 fragment that could be elaborated with 
various C-H functionalisation chemistries. Screening of the reaction mixtures would identify 
which C-H functionalisation strategy gave rise to bioactive mixtures.  
- 26 - 
Chapter 2. 
Evaluation of C-H Functionalisation Chemistry for Activity-
Directed Synthesis 
C-H functionalisation has been highlighted as a powerful tool for hit-to-
lead studies,44,81 due to its potential to synthetically elaborate a hit along any 
C-H vector of the molecule. The application of C-H functionalisation in ADS, 
has the potential to enable the structure-blind identification of productive 
vectors for fragment elaboration, contrasting starkly to conventional hit-to-lead 
studies. An overview of C-H functionalisation, including recent examples of 
functionalisations at sp2- and sp3-hybridised carbons is discussed. A range of 
C-H functionalisation transformations was evaluated for their implementation 
in plate-based arrays, by comparing reaction performance in flask- and  
various plate-based formats, followed by a post reaction work-up study to 
ensure crude reaction mixtures can be screened, without assay interference, 
against a biological target. The study enabled the identification of a portfolio 
of C-H functionalisation reactions for implementation in ADS, and the 
configuration and optimisation of a operationally simple ADS workflow.  
 
2.1  Overview of C-H Functionalisation 
The Carbon-Hydrogen bond is a generally unreactive bond (bond 
energies of C(sp3)-H and C(sp2)-H range from 370 to 460 kJ/mol) found in 
nearly all organic compounds.82–84 The direct functionalisation of C-H bonds 
has emerged as powerful tool in synthetic chemistry as it provides the 
opportunity for new disconnections in complex molecules that were not 
previously possible. The field has applications in a wide range of sectors 
including polymers, agrochemicals, energy, natural products and 
pharmaceuticals.82  
C-H functionalisation is the controlled activation and functionalisation of 
specific and remote C-H bonds in a molecule, generally in the presence of 
more reactive functional groups.84 However, the inert nature of C-H bonds, 
and their ubiquitous nature in organic molecules, makes the selectivity and 
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reactivity of these bonds particularly challenging. The past few decades has 
seen the emergence of transition metal-catalysed C-H functionalisation, 
enabling the efficient construction of C-C and C-X (X = Heteroatom) bonds.84  
Site selectivity can be controlled by the proximity of a C-H bond to a 
reactive metal centre, which is controlled by the use of directing groups within 
an organic molecule. Typically, coordination between heteroatoms in the 
directing group and the metal catalyst, bring the metal centre into close 
proximity to a C-H bond, which inserts into the C-H bond to create a carbon-
metal bond (Figure 2.1).84 This more reactive bond is then able to undergo a 
range of transformations with different reaction partners to give rise to new C-
C and C-heteroatom bonds (Section 2.1.2). The advancement in mild C-H 
functionalisation reactions has enabled once latent C-H bonds to be seen as 
a reactive functional group in its own right, transforming synthetic strategies 
for chemists.83,84   
 
The recent emergence and advancements in C-H functionalisation via 
photoredox catalysis is seen as a complementary approach to transition 
metal-catalysed C-H functionalisation.29 Photoredox catalysis has made the 
functionalisation of C(sp3)-H bonds more accessible under mild reaction 
conditions and has also been highlighted as being of significant value in 
enabling new disconnections in synthetic strategies.81 
 
2.1.1  The potential of C-H Functionalisation in Bioactive Small 
Molecule Discovery 
C-H functionalisation has applications in a broad range chemical sectors, 
but has been highlighted and demonstrated as being of particular value in the 
 
Figure 2.1 Overview of C-H functionalisation: site selectivity is controlled by proximity of a   
C-H bond to directing group (DG), transition metal (TM) coordination and insertion and 
reaction with a substrate (RX).  
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pharmaceutical industry. For instance, C-H functionalisation has been utilised 
in the synthesis of a range of medicinally relevant molecules85 and in late-
stage functionalisation of complex molecules.86,87 For the pharmaceutical 
industry, late-stage functionalisation can facilitate the development of 
structure-activity relationships and the optimisation of potency and selectivity 
of lead compounds by reaction along C-H vectors unexplored by conventional 
synthetic strategies.88 
In fragment-to-lead optimisation studies, structural information is key for 
making synthetic elaboration decisions, however the nature of the fragment-
protein binding orientation can often mean there is disparity between the 
favoured growth vector and its synthetic accessibility. Often, fragment 
analogues containing functional handles for synthetic elaboration are 
required. This can result in a trade-off between the potential value and 
synthetic tractability of the elaborated fragment. C-H functionalisation and 
photoredox catalysis have been highlighted as a powerful tools in fragment-
to-lead studies in fragment-based drug discovery (Figure 2.2).31,44  
 
Figure 2.2 Potential for C-H functionalisation in fragment elaboration a) Elaboration of 
Hsp90 fragments through transition-metal catalysed C-H Functionalisation b) Elaboration of 
Hsp90 fragments through photoredox catalysis.  
 
It was proposed that the application of C-H functionalisation in ADS 
would enable the structure-blind and function-driven elaboration of fragments. 
The range of potential C-H functionalisation chemistries for ADS is discussed 
(Section 2.1.2) and the evaluation and configuration of C-H functionalisation 
for ADS is described (Section 2.2).  
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2.1.2  The Scope of C-H Functionalisation Reactions 
A vast range of C-H functionalisations reactions have been published 
over the last few decades, enabling a broad range of new synthetic 
connections to be made.83,84 The use of directing groups and transition metals 
enables the selection and activation of a specific C-H bond, the most common 
of which is ortho-directed C(sp2)-H functionalisations onto an aromatic ring 
(Figure 2.3 for selected examples). The use of directing groups has been 
widely studied, of which there are now a broad range; amides (Figure 2.3a), 
heteroaryls (Figure 2.3b), amines (Figure 2.3c), carboxylic acids (Figure 2.3d) 
as well as many others.84 The range of C-H functionalisation types include, for 
example, introduction of alkyl, alkene and alkyne chains, amines, amides and 
aromatic rings, as well as much smaller groups, or even single atoms, such 
as hydroxyl groups and halogens, which are considered part of the late-stage 
functionalisation toolkit.87 The choice of catalyst is often critical for the reaction 
progression, as well as the choice of additives such as base and oxidant.  
There have also been numerous reported examples of directing C-H 
insertion to the meta- and para- positions of an aromatic rings, via the use of 
specifically designed (or transient) directing groups (Figure 2.3f).89 The use of 
directing groups isn’t always required, as the intrinsic reactivity of the 
substrate itself can control the position of functionalisation. For instance, the 
C-H alkenylation of pyrroles can be controlled by the choice of N-protecting 
group (Figure 2.3ei).90 The N-Boc protected pyrrole 54 directs C-H insertion 
to the C2 position under electronic effects, whereas the N-TIPS protected 
pyrrole 55 directs insertion to the C3 position due to the steric bulk of the 
protecting group. Similarly, under palladium catalysis, C-H arylation of N-
methylindole is directed to the C2 position (Figure 2.3eii).91  
C-H functionalisation onto sp3 hybridised carbons has also become 
common practice (Figure 2.3g).92 Again, the choice of directing group and 
catalyst is crucial for reaction selectivity and a similarly broad range of 
transformations is possible. Strategies that enable the enantioselective 
reaction of C-H bonds are now emerging in the field, for example in the 
enantioselective C(sp3)-H arylation of carboxylic acids (Figure 2.3g).93  
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Figure 2.3 C-H functionalisation chemistries: a) Amide-directed i) C-H alkenylation94 ii) C-H 
amination95 b) Heteroaryl-directed i) C-H amidation96 ii) C-H alkenylation97 c) Amine-directed 
i) C-H alkenylation98 ii) C-H alkenylation99 d) Carboxylic Acid-directed i) C-H alkenylation100 
ii) C-H arylation101 e) Intrinsic C-H functionalisation i) C-H alkenylation90 ii) C-H arylation91 f) 
Meta C-H alkenylation102 g) Enantioselective C(sp3)-H arylation93  
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C-H functionalisation reactions typically proceed via a similar catalytic 
cycle (Figure 2.4). The first step requires activation of the substrate 
undergoing C-H functionalisation, in which the catalyst coordinates to the 
directing group, and inserts into a proximal C-H bond. The metal centre then 
coordinates and inserts into the reaction partner, allowing formation of a 
substrate carbon-reaction partner bond. The product is released, followed by 
oxidation of the catalyst to reform the active catalytic species. The example 
shown (outer blue circle) is the palladium catalysed ortho C-H alkenylation 
reaction into the acetamide 67 with nButyl acrylate 32.94 The product 68 is 
released via a dehydropalladation and the catalyst is regenerated via 
oxidation with 1,4-benzoquinone (Figure 2.4).  
 
 
Figure 2.4 General catalytic cycle for C-H functionalisation reactions with transition metal 
catalysts (centre).83 Example (outer circle) palladium catalysed C-H alkenylation reaction in 
which substrate 67 is alkenylated ortho to the acetamide group with nbutyl acrylate 32.94 
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2.1.3  Summary 
C-H functionalisation has the potential to transform chemical strategies, 
and provides the opportunity for new disconnections, not previously possible, 
to be made. Mild C-H functionalisation reactions have become well 
established in recent years, through the development of a broad range of 
transition metal catalysts and directing groups. The direct functionalisation of 
C-H bonds has implications in a wide range of chemical industries, for 
instance in the discovery of bioactive small molecules, in particular hit-to-lead 
studies. C-H functionalisation applied in ADS has the potential to enable 
structure-blind and function-driven fragment elaboration. 
 
2.2  Configuration of C-H Functionalisation Chemistry for 
Activity-Directed Synthesis 
To enable the use of C-H functionalisation in activity-directed synthesis, 
a range of candidate C-H functionalisation reactions, that proceed under mild 
conditions, was identified (Section 2.2.1). As reactions in ADS are performed 
on microscale (typically 100 L volume), in parallel-based format, at room 
temperature, under atmospheric conditions and without stirring, the C-H 
functionalisation reactions chosen must be amenable to these conditions. C-
H functionalisation reactions often proceed under harsh conditions, with 
stoichiometric additives, high temperatures and with inert atmospheres, 
however there has been recent efforts within the field to identify milder C-H 
functionalisations reactions.83  
A series of mild C-H alkenylations (Section 2.2.1.1), C-H aminations 
(Section 2.2.1.2) and C-H arylations (Section 2.2.1.3) was identified, and 
replicated as described in the literature on mmol scale in round-bottom flasks. 
LC-MS analysis of the crude reactions was performed followed by subsequent 
purification to characterise and identify the products. The reactions were then 
replicated under conditions representative of the ADS workflow (room 
temperature, air/moisture stable and without stirring) and prepared from stock 
solutions, in plate-based format. Comparison of flask- and plate-based crude 
reaction mixtures was used to identify C-H functionalisation reactions 
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amenable to ADS. The reactions were chosen to ensure a broad range of 
reaction type, directing groups and catalysts.  
 
2.2.1 Evaluation of a Range of C-H Functionalisation Reaction 
Types for Parallel Microscale Reaction Arrays 
2.2.1.1  Analysis of C-H Alkenylation Reactions 
A broad range of C-H alkenylations have been reported which proceed 
under various catalytic systems and directing groups with a range of reaction 
partners (alkenes, acrylates acrylamides and alkynes).83,84 The mild C-H 
alkenylations chosen for assessment in ADS (Table 2.1) were replicated in 
round-bottom flasks as reported in the literature (unless stated).  
Reaction of nbutyl acrylate 32 with substrate 31 (Entry 1, Table 2.1)94 
proceeded in much lower yield, 25%, compared to the reported literature yield, 
72%. This was due to the reaction of 32 at both ortho positions of substrate 
31. The addition of a meta-methyl, 67, resulted in the single C-H alkenylation 
to 68 in much higher yield, 55% (Entry 2, Table 2.1).94 Both reactions proceed 
through coordination of the palladium catalyst to the acetamide directing 
group, followed by activation of the ortho C-H bond. Similarly, the -NH2 of 
cumylamine 43 (Entry 3, Table 2.1)98 directs C-H insertion to the ortho C-H 
under ruthenium catalysis. Following C-H functionalisation, the substrate 
undergoes cyclisation to form a five membered ring, due the electron 
withdrawing nature of substrate 44. The reaction was performed under 
atmospheric conditions in 76% yield, compared to a literature yield of 91% 
which was performed under an inert atmosphere of nitrogen.  
Finally reaction of N-Boc pyrrole 54 with nbutyl acrylate 32 resulted in 
the C2 C-H functionalisation to 56 in 26% yield (Entry 4. Table 2.1)90, 
compared to 72% reported in the literature. However, the literature procedure 
was modified to enable greater compatibility in ADS. In the literature, the 
reaction was performed under an atmosphere of O2 at 35 oC, however in this 
instance the reaction was performed at room temperature with benzoquinone 
as the oxidant. Interestingly, protecting the pyrrole nitrogen with TIPS can 
enable C3, instead of C2, C-H functionalisation (see Section 2.1.2).  
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Entry Substrate Co-Substrate Conditions Product Ref. 
1 
 
 
Pd(OAc)2 [2 mol%] 
BQ, TsOH 
AcOH/Toluene (2:1) 
RT, 16 h 
 
Yield: 25% 
Lit. Yield: 72%  
94 
2 
 
Pd(OAc)2 [2 mol%] 
BQ, TsOH 
AcOH/Toluene (2:1) 
RT, 16 h 
 
Yield: 55% 
Lit.  Yield: 91%  
94 
3* 
 
[Ru(p-cymene)Cl2]2 
[2.5 mol%] 
Cu(OAc)2.H2O 
Dioxane, AgSbF6 
RT, 6 h 
 
Yield: 76% 
Lit. Yield: 91% 
 
98 
4** 
 
Pd(OAc)2 [10 mol%], BQ, 
AcOH/DMSO/Dioxane 
(3:9:1) 
RT, 96 h 
 
Yield 26% 
Lit. Yield: 72% 
 
90 
Table 2.1 Exemplar C-H alkenylation reactions that were reproduced in flask (mmol scale) 
from the literature to identify reactions that proceed under mild conditions which could prove 
amenable to ADS microscale reaction array format. Deviation from literature procedures: 
*Performed under N2 atmosphere in literature **Performed at 35 oC under O2 atmosphere in 
the literature.  
 With a range of mild C-H alkenylations identified, the reactions were 
replicated under ADS-conditions in plate-based format. Following reaction for 
24 h, an LC-MS of the crude reaction mixture was collected, and comparison 
of the LC-MS trace of the crude reaction mixtures in flask and plate-based 
format was performed (Table 2.2). Similar LC-MS traces of flask and plate-
based reactions demonstrated the reactions could be reproduced for ADS 
plated-based reaction arrays. The LC-MS traces for each of the three C-H 
alkenylation reactions replicated in flask and plates (Table 2.2) showed a 
similar product distribution and product masses with the same retention times. 
This demonstrated that the mild C-H alkenylation reactions were amenable for 
ADS and so these reactions were taken forward for their utilisation in activity-
directed fragment elaboration.  
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MH+: 150.1 
MNa+: 298.1 
67 
68 
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MH+: 276.4 68 
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MH+: 262.5 44 
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MH+: 262.5 44 
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LC-MS Analysis 
Mass 
Found 
Compound 
No. 
F
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s
k
  
MH+: 294.2 56 
P
la
te
  
MH+: 294.4 56 
Table 2.2 C-H alkenylation literature reactions reproduced in flask and plate-based formats. 
Plate-based reactions were repeated under ADS-array conditions and the crude plate 
reactions analysed against the crude flask reactions, by analysing LC-MS traces to determine 
their amenability in ADS. For the three C-H alkenylations replicated, comparable LC-MS 
traces demonstrated the successful transfer of reactions to plate-based format.  
 
67 
68 
44 
68 
44 
56 
56 
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2.2.1.2  Analysis of C-H Amination Reactions 
C-H amination is the functionalisation of C-H bonds to form C-N bonds, 
of which there have been numerous reported examples.103 The C-H 
aminations chosen for assessment in ADS (Table 2.3) were repeated in 
round-bottom flask, as described in the literature (unless stated).  
 
Entry Substrate Co-Substrate Conditions Product Ref. 
1† 
 
 
IrCp*(OAc)2  
[10 mol%] 
AgNTf2, Cu(OAc)2, 
1,2-DCE, RT, 24h 
 
Yield: 58% 
Lit. Yield: 72%† 
 
95 
2†† 
 
[IrCp*(Cl)2]2 [5 mol%] 
AgNTf2, Cu(OAc)2,  
1,2-DCE:HFIP (50:50) 
RT,  24 h 
 
Yield: 38% 
Lit.  Yield: 50%†† 
 
104 
3 
 
 
[RhCp*Cl2]2 [5 mol%] 
CsOAc, PivOH 
MeOH, RT, 16h 
 
Yield: 61% 
Lit. Yield: 80%  
105 
Table 2.3 Exemplar C-H amination reactions that were reproduced in flask (mmol scale) 
from the literature to identify reactions that proceed under mild conditions which could prove 
amenable to ADS microscale reaction array format. Deviation from the literature: † No meta-
methyl present on substrate 69 in the literature. †† No meta-methyl present on substrate 69 
in the literature and reaction temperature dropped from 60 oC to room temperature.  
 
The iridium-catalysed ortho C-H amination of substrate 69 with para-
(trifluoromethyl)aniline 35 gave product 70 in 58% yield, compared to the 
reported literature yield of 72% (Entry 1, Table 2.3).95 However, substrate 69 
incorporated a meta-methyl, to prevent C-H amination of both ortho positions, 
which was not present in the literature reaction. Similarly, reaction of 69 with 
cyclohexylamine 71 gave product 72 in 38% yield, compared to 50% in the 
literature (Entry 2.2, Table 2.3).104 In this case the reaction was performed at 
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room temperature, compared to 60 oC in the literature, to ensure the reaction 
was compatible for ADS. Finally, the rhodium-catalysed ortho C-H amination 
of substrate 73 with N-chloroamine 74 gave product 75 in 61% yield (Entry 3, 
Table 2.3).105 However, N-chloroamines would require synthesis for use as 
substrates in ADS due to their limited commercial availability.  
C-H amination reactions one and three (Table 2.3) performed well in 
flask-format and were hence taken forward for study under ADS conditions in 
plate-based format. Similarly to the C-H alkenylations, LC-MS traces of the 
crude reaction mixtures, after 24 h, for each of the reactions in flask- and plate-
based formats were compared to determine their compatibility in ADS (Table 
2.4). As for the C-H alkenylations, the two C-H amination reactions produced 
similar LC-MS traces in both reaction formats, with similar product 
distributions and product retention times. Interestingly, in the cases of the C-
H amination under iridium catalysis, the lack of stirring appeared to have 
minimal impact on product formation given the heterogenous nature of the 
reaction mixture. As reaction two (Table 2.3) proceeded in much lower yield 
than reported, due in part to the lower reaction temperature, heated reaction 
arrays were also explored for ADS (see Section 2.2.2). In this case similar LC-
MS traces were also observed. As all three reactions performed well under 
ADS conditions they were taken forward for implementation in C-H 
functionalisation reaction arrays.  
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MH+: 191.6 
MH+: 351.7 
69 
70 
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MH+: 191.4 
MH+: 351.1 
69 
70 
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MH+: 307.0 75 
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MH+: 307.7 75 
Table 2.4 C-H amination literature reactions reproduced in flask and plate-based formats. 
Plate-based reactions were repeated under ADS-array conditions and the crude plate 
reactions analysed against the crude flask reactions by analysing LC-MS traces to determine 
their amenability in ADS. For the C-H aminations replicated, comparable LC-MS traces 
demonstrated the successful transfer of reactions to plate-based format.  
 
2.2.1.3  Analysis of C-H Arylation Reactions 
Finally, a series of C-H arylations was identified and repeated in flask-
based format as described in the literature (Table 2.5). C-H arylations is the 
replacement of  a C-H bond with a C-aryl bond and would potentially prove 
valuable for fragment elaboration, as the hydrophobic nature of aromatic 
substituents would enable the elaborated fragment to fill the shape of a protein 
binding pocket through hydrophobic interactions. Any additional heteroatoms 
70 
69 
69 
70 
75 
75 
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would also have the potential to pick up additional hydrogen-bonding 
interactions, which are essential for increasing potency.31  
The palladium-catalysed C-H arylation of substrate 76 with boronic acid 
77 gave 78 in 75% yield (Entry 1, Table 2.5),106 comparable to the literature 
yield of 85% (a small amount of product in which both ortho C-Hs were 
arylated was observed). The double C-H activation of acetamide 67 and 
xylene 79 produced 80 in 52% yield (Entry 2, Table 2.5).107 The least sterically 
hindered position of xylene 79 is favoured for this transformation. C-H 
arylation of N-methylindole 58 with iodobenzene 59 produced 60 in 27%, 
much lower than the reported yield of 92% (Entry 3, Table 2.5).91  
 
Entry Substrate Co-
Substrate 
Conditions Product Ref. 
1 
 
 
Pd(OAc)2 
[20 mol%], BQ 
CH2Cl2/iPrOH 
(50:50), RT, 24 h 
 
Yield: 75% 
Lit. Yield: 85%  
106 
2 
 
 
Pd(OAc)2 
[10 mol%],  
NH4S2O8, TFA 
RT, 24 h 
 
Yield: 52% 
Lit. Yield: 82% 
 
107 
3 
  
Pd(OAc)2 
 [5 mol%], Ag2O, 
o-Nitrobenzoic 
acid, DMF, 
RT, 24 h 
 
Yield: 27% 
Lit. Yield: 92% 
 
91 
Table 2.5 Exemplar C-H arylation reactions that were reproduced in flask (mmol scale) from 
the literature to identify reactions that proceed under mild conditions which could prove 
amenable to ADS microscale reaction array format. 
 
C-H arylations (Entries 1 and 2, Table 2.5) were replicated under ADS 
conditions in plate-based format. LC-MS traces for crude reaction mixtures in 
flask and plate-based formats were compared (Table 2.6). As for the C-H 
alkenylations and C-H aminations, similar LC-MS traces, with similar 
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production distribution and retention times demonstrated the compatibility of 
C-H arylations for ADS. Due to the poor yield of the C-H arylation of N-
methylindole 60, and limited substrate scope, it was decided not to take 
forward this reaction for ADS.  
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MH+: 282.1 
MH+: 358.1 
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76 
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LC-MS Analysis 
Mass 
Found 
Compound 
No. 
F
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MH+: 150.7 
MH+: 254.7 
67 
80 
P
la
te
  MH+: 150.3 
MH+: 254.4 
67 
80 
Table 2.6 C-H arylation literature reactions reproduced in flask and plate-based formats. 
Plate-based reactions were repeated under ADS-array conditions and the crude plate 
reactions analysed against the crude flask reactions by analysing LC-MS traces to determine 
their amenability in ADS. For the two C-H arylations replicated, comparable LC-MS traces 
demonstrated the successful transfer of reactions to plate-based format.  
 
 
 
76 
78 
76 
78 
67 
80 
80 
67 
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2.2.2  Configuration of Parallel Heating Technology for C-H 
Functionalisation Arrays 
To enable a broader range of chemistries, and potentially broader range 
of substrates, to be used in activity-directed synthesis, the options of heated 
and stirred reactions in parallel-based formats was investigated. Heating was 
investigated as examples already chosen (C-H amination with alkylamines, 
Entry 2 Table 2.4 and C-H alkenylation, Entry 4 Table 2.1) proceeded at 
elevated temperatures. The necessity for stirring in the reaction outcome was 
also investigated given the heterogenous nature of some of the reaction 
mixtures. A small range of reactions (Table 2.7) was investigated, by repeating 
the reactions in microvial format at room temperature and 60 oC both with and 
without stirring. As before, LC-MS traces of crude reaction mixtures were 
collected and compared to determine reaction progress. In all three cases, 
similar LC-MS traces under all reaction conditions demonstrated that stirring 
was not essential and that heated microscale reactions were possible in 
parallel format.  
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LC-MS Analysis 
a) 
b) 
c) 
d) 
M2H+: 551.6 
M2H+: 551.6 
M2H+: 551.6 
M2H+: 551.6 
68 
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No Stirring Stirring 
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LC-MS Analysis 
a) 
b) 
c) 
d) 
MH+: 262.4 
MH+: 262.4 
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a)  b)  
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LC-MS Analysis 
a 
b 
c 
d 
MH+: 289.5 
MH+: 289.5 
MH+: 289.5 
MH+: 289.5 
72 
72 
72 
72 
No Stirring Stirring 
R
T
 
a)  b)  
6
0
 o
C
 
c)  d)  
Table 2.7 Evaluation of exemplar literature C-H Functionalisation reactions to determine 
importance of heating and stirring in reaction outcome by LC-MS.  
 
68 68 
68 68 
44 44 
44 44 
72 72 
72 72 
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2.2.3  Summary 
A selection of C-H functionalisation reactions (alkenylations, arylations and 
aminations) was chosen and successfully demonstrated as being applicable 
in plate-based microscale reaction arrays. It was determined that stirring was 
not essential for reaction progression and that heated reaction arrays could 
enable a broader range of chemistries and substrates scope used in ADS. 
2.3  Post Reaction Work-up Procedures for C-H 
Functionalisation Chemistry in Reaction Arrays 
To ensure crude reaction mixtures can be screened against the 
biological target of interest, without assay interference, it was proposed that 
incorporating a post reaction work-up procedure for parallel-based chemistry 
into the ADS workflow was needed. An operationally simple procedure for 
removing residual catalysts and Michael acceptors from crude reaction 
mixtures would ensure an efficient and streamlined workflow for ADS. For the 
proof-of-concept studies in ADS,16,17 metal catalysts were scavenged form 
crude reaction mixtures using a QuadraPure Thiourea resin.  
For C-H functionalisation a much broader range of catalysts are used, 
for example, from the configured chemistries (Section 2.2.1), palladium, 
iridium, rhodium and ruthenium as well as copper as an oxidant. The 
stoichiometric use of electrophiles is also prevalent in some of the chosen 
reactions; the use of benzoquinone as an oxidant and acrylates as reaction 
partners, which have the potential to undergo reaction with nucleophilic 
protein residues during the screening process. To ensure minimal assay 
interference, it was proposed that the use of a resin that could scavenge a 
broad range of metals and strong electrophiles from reaction mixtures was 
needed. A range of potential scavenger resins (Table 2.8) was used to 
investigate the potential to scavenge metals and electrophiles from crude 
reaction mixtures.  
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Quadrapure DET Qaudrapure MPA Quadrapure BzA 
   
Macroporous Resin 
Loading: 1-2 mmol/g 
Metals Scavenged†: Cu, Fe, 
Pd, Rh 
Macroporous Resin 
Loading: 1.5 mmol/g 
Metals Scavenged†: Ag, Au, 
Cd, Hg, Pb, Pt, Ru, Pd, Sn 
Macroporous Resin 
Stated Loading††: 20 mg/g 
Metals Scavenged†: Co, Cu, 
Ni, Pd, Rh 
Biotage MP-TNT Aminomethyl Polystyrene QudraSil MP 
 
  
Macroporous Resin 
Loading: 0.66 mmol/g 
Metals Scavenged†: Pd and 
other heavy metals 
Electrophile Scavenger 
Loading: 4.0 mmol/g 
Metals Scavenged†: - 
Mesooporous Resin 
Loading: 1.2 mmol/g 
Metals Scavenged†: Cu, Ni, 
Pd, Rh, Ru, Pt, Ag 
Table 2.8 Functionalised resins that were investigated for their metal catalysts and 
electrophile scavenging capabilities. †Metals scavenged according to manufacturer’s specification 
guidelines. †† Manufacturer’s stated loaded presumed as 20 mg of benzylamine per 1 g of resin. 
 
2.3.1  Scavenging of Michael Acceptors 
To establish the electrophile scavenging capabilities of the chosen resins 
(Table 2.8), a series of Michael acceptors with a range of electrophilicities was 
chosen (Figure 2.5). The aim was to identify the resin best able to scavenge 
the most electrophilic Michael acceptors, which would then be tested for its 
metal scavenging capabilities. Cinnamyl alcohol is a control substrate not 
expected to be scavenged, and substrates 68 and 70 are C-H functionalisation 
reaction products. Product 70 is not a Michael acceptor and not expected to 
be scavenged. The Quadrapure resins are macroporous and therefore non-
swell resins, which are capable of scavenging in all organic solvents (see 
manufacturers guidelines). Deuterated chloroform was therefore selected for 
the scavenging study.   
 
 
 
 
- 45 - 
 
Cinnamaldehyde 
 
 
Crotonaldehyde 
 
3-Methyl 
crotonaldehyde 
 
3-Methyl- 
3-pent-2one 
 
1,4-Benzoquinone 
 
2-Cyclohexen-1-
one 
 
Methyl tiglate 
 
nButyl acrylate 
(32) Benzyl acrylate 
 
Methyl cinnamate 
 
N,N-Dimethyl 
acrylamide 
 
 N-Isopropyl 
acrylamide 
 
N-Phenyl 
acrylamide 
 
Phenyl  
vinyl sulphone Testosterone 
 
 
Cinnamyl alcohol 
 
70 
 
 
68 
 
 
 
Internal Standard: 
2,3,5-Trichloro-
methoxybenzene 
Figure 2.5 Michael acceptors, with a broad range of electrophilicities, that were tested with a 
range of resins (Table 2.8) to determine which of the Michael acceptors could be scavenged 
with the resins. 2,3,5-trichloromethoxybenzene was the internal standard used in the NMR 
studies to quantify the amount of electrophile scavenged.  
 
A 1H NMR spectroscopy (300 MHz) study was performed to determine 
the scavenging capabilities of the chosen resins with the range of Michael 
acceptors. Initially, a 1H NMR spectrum for each of the Michael acceptors 
(0.03 mmol/mL of CDCl3) was recorded with the addition of the internal 
standard 2,3,5-trichloro-methoxybenzene (0.03 mmol/mL). 2-3 eq. of each of 
the resins was then incubated with each of the Michael acceptors at room 
temperature for 24 h. After 24 h a second 1H NMR spectrum was recorded. 
The peaks of the Michael acceptor before and after scavenging were set 
relative to the standard, and the difference in relative integrations between the 
two spectra was used to determine the amount of Michael acceptor 
scavenged (nearest 5%, Table 2.9). The Quadrapure DET and MPA resins 
were subsequently discontinued by the supplier and so results are not shown.  
The results from the 1H NMR data (Table 2.9) show that the Biotage MP-
TMT and QuadraSil MP resins were only able to partially scavenge a small 
range of the Michael acceptors. The Aminomethyl PS and QuadraPure BzA 
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have a stronger correlation in their capability to scavenge more electrophilic 
Michael acceptors. They were both able to scavenge the majority of the -
unstaurated aldehydes and ketones with greater than 95% effectiveness (with 
exception of 3-methyl-3-pent-2-one). Quadrapure BzA was better able to 
scavenge less electrophilic Michael acceptors, compared to the aminomethyl 
PS resin, however left non-Michael acceptor substrates, such as cinnamyl 
alcohol and product 70 unscavenged. The Michael acceptor-containing 
product 68, was left mostly unscavenged too (5%), which is ideal for the 
reaction arrays. The results demonstrated that Quadrapure BzA is able to 
remove highly electrophilic reaction substrates from reaction mixtures, but will 
not scavenge potential products formed in C-H functionalisation arrays, 
allowing the products to be screened in the biological assay. Quadrapure BzA 
was subsequently tested for its ability to scavenged metal catalysts from 
solution (Section 2.3.2).
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Resin Biotage MP-TMT 
 
% of MA removed 
QuadraSil MP 
 
 
% of MA removed 
Aminomethyl PS 
 
 
% of MA removed 
QuadraPure BzA 
 
% of MA removed 
Michael Acceptor 
Phenyl vinyl sulphone 25 10 75 >95 
Cinnamaldehyde <5 40 95 >95 
Crotonaldehyde 25 70 >95 >95 
3-Methyl crotonaldehyde 5 85 >95 >95 
3-Methyl-3-pent-2-one <5 50 <5 <5 
1,4-Benzoqinone 95 85 >95 >95 
2-Cyclohexen-1-one 50 >95 55 90 
Benzyl acrylate 20 20 25 75 
nButyl acrylate, 32 <5 5 <5 35 
Methyl tiglate 25 30 25 25 
Methyl cinnamate <5 5 <5 <5 
N-Phenylacrylamide 20 45 10 70 
N-Isopropylacrylamide <5 35 <5 <5 
N,N-Dimethylacrylamide 30 55 15 20 
Cinnamyl alcohol 5 55 <5 10 
Testosterone 10 45 5 >95 
70 <5 <5 <5 <5 
68 <5 40 10 5 
Table 2.9 Scavenging capabilities of the resins against a range of Michael acceptors. Values shows the percentage of Michael acceptor scavenged as 
determined by 1H NMR (300 MHz) spectroscopy, which were calculated to the nearest 5% by determining the difference in integrations of unscavenged 
scavenged mixtures relative to an internal standard (2,3,5-Trichloro-methoxybenzene). 
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2.3.2  Scavenging of Metal Catalysts 
Studies into the ability to scavenge metal catalysts from solution were 
conducted, to ensure catalysts could be removed from reaction mixtures to 
minimise any interference against the biological target in the assay. Stock 
solutions at the desired reaction array concentrations were prepared for each 
of the metal catalysts to be implemented in the reaction arrays (5 mM of 
Pd(OAc)2, [Ru(p-Cymene)Cl2]2, [RhCP*Cl2]2 and [IrCp*Cl2]2 and 50 mM of 
Cu(OAc)2). 100 L samples of the catalyst mixtures were scavenged with 
increasing amounts of the Quadrapure BzA resin (0 mg, 10 mg, 20 mg, 30 mg 
and 40 mg) for 24 hours. After 24 hours there was a visible reduction in colour 
(coloured → colourless) for all the metal catalyst solutions scavenged with the 
different amounts of resin, and a visible increase, of the catalyst colour on the 
Quadrapure BzA resin. However, subsequent Atomic Absorption 
Spectroscopy (AAS), to quantitatively measure the metal content of the 
unscavenged and scavenged catalyst solutions, proved difficult due to the 
small sample size (scale up to ensure enough sample (10 mL) for AAS studies 
would prove impractical).  
To establish whether residual catalyst from the reaction mixtures 
interfered in the assay, scavenged reaction mixtures were screened as 
controls (see Appendix B) and there was no observed interference against the 
biological target. The Quadrapure BzA resin was shown to successfully 
scavenge strong electrophiles and metal catalysts from reaction mixtures, 
providing a simple and reliable post reaction work-up protocol to implement in 
the reaction arrays.  
 
2.3.3  Evaluation of Scavenging Protocol for Crude C-H 
Functionalisation reaction mixtures 
To further validate the QuadraPure BzA resin as a simple and efficient 
work-up procedure to implement in parallel plate-based reaction arrays, the 
resin was tested on an example literature reaction, (Entry 2, Table 2.1), which 
contained multiple electrophiles, from the starting material, additive and 
product, and the metal catalyst. The reaction was performed in 5 x 100 L 
aliquots under ADS-conditions with 100 mM of substrate 67, 200 mM of 
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substrate 32, 50 mM benzoquinone and TsOH and 5 mM of Pd(OAc)2 in 
CDCl3. The reaction was left for 24 h, and a 1H NMR (300 MHz) spectrum of 
one of the aliquots, including the internal standard 2,3,5-trichloro-
methoxybenzene, was recorded. To each of the four remaining reaction 
aliquots, was added 10, 20, 30 and 40 mg of Quadrapure BzA resin 
respectively. The resin was left to incubate with the reaction mixture for 24 h, 
and then a 1H NMR (300 MHz) of each of the aliquots was recorded, including 
the internal standard. The product mixture peaks were integrated relative to 
the standard peaks, and used to quantify the amount of each reaction 
component scavenged with the increasing amount of resin (1H NMR (300 
MHz) spectra for each aliquot after scavenging is shown in Figure 2.6).  
In the presence of 10 mg of QuadraPure BzA resin (Figure 2.6b), >95% 
of the benzoquinone and 50% of the unreacted nbutyl acrylate 32 were 
scavenged from the reaction mixture after 24 h. With 20 mg (Figure 2.6c) the 
amount of nbutyl acrylate 32 scavenged increased to 90% and with 30 mg 
(Figure 2.6d) this amount increased to >95% as well a small amount (10%) of 
the reaction product 68. When the amount of resin was increased to 40 mg, 
both the benzoquinone and nbutyl acrylate were completely scavenged, with 
just 25% of the reaction product 68 scavenged (Figure 2.6e).  
This demonstrated the ability of Quadrature BzA to scavenge highly 
electrophilic Michael acceptors, while leaving reaction products unscavenged. 
The resin was also demonstrated to successfully scavenge a range of metal 
catalysts used in C-H functionalisation to a level where no assay interference 
was observed (Chapter 4). The use of 30 mg of Quadrapure BzA as a parallel 
reaction array work-up procedure in C-H functionalisation reaction arrays, will 
provide an efficient step in the ADS work flow, prior to screening in the 
biological assay. 
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Internal Standard 
% Scavenged 
a)  0 mg of BzA Resin 
BQ:  
32:  
68:  
 
b)  10 mg of BzA Resin 
BQ: > 95 
32: 50 
68: 0 
 
c)  20 mg of BzA Resin 
BQ: > 95 
32: 90 
68: 0 
 
d)  30 mg of BzA Resin 
BQ: > 95 
32: >95 
68: 10 
 
e)  40 mg of BzA Resin 
BQ: >95 
32: >95 
68: 25 
 
Figure 2.6 Capability of Quadraupre BzA resin to scavenge an exemplar C-H 
alkenylation reaction (100 L reactions with 100mM 67, 200mM 32, 50 mM BQ and 
TsOH and 5 mM Pd(OAc)2). 1H-NMR (300 MHz) spectra recorded A) before 
scavenging (reference spectrum) and after scavenging for 24 h with  b) 10 mg of resin, 
c) 20 mg of resin, d) 30 mg of resin and e) 40 mg of resin.  
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2.4  Summary 
A vast range of C-H functionalisation reactions has been reported over 
the past few decades, which have the potential to transform synthetic 
strategies for chemists, by enabling new disconnections to be made. The 
ability to elaborate fragments along any C-H vector with C-H functionalisation 
chemistry has the potential to greatly enhance fragment-to-lead studies. It was 
proposed the use of C-H functionalisation in Activity-Directed Synthesis would 
enable fragment-to-lead studies to be conducted in a structure-blind and 
function-driven manner. 
A range of reported C-H functionalisation reactions was repeated in flask 
and plate-based formats, to configure the chemistry for use in plate-based 
microscale reactions arrays. The study demonstrated that a range of reaction 
types (C-H alkenylations, aminations and arylations) could be reproduced in 
plates without stirring. Parallel heating technology for microscale reaction 
arrays was also established to enhance the range of chemistries and 
substrates used in ADS.  
An efficient post reaction work-up procedure for parallel chemistry was 
established, with the use of 30 mg of Quadrapure BzA to scavenge metal 
catalysts and strong electrophiles. With the simple and efficient workflow for 
ADS established, C-H functionalisation reaction arrays can be performed 
under ADS conditions, scavenged, filtered and crude mixture screened 
against the biological target of interest.  
The configuration of a range of mild C-H functionalisation chemistry at room 
and elevated temperatures in parallel-array format and the establishment of a 
operationally simple procedure for scavenging metal catalysts and Michael 
acceptors from crude reaction array mixtures has ensured a streamlined and 
efficient workflow. The established procedures can be exploited to potentially 
enable the structure-blind and function-driven identification of productive 
fragment elaboration vectors in ADS. 
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Chapter 3. 
Configuration of a High-throughput Assay and Identification 
of Fragments for Hsp90 
Hsp90 (Heat shock protein 90) is a molecular chaperone that has been 
linked to diseases such as Alzheimer’s, cystic fibrosis and cancer, prompting 
the development of chemical inhibitors of the ATP-binding (N-terminal) 
domain of Hsp90.108–110 Numerous chemical ligands have been reported from 
drug discovery programmes, many of which have been discovered via 
fragment-based workflows.111–116 It was proposed the fragment and ligand 
chemical matter for Hsp90 would provide strong starting points for fragment 
elaboration strategies with C-H functionalisation chemistry in activity-directed 
synthesis. An overview of the biology, high-throughput assay and known 
chemical matter of Hsp90 is given. The design and synthesis of fragments 
which have the potential for elaboration with C-H functionalisation chemistry 
is discussed. A high-throughput fluorescence anisotropy assay for Hsp90 was 
established,80 to screen and aid the selection of weakly binding fragments that 
could provide starting points for activity-directed fragment elaboration.   
3.1  Biology of Hsp90 
Hsp90 is a molecular chaperone that ensures eukaryotes maintain 
homeostasis under physiological changes, by maintaining the integrity of the 
cellular protein network (proteostasis).110,117 Molecular chaperones are 
proteins that form reversible complexes with other protein substrates (clients), 
inducing the adoption of a client proteins active conformation. Hsp90 
machinery is essential under stress conditions, such as an increase in 
temperature (heat shock)118 and has also been found to play important roles 
under physiological conditions, for example, in the signalling of steroid 
hormone receptors.119  
 
3.1.1  The Structure and Function of Hsp90 
Hsp90 is a central component of eukaryotic cellular machinery and has 
hundreds of client proteins, which bind reversibly to Hsp90.120 Hsp90 controls 
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the function and activity of its client proteins by facilitating protein folding, 
client-substrate binding and the assembly of multiprotein complexes (Figure 
3.1 ai). Hsp90, through the binding to client proteins, is consequently involved 
in many cellular processes; DNA repair, cellular development, immune 
response and neurodegenerative disease.110,120  
Hsp90 functions as a homodimer, in which each monomer consists of 
three highly conserved domains. The amino terminal domain (NTD), 
responsible for ATP binding,121 the middle domain (MD), which is important 
for ATP hydrolysis and the binding of client proteins and the carboxy terminal 
domain (CTD) which is responsible for dimerisation (Figure 3.1 ai-iii).122 The 
NTD and MD are connected by a flexible charged linker that helps mediate 
Hsp90 function.123 Dimerisation of Hsp90 is essential for its in vivo 
function.124,125 In the absence of ATP, Hsp90 adopts an open V-shaped 
conformation (Figure 3.1b).126 ATP binding induces large conformational 
changes, which results in an NTD-closed state. For ATP hydrolysis to occur, 
the ATP-binding site of the NTD must interact with the MD. The NTD has low 
ATPase activity, Kd for ATP is approximately 400 M, with a hydrolysis 
turnover in human Hsp90 of 0.1 min-1.121 Following ATP hydrolysis, ADP and 
inorganic phosphate (Pi) are released and Hsp90 readopts its open conformer 
(Figure 3.1b).  
Hsp90 function is regulated by expression, post-translational 
modifications and interactions with co-chaperones (non-client proteins) and 
clients.110,127 The expression of Hsp90 is induced by the stress-related 
transcription factor Heat-Shock Factor 1 (HSF1).127,128 Hsp90, along with co-
chaperone Hsp70, bind to HSF1 to keep it in its inactive state.129 When co-
chaperone proteins are needed for other functions and are unbale to bind to 
HSF1 to keep it in its inactive state, the expression of Hsp90 increases. Post-
translational modifications, including phosphorylation, SUMOylation, 
acetylation and S-nitrosylation, modulate Hsp90 function, by altering the 
accessibility at binding sites.130 Phosphorylation slows down the 
conformational cycle, affects client maturation and the interaction with co-
chaperones.131,132 
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Figure 3.1 Function and structure of Hsp90 (PDB ID: 2CG9, Saccharomyces cerevisiae) 
ai) Functions of Hsp90  aii) Hsp90 Monomer with ATP (red) bound to the N-terminal domain 
(NTD) ii) Hsp90 dimer: NTD (dark blue) linked to middle domain (Large and small central 
blue sections) and C-terminal domain (CTD – Light purple). b) Conformation cycle of 
Hsp90.110 
 
Co-chaperones are non-client proteins that interact with chaperones and 
assist with the folding and activation of a chaperones client proteins.110 Co-
chaperones are the key regulators of Hsp90 and their binding sites have been 
identified in all three binding domains of Hsp90. Some co-chaperones are 
modulators of Hsp90s conformational cycle and others assist with client 
recruitment.133 The co-chaperone p23, for example, binds to the NTD and MD 
of Hsp90 and inhibits ATPase activity and stabilises the closed state of 
Hsp90.134 
Hsp90 has hundreds of client proteins, making it central to many cellular 
processes.120 The identification of client binding sites is challenging, due to 
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the large size and dynamic nature of Hsp90-client complexes making 
crystallisation and NMR studies difficult. However, analysis of Hsp90-client 
complexes revealed 60% of the humane kinome and 30% of human E3 
ubiquitin ligases associate with Hsp90.135 Example client proteins include the 
tumour suppressor p53 which binds to all three domains of human Hsp90136 
and the Alzheimer disease related protein tau, which has been shown to bind 
to a large surface between the NTD and MD of Hsp90137 (Hsp90 and 
Hsp90 are the two prominent functional isoforms found in the cytosol). 
 
3.1.2  Heat Shock Protein 90 and Disease 
Hsp90 has been implicated in various diseases and the role it plays in 
each disease varies.110 Given Hsp90 is upregulated under changes to 
physiological conditions, it plays a key role in the survival of tumour cells which 
are under stress-conditions due to the presence of mutant proteins and rapid 
proliferation.138 Indeed, increased levels of Hsp90 are found in tumour cells. 
Many of Hsp90s clients are involved in the progression of tumour growth, for 
example, tumour suppressor p53, telomerase and hypoxia-inducible factor 1 
(HIF1). Inhibition of Hsp90 disrupts multiple signalling cascades responsible 
for oncogenic progression. Given higher expression of Hsp90 in tumour cells, 
tumour cell Hsp90 has a higher affinity for chemical inhibitors than normal 
somatic cells.139,140  
Other Hsp90 clients include the fibril- and plaque-forming protein 
amyloid-β (Aβ) and the hyperphosphorylated tau protein, which are implicated 
in Alzheimer’s disease.141 Inhibition of Hsp90 reduces the activity of kinases 
that phosphorylate tau, reducing aggregation.142 Hsp90 has also been 
associated with diseases that include cystic fibrosis143 and in viral144 and 
protozoan145 infections. The development of chemical inhibitors of Hsp90 
offers an attractive potential to treat a wide range of diseases, due to its 
interaction and complexation with a large number of client proteins.  
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3.1.3  Chemical Inhibitors of the N-Terminal Domain of Heat 
Shock Protein 90 
Chemical inhibition of the ATPase function of the NTD of Hsp90 is an 
attractive target in medicinal chemistry programmes, due to the many clients 
and subsequent related diseases of Hsp90. The development of chemical 
inhibitors of Hsp90 gained huge interest following the discovery that 
geldanamycin and radicicol were natural product inhibitors of Hsp90(NTD) 
(Figure 3.2a).109,146 
Inhibition of Hsp90 with geldanamycin, a naturally occurring 
benzoquinone annamycin, isolated from Streptomyces hygroscopicus,109 was 
shown to reduce cancer cell growth and depleted oncogenic proteins.147 
Despite its anticancer properties, geldanamycin failed to significantly progress 
through clinical trials due to its poor solubility and high toxicity. To address 
such issues with solubility and toxicity, various synthetic analogues have been 
reported which have subsequently entered clinical trials. 17-AGG (not shown), 
for example, is a geldanamycin analogue in which the 17-methoxy 
(benzoquinone methoxy) was replaced with an allylamino group, which 
entered phase I clinical trials; however, again failed to progress due to poor 
solubility.109,148 Due to either poor solubility, toxicity or efficacy there are 
currently no synthetic analogues of geldanamycin undergoing clinical 
assessment.109  
 Radicicol is a macrocyclic lactone, isolated from Monosporium 
bonorden, which binds to Hsp90(NTD).149 However, radicicol undergoes rapid 
metabolism in vivo and therefore shows no antitumor activitiy.150 Several 
synthetic analogues have been developed, e.g. Onalespib111,112 (AT13387) 
and NVP-AUY922115,151 (Figure 3.2b), in which the resorcinol ring mimics the 
adenine ring of ATP, and is required for inhibition.109 Indeed, the resorcinol 
ring is found in a wide range of chemical inhibitors and its binding mode is 
conserved in the crustal structures with Hsp90(NTD). NVP-AUY922 was 
discovered by Vernalis in a fragment-based discovery programme, which 
identified fragment 86 (Figure 3.4a, PDB: 2YE2) from a combination of 
fragment and in silico screening techniques.115 Fragment 86 was 
subsequently confirmed as a hit through NMR experiments. Elaboration of 86 
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(IC50: 1 mM) through structure-guided design lead to the discovery of NVP-
AUY922 which is nanomolar inhibitor (IC50: 9 nM) of the Hsp90(NTD). NVP-
AUY922 is currently undergoing clinical assessment for the treatment of stage 
IV non-small cell lung cancer.  
 
Figure 3.2 Overview of Hsp90(NTD) inhibitors a) Natural product (inspired) inhibitors of 
Hsp90(NTD): Geldanamycin, Radicicol and PU3 have high affinity for Hsp90(NTD), 
however failed in clinical trials due to high toxicity. Geldanamycin bound to Hsp90(NTD) 
PDB: 1YET b) Synthetic inhibitors of Hsp90(NTD) PU-H71, Onalespib, NVP-AUY922 and 
SNX-2112. Onalespib bound to Hsp90(NTD), PDB: 2XJX and SNX-2112 bound to 
Hsp90(NTD), PDB: 6CJR.   
 
 Onalespib 85 (Figure 3.2) was also discovered during a fragment-
based discovery programme by Astex pharmaceuticals.112 Fragment 81 
(Figure 3.3 and Figure 3.4, PDB: 2XDL) was identified in a fragment screen 
using ligand-observed NMR. Fragment 81 was determined to have a 
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dissociation constant of 790 M via isothermal calorimetry and was subjected 
to structure-guided optimisation, to yield 84 (Kd: 0.54 nM, LE: 0.57) as a lead 
compound (Figure 3.3). Subsequent optimisation identified clinical candidate 
Onalespib 85 (Kd: 0.71 nM, LE: 0.42),111 which is currently undergoing clinical 
assessment against BRAF-mutant melanoma in combination with Dabrafenib 
and Trametinib.  
 
Figure 3.3 Development of Onalespib 85 from fragment 81 in fragment-to-lead optimisation 
study by Astex pharmaceuticals.112 
 
Another class of chemical inhibitors include purine-based ligands, such 
as PU3 and PU-H71 (Figure 3.2), which were designed to mimic the binding 
mode of ADP to Hsp90.152 PU-H71 is currently undergoing clinical 
assessment for the treatment of advanced malignancies and in combination 
with Nab-placlitaxel for the treatment of metastatic breast cancer. SNX-2112 
(Figure 3.2) is a chemical inhibitor discovered be Serenex in a fragment-based 
approach,111 in which the indazolone 2-aminobenzamide core mimics the ADP 
adenine core and is currently undergoing efficacy and safety assessment in 
combination with Ibrutinib.  
3.2  Design and Synthesis of Hsp90 Fragments for Activity-
Directed Synthesis 
Hsp90 has been well studied as druggable target and there have been 
many chemical ligands (clinical candidates, lead-like ligands and fragments) 
which have been developed and reported. For this reason, along with the 
reported high-throughput fluorescence anisotropy assay (Section 3.3), it was 
proposed Hsp90 would make a tractable target for demonstrating C-H 
functionalisation as a potential methodology for elaborating fragments using 
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activity-directed synthesis. The fragments were designed to include at least 
one potential directing group for C-H functionalisation.  
 
3.2.1  Design of Hsp90(NTD) Fragments for elaboration with C-H 
Functionalisation chemistry 
For the evaluation of C-H functionalisation as a fragment elaboration 
strategy in activity-directed synthesis, a set of  Hsp90 fragments was designed 
and then either purchased or synthesised to enable their biological evaluation 
and subsequent implementation in ADS. Fragments 81 and 86-92 have been 
reported as inhibitors (~10 M – 5 mM affinities) of Hsp90 and have the 
potential to undergo C-H functionalisation reactions (Figure 3.4).112,113,115,116 
Assessment of the crystal structures of fragments 81, 87, 89 and 92, revealed 
potentially productive C-H vectors within the fragments which would 
potentially be accessible synthetically due to their proximity to a directing 
group, e.g. C-H functionalisation ortho to the ketone directing group of 
fragment 87. C-H functionalisation along the identified vectors has the 
potential to enhance the activity of the fragments by establishing new 
hydrogen-bonding and hydrophobic interactions with the target. A further 21 
fragments (93-97, 99, 101 and 103-116, Figure 3.8) were designed based on 
these eight published fragments and through deconstruction of known Hsp90 
ligands to identify new potential Hsp90 fragments. The rationale for the design 
of the 29 fragments is outlined below.  
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Figure 3.4 a) Known Hsp90(NTD) fragments 81, 86-92 chosen for potential implementation 
in ADS based on their possibility to undergo C-H functionalisation elaboration. b) Crystal 
structures show fragments 87 (PDB: 2YE4), 89 (PDB: 2YE2), 81 (PDB: 2XDL) and 92 
(PDB: 4L94, no reported affinity) bound to Hsp90(NTD). c) Potential synthetically tractable 
C-H vectors for elaboration of fragments 87, 89, 81 and 92 with C-H functionalisation 
chemistry (blue arrows indicate potential C-H functionalisation elaboration 
vectors).112,113,115,116  
  
Fragments 93-97 were designed based on published fragments 86-89 
and 92 respectively, by removal of one of the hydroxyl groups from the aryl 
ring (Figure 3.5a). As discussed, the published fragments binding modes offer 
the potential to productively elaborate the fragments using C-H 
functionalisation chemistry (Figure 3.4). However, it was proposed hydroxy 
groups within phenol/resorcinol substrates may potentially dominate reactivity 
under C-H functionalisation conditions and, as discussed in chapter 2, 
substituents meta to a directing group can inhibit reaction at the ortho-
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positions. Therefore, removal of one hydroxyl group may enable the fragments 
to maintain key hydrogen bonds to Hsp90 but enables greater synthetic 
accessibility, as well as the potential to select a series of phenol/resorcinol 
fragments with similar Hsp90(NTD) affinities.  
 
 
Figure 3.5 Fragments 93-97, 99, 101 and 103 were designed from known Hsp90(NTD) 
fragments on the basis of their potential to undergo C-H Functionalisation in ADS (Blue 
arrow indicates potential C-H functionalisation elaboration vectors).112,113,115 
 
Fragments 99 and 101 were designed from reported fragments 98 and 
100 respectively (Figure 3.5b).113,115 Again, hydroxyl substituents of 98 were 
removed to give 100, for reasons previously discussed, and was chosen due 
to the potential of the benzamide 100 to direct C-H functionalisation onto the 
ortho-positions of both aryl rings. The naphthalene ring of 100 was changed 
to a benzene ring to reduce the lipophilicity of the fragment and was chosen 
on the basis heteroaryl rings can direct C-H functionalisation onto the ortho 
position of an adjacent aryl ring. Finally, fragment 103 was designed from 
fragment 102 by moving the nitrogen of the pyridine ring one position on the 
ring, to enable both heteroaryl rings to direct C-H functionalisation onto the 
ortho-position of the adjacent aryl ring (Figure 3.5c).112 Analysis of the crystal 
structure of 102 bound to Hsp90(NTD) shows the nitrogen of the pyridine does 
not make a hydrogen-bonding interaction and so moving it one position in the 
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ring was not expected to prove detrimental to binding but enable synthetic 
accessibility to both aryl rings with C-H functionalisation chemistry.  
 Fragments 104-110 (Figure 3.6) were designed from fragments 81 and 
90 (Figure 3.6, which is an optimised fragment reported in the discovery of 
Onalespib).112 The 4-hydroxy and 3-methoxy of 81 make key hydrogen 
bonding interactions with Hsp90(NTD) (Figure 3.4) however, the possibility of 
removing and/or swapping the 4-hydroxy to a methoxy was explored, again to 
minimise the potential of the hydroxyl to dominate reactivity under C-H 
functionalisation conditions. The amide group was also varied to include 
secondary and tertiary amides to enable this potential directing group to match 
to literature C-H functionalisation reactions (Chapter 2).  
 
 
Figure 3.6 Fragments 104-110 were designed by analysis of known Hsp90(NTD) 
fragments 81 and 90 on the basis of their potential to undergo C-H functionalisation in 
ADS.112 
 
Finally, a series of fragments was designed by deconstructing known 
Hsp90 ligands to identify core fragments which have the potential to undergo 
C-H functionalisation reactions. Deconstruction of AUY922-Lead and AUY922 
itself revealed two potential fragments 111 and 112 which have the potential 
to undergo C-H functionalisation chemistry along vectors that look promising 
for productive fragment elaboration (Figure 3.7a). The fragment 112 contains 
and amide directing group which can direct C-H functionalisation onto the aryl 
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ring, and 111 contains a heteroaryl ring which can direct C-H functionalisation 
onto the adjacent ring.  
Deconstruction of clinical candidate SNX-2112 revealed two core 
fragment structures, 113 and 114-116 which have the potential to undergo C-
H functionalisation (Figure 3.7b). Both core fragments possess amide 
directing groups to direct ortho C-H functionalisation, with fragments 114-116 
containing a heteroaryl to direct C-H functionalisation onto the adjacent aryl 
ring. Fragments 114-116 was deigned to incorporate primary and secondary 
amide directing groups to align with previously established C-H 
functionalisation reactions (Chapter 2).  
 
Figure 3.7 Fragments 111-116 were designed by deconstructing known Hsp90(NTD) 
ligands on the basis of their potential to undergo C-H functionalisation in ADS (Blue arrow 
indicates potential C-H functionalisation elaboration vectors). 
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3.2.2  Synthesis of Hsp90(NTD) Fragments 
A total of 29 fragments (Figure 3.8) was designed, from known fragments 
and ligands of Hsp90(NTD), which have the potential (i.e. suitable directing 
groups) to undergo C-H functionalisation elaboration chemistry. Of the 29 
fragments, fragments 81, 86-89, 92-96, 99, 103 and 111  were commercially 
available and hence purchased (green, Figure 3.8). The remaining 16 
fragments required synthesis (red, Figure 3.8), and their syntheses are 
described below.  
 
Figure 3.8 Designed Hsp90(NTD) fragments for their potential to undergo synthetic 
elaboration in ADS using C-H functionalisation chemistry. a) Reported Hsp90(NTD) 
fragments from FBDD programmes. b) Fragments designed from reported fragments and 
have the potential to undergo C-H functionalisation elaboration. c) Fragments designed 
from reported ligands and have the potential to undergo C-H functionalisation elaboration. 
Design rationale is discussed in main text. Green fragments were commercially available 
and red fragments required synthesis (Section3.2.2).  
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Fragments 90 and 104 were prepared via the same synthetic route in 
four steps, from commercially available 2-isopropylphenol 117 (Scheme 3.1). 
The phenol 117 was first protected as the triisopropyl silyl (TIPS) ether 118, 
by reaction with TIPS-Cl in the presence of imidazole in good yield (74%). 
Subsequent bromination with N-bromosuccinimide resulted in the 
monobrominated silyl ether 119 after 3 h, also in good yield (81%). 
Bromination was electronically directed para to the oxygen substituent and 
ortho-bromination was not observed presumably due to the steric bulk of the 
silyl protecting group. The bromide 119 underwent lithium-halogen exchange 
upon treatment with butyl lithium. The resulting aryl-lithium species was 
subsequently trapped with the appropriate dialkyl carbomoyl chloride to yield 
120 (40%) and 121 (44%). Deprotection of the silyl ether by treatment with KF 
afforded 104 in poor yield (12%) and 90 in modest yield (27%). Despite the 
modest yields, both fragments were readily accessible in four steps.  
 
 
Scheme 3.1 Synthesis of fragments 90 and 104  from 2-isopropylphenol 117. 
 
 
Fragment 91 was prepared via a known synthetic route in two steps 
(Scheme 3.2).153 Condensation of -butyrolactone 122 with ethyl formate 123 
in the presence of strong base (NaH) gave sodium salt 124 in very good yield 
(98%), which upon treatment with aniline hydrochloride in methanol produced 
the desired enaminolactone 91 in good yield (73%). As hypothesised in the 
reported methodology paper the use of polar solvent promotes formation of 
the E-isomer and 1H and 13C NMR data was identical to that previously 
reported. There was no observed correlation in the NOESY spectrum between 
the alkene C-H and the CH2 at the 4-position of the oxolanone ring, supporting 
the formation of the E-isomer.  
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Scheme 3.2 Synthesis of fragment 91 from -butyrolactone 122 and ethyl formate 123.153  
 
Fragment 101 was prepared from a known literature procedure in a 
single step (Scheme 3.3).154 Reaction of 2-bromobenzonitrile 125 with 
cyanoguanidine 126 in the presence of potassium hydroxide gave 101 (85%).  
 
Scheme 3.3 Synthesis of fragment 101 from 2-bromobenzonitrile and cyanoguanidine.154  
 
 Fragment 113 was prepared via a two-step synthesis (Scheme 3.4). In 
the first step a palladium-catalysed Buchwald-Hartwig coupling of 2-
bromobenoznitrile 125 with cyclohexylamine 71 gave 127 in 72% yield. The 
reaction proceeded under microwave irradiation with a dry and inert (N2) 
atmosphere. Hydrolysis of the cyano group of 127 with potassium tertbutoxide 
and dry tert-butanol to the primary benzamide gave 113 in 58% yield 
(nucleophilic attack of the tertbutoxide into the nitrile and then addition of H2O 
in the work up ensures hydrolysis to the primary amide).  
  
 
Scheme 3.4 Synthesis of fragment 113. 
 
Finally, fragments 97, 105-110, 112 and 114-116 were prepared via a 
series of amide coupling reactions from either the appropriate benzoic acids 
or benzoyl chlorides (Scheme 3.5). Benzamides were prepared from benzoic 
acids with two equivalents of amine in the presence of the coupling agent 
TBTU and DIPEA, with yields ranging from 48% to 89%. Fragments 114 and 
97 were prepared from their benzoyl chlorides in 55% and 90% yields 
respectively.  
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Scheme 3.5 Synthesis of fragments 105-110, 112, 115 and 116  via amide coupling from 
the appropriate benzoic acids and synthesis of 97 and 114 via amide coupling from the 
appropriate benzoyl chlorides.  
  
A total of 29 fragments was successfully prepared or purchased, which 
were designed, from known fragments and ligands of Hsp90, to incorporate 
at least one potential directing group for C-H functionalisation chemistry. The 
fragments were subsequently screened to enable hits to be identified (Section 
3.4).  
3.3  Configuration of High-throughput Assay for Heat Shock 
Protein 90 
3.3.1  Hsp90(NTD) Fluorescence Anisotropy Assay 
Anisotropy is a molecular property that demonstrates the interaction of a 
fluorescent molecule (tracer) with plane polarised light.155 The tracer is excited 
with light that is linearly polarised (Figure 3.7). The subsequent emitted 
polarised fluorescence is measured, at a given time, parallel and 
perpendicular to the plane of polarisation of the excitation light. The difference 
in intensities of the parallel and perpendicular emitted light arises from how 
quickly the tracer tumbles in solution, relative to the fluorescence lifetime of 
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the fluorophore. When the tracer molecule is free in solution, it tumbles very 
quickly and so when excited with plane polarised light, the emitted light is 
random with respect to the plane of polarisation (polarisation is small).  When 
the tracer becomes tightly bound to a larger molecule e.g. its protein target, 
the rate the tracer tumbles is much slower and so when excited with plane-
polarised light, the light emitted is also polarised (the observed polarisation is 
large), (Figure 3.9). Anisotropy can be used to determine the dissociation 
constant (Kd) of the fluorescent tracer, which in turn can be used to determine 
the affinity of unlabelled molecules using competition experiments.  
 
 
Figure 3.9 Principles of fluorescence anisotropy assay used to determine the dissociation 
constants of labelled and unlabelled compounds for a protein (illustrated with Hsp90). The 
tracer is BODIPY-labelled geldanamycin. When the tracer is free in solution (not bound to 
Hsp90(NTD)) the observed polarisation is small, when the tracer is bound to Hsp90(NTD) 
the observed polarisation is large.  
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3.3.2  Synthesis of Fluorescence Anisotropy Tracer: BODIPY-
labelled Geldanamycin 
The fluorescence anisotropy assay required the use of a fluorescently 
labelled ligand (tracer) in order to measure IC50 (and Ki) values of unlabelled 
compounds that interact with Hsp90(NTD). Established fluorescence 
polarisation (anisotropy) assays for Hsp90(NTD) report the use of 
geldanamycin labelled with a BODIPY fluorophore (BODIPY-GM) as the 
tracer.80 BODIPY-GM 130 was prepared in a single step via Michael reaction 
of geldanamycin 128 with 4,4-difuoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene-3-propionylethylene-diamine hydrochloride 129 in the presence of 
diisopropylamine in excellent yield (86%).156 DMSO stocks of the tracer were 
prepared, at a concentration of 190 M, which was determined using the Beer-
Lambert law from the measured absorbance and the fluorophore molecular 
extinction coefficient (79000 ± 6000 cm-1). The Kd of the tracer for Hsp90(NTD) 
was subsequently determined as described in Section 3.3.4.  
 
 
Scheme 3.6 Synthesis of fluorescence anisotropy tracer, BODIPY-labelled Geldanamycin  
 
3.3.3  Hsp90(NTD) Protein Expression 
The plasmid containing the gene for His6-tagged N-terminal Hsp90, 
residues D9-E236, (His6-Hsp90(NTD)) was transformed in E. Coli and cells 
were grown, harvested and purified (Ni-affinity and size-exclusion 
chromatography), as described (see experimental). The purified protein was 
stored in a sodium phosphate buffer (NaPi) and analysed by SDS PAGE 
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(Figure 3.10) and HRMS (expected mass from amino acid sequence: 27791 
Da, HRMS found: 27791 Da) to confirm protein expression and purity.  
 
Figure 3.10 SDS PAGE analysis for purification of Hsp90(NTD) by Ni-chromatography and 
size-exclusion chromatography. (S/N = supernatant, the cell lysate pellet was the 
centrifuged pellet after cells has been lysed and supernatant decanted).  
 
3.3.4  Configuration of Fluorescence Anisotropy Assay 
Following successful protein expression and tracer synthesis, an initial 
set of experiments was performed to establish the optimal conditions under 
which to perform the assay for measuring both IC50 values of unlabelled 
ligands and for the screening of crude reaction mixtures from C-H 
functionalisation reaction arrays. The assay was adopted from previously 
reported fluorescence anisotropy assays for Hsp90(NTD).80 The aim was to 
determine the limits of anisotropy (i.e. largest assay window: anisotropy of free 
and complexed tracer) by titrating protein (serial two-fold dilution) into fixed 
tracer (50 nM). The polarisation of emitted light was measured parallel and 
perpendicular to the plane of polarisation of the excited light, and an 
anisotropy value for each protein concentration was calculated. The plate was 
incubated at 4 oC and read at four time points, 0 h, 3 h, 4 h and 20 h. The 
anisotropy was plotted against protein concentration and the data fitted using 
a logistic fit (Figure 3.11). The limits of anisotropy were reached after 
approximately 4 h, however due to the slow and tight binding of geldanamycin 
(and BODIPY-GM), 20 h incubation was determined to give the best logistic 
fit with smallest error. The limits of anisotropy were determined to be rmax = 
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139 and rmin = -4 by fitting the data to a logistic fit (Equation 3, experimental 
6.4). 
 
Figure 3.11 The calculated anisotropy plotted against protein concentration in the 
presence of fixed amount of tracer (50 nM). The anisotropy was calculated at 0 h, 3 h, 4h 
and 20 h time points and the upper and lower anisotropy limits were determined to be rmax 
= 139 and rmin = -4 respectively.  
 
The total fluorescence for each protein concentration was calculated 
(Equation 2, experimental 6.4) to measure the change in quantum yield 
between the bound and free states (Figure 3.12c,  = 2.39). The Kd of the 
tracer was determined by converting the measured anisotropy into the fraction 
of tracer bound (Equation 4, experimental 6.4) and then subsequently the 
amount of tracer bound, by multiplying the fraction bound by the concentration 
of the tracer (50 nM). The amount of tracer bound was plotted against the 
concentration of protein and the data fit to a non-linear least squares fitting 
algorithm (Figure 3.12d, Equation 5, experimental 6.4). The dissociation 
constant was determined to be Kd = 23.0 ± 3.3 nM (reported literature values 
range 6-30 nM).80  
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Figure 3.12 Determination of limits of anisotropy and Kd of a) BODIPY-labelled 
geldanamycin 130. b) Limits of anisotropy (upper r = 139, lower r = -4) determined from 
logistic fit of anisotropy vs protein concentration. IC50 of tracer: 22.6 ± 1.5 nM. c) Change 
in fluorescence ( = 2.39) measured from total fluorescence vs protein concentration d) 
Determination of Kd from plotting the amount of tracer bound vs protein concentration, Kd 
of tracer: 23.0 ± 3.3 nM. See appendix D for calculations. 
 
To assess the ability of the assay to determine affinities of unlabelled 
compounds, a series of control experiments was performed with ligands which 
have reported IC50 values for their affinities to Hsp90(NTD). Dose response 
curves for geldanamycin, ATP and ADP were performed with fixed protein 
concentration (500 nM) and tracer concentration (50 nM). Plates were 
incubated at 4 oC for 20 h, and calculated anisotropy plotted against ligand 
concentration. The amount of tracer bound was then plotted against 
Log10[competitor] and IC50 values were determined (Table 3.1 and Figure 
3.13). The IC50 values are broadly in-line with reported literature values, 
however variation in values stems from the conditions of the assay used.  
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 Calculated IC50  Reported IC50  
BODIPY-Geldanamycin Kd: 23.0 ± 3.3 nM Kd: 6-30 nM 
Geldanamycin 8.9 ± 1.7 M 76.9 ± 2.5 nM 
ATP 145 ± 19 M 100 ± 15 M 
ADP 54.8 ± 2.8 M 20 ± 8 M 
Table 3.1 Calculated and reported IC50 values for known Hsp90(NTD) inhibitors. Kd (not 
IC50) shown for BODIPY-geldanamycin.80  
 
 The IC50 values for ADP and ATP match those previously reported, 
however the IC50 for geldanamycin is two orders of magnitude higher than that 
reported from previous fluorescence anisotropy/polarisation assays (however, 
IC50 values were calculated from different protein and tracer concentrations). 
Geldanamycin is a slow Hsp90(NTD) binder157 and notorious for poor 
solubility. Reports from various assays report geldanamycin with a broad 
range of IC50 values (0.3 – 1.2 M) and can vary depending on the construct 
and length of Hsp90 used in the assay.157–159 Given ATP and ADP behaved 
as previously reported and fragments 81 and 86-91 IC50/Kd values matched 
those previously reported (see Table 3.2, fragments 81 and 86-90 affinities 
were also calculated from a fluorescence polarisation assay), the assay was 
deemed to be performing as expected.  
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a) Geldanamycin, IC50: 8.9 ± 1.7 M  
  
b) ATP, IC50: 145 ± 19 M  
  
c) ADP, IC50: 54.8 ± 2.8 M  
  
Figure 3.13 Dose response curves for known Hsp90(NTD) inhibitors a) geldanamycin, b) 
ATP and c) ADP with anisotropy plotted against ligand concentration and tracer bound 
plotted against Log10[Competitor] in order to calculate IC50 values. Competition assays 
were performed with 50 nM tracer, 500 nM Hsp90 and incubated at 4 oC for 20 h. 
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3.4  Fragment Screen against Hsp90 
To aid the selection of fragments implemented in C-H functionalisation 
reaction arrays in ADS, a screen of the prepared fragments (Section 3.3) was 
performed by generating dose response curves of each fragment at a range 
of fragment concentrations. At each concentration, fragment was incubated 
with 50 nM tracer and 500 nM Hsp90 at 4 oC for 20 h with a final DMSO 
concentration of 2%. The anisotropy at each fragment concentration was 
calculated, and a dose response curve (logistic fit) generated (Table 3.2). The 
anisotropy was converted to the amount of tracer bound (Equation 4, 
experimental 6.4) at each fragment concentration and plotted against 
log10[Ligand] and the data fit to a single site competition model (Table 3.2). 
The logIC50 was converted to an IC50 value for each fragment (Table 3.2), and, 
if required for comparison with reported affinities a Ki was calculated. 
From the 29 prepared fragments, 15 had measurable biologically activity 
against Hsp90(NTD), in that they were shown to displace tracer. The eight 
reported fragments 81 and 86-92 showed affinity to Hsp90 with measurable 
IC50s. IC50/Ki values calculated for previously reported fragments 81 and 86-
92 were broadly in line with the reported value (e.g. 86 IC50: ~1.5 ± 0.2 mM 
(reported 1 mM), 81 Ki: ~850 ± 150 M (reported Kd: 790 M) and 90 Ki: ~17 
± 5 M (reported Kd: 7 M)). However, perhaps unsurprisingly, only seven of 
the remaining 21 designed fragments showed partial activity. However, 
designed fragments 99, 101 and 104 did demonstrate activity of Hsp90(NTD) 
with a measurable IC50’s of ~1.0 ± 0.2 mM, ~32 ± 11 M and ~39 ± 13 M 
respectively. 104 is comparable to the closely related and previously reported 
analogue 90.  
The 15 fragments which demonstrated (partial) activity with Hsp90(NTD) 
(Figure 3.14) can be placed into three clusters; previously reported fragments 
81 and 86-92, the designed fragments 99, 101 and 104 with measurable IC50’s 
and the four designed fragments 106 and 114-116 which demonstrated partial 
activity and had no previous biological activity reported against Hsp90(NTD). 
Three key binding moieties were identified from the fragment hits; the 
resorcinol fragment, the para-hydroxy benzamide fragment and the para-
pyrazoyl benzamide fragment (Figure 3.14). The remaining 14 fragments 
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demonstrated no biological activity against Hsp90(NTD). With the biological 
data for the fragment set, ten fragments were chosen for implementation in C-
H functionalisation reaction arrays (Chapter 4).  
 
 
Figure 3.14 Summary of fragment hits for Hsp90 a) Resorcinol key for fragment binding b) 
4-acetamide-phenol key for fragment binding c) 4-pyrazoyl benzamide key for fragment 
binding d) Other fragment chemotypes 
 
 
 
 
 
 
 
 
a) 
b) 
c) 
d) 
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Fragment Dose response curves 
 
IC50: ~1.7 ± 0.8 mM 
Reported IC50: 400 M115   
 
IC50: ~1.5 ± 0.2 mM 
Reported IC50: 1 mM115 
  
 
IC50: > 5mM 
Reported IC50: 570 M115   
 
IC50: ~1.0 ± 0.1 mM 
Reported IC50: 490 M115   
 
IC50: >5 mM 
Ki: ~850 ± 150 M 
Reported Kd: 790 M112 
  
 
IC50: 370 ± 90 M 
Ki: ~17 ± 5 M 
Reported Kd: 7 M112 
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IC50: ~ 
Reported Kd:  
150 M113   
 
IC50: ~450 ± 140 M 
  
 
IC50: N/A (> 5mM) 
  
 
IC50: N/A (> 5mM) 
  
 
IC50: N/A (> 5mM) 
  
 
IC50: N/A (> 5mM) 
  
 
IC50: ~1.0 ± 0.2 mM 
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IC50: N/A (> 5mM) 
  
 
IC50: ~32 ± 11 M 
  
 
IC50: N/A (> 5mM) 
  
 
IC50: ~39 ± 13 M 
  
 
IC50: N/A (> 5mM)   
 
IC50: N/A (>5 mM) 
  
 
IC50: N/A (>5 mM) 
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IC50: N/A (>5 mM)   
 
IC50: N/A (>5 mM)   
 
IC50: N/A (>5 mM) 
  
 
IC50: N/A (>5 mM) 
  
 
IC50: N/A (>5 mM) 
  
 
IC50: N/A (>5 mM) 
  
 
IC50: N/A (>5 mM)   
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IC50: N/A (>5 mM)   
 
IC50: N/A (>5 mM) 
  
Table 3.2 Fragment data generated from dose response curves to determine 
affinites of fragments for Hsp90(NTD).  
 
3.5  Summary 
A series of Hsp90 fragments was designed and prepared based upon 
their potential to undergo productive C-H functionalisation reactions. 
Hsp90(NTD) was successfully expressed and purified and the tracer, 
BODIPY-GM, for the high-throughput fluorescence anisotropy assay 
synthesised. The controls experiments were performed to confirm the 
successful configuration of the assay, prior to the screening of the prepared 
fragment library. The establishment of the high-throughput assay will enable 
the rapid assessment of crude reaction array mixture for biological activity. 
 A range of fragments were identified as inhibitors of Hsp90(NTD), 
including novel fragments, all be it with modest biological activity, that had not 
previously been reported as Hsp90 inhibitors (Figure 3.14). The fragment data 
aided the selection of fragments with both biological activity and suitable 
directing groups for implementation in C-H functionalisation reaction arrays. 
With the assay and fragment hits established, reaction arrays using C-H 
functionalisation chemistry with Hsp90 fragments could be performed and 
assessed for biological activity, with the aim of identifying productive 
elaboration vectors of Hsp90 fragments.  
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Chapter 4. 
Evaluation of Chemistries for the Structure-Blind and 
Function-Driven Elaboration of Hsp90 Fragments 
Activity-directed synthesis has the potential to enable the structure-blind 
and function-driven elaboration of fragments, contrastingly starkly to 
conventional fragment-based ligand discovery, which is generally reliant on 
structural information to be successful. It was envisaged the use of C-H 
functionalisation and metal-catalysed carbenoid chemistry in activity-directed 
synthesis would potentially enable the identification of productive elaboration 
vectors of a fragment. A series of reaction arrays implementing both types of 
chemistry was performed, adopting different approaches for reaction array 
design, by varying the method for combining the reaction array components. 
It was envisaged the study would enable the identification of the more 
productive chemistry for structure-blind fragment elaboration and the more 
productive method for combining reaction components in the design of 
reaction arrays. The established high-throughput assay and LC-MS analysis 
of the crude reaction mixtures enabled the biologically activity and the success 
of the reactions to be rapidly assessed. 
 
4.1  Preparation of Hsp90 Fragments for Implementation in 
Reaction Arrays 
4.1.1  Acetate Protection of Phenol Fragments 
Ten Hsp90 fragments (Section 4.2.1, Figure 4.2) were chosen from the 
set of 29 (Chapter 3) for implementation as substrates in reaction arrays, on 
the basis they demonstrated biological activity against Hsp90 and possessed 
at least one potential directing group for C-H functionalisation chemistry. The 
ten fragments were also chosen to possess a broad range of fragment 
chemotypes to maximise diversity in the reaction arrays. Of the ten chosen 
fragments, six were phenol fragments, which have the potential to dominate 
reactivity under the C-H functionalisation reaction conditions. It was envisaged 
acetyl protection of phenols would minimise reaction interference, and then 
the development of a simple deprotection strategy in parallel reaction array 
- 83 - 
format would reveal the phenol prior to screening in the assay. The six phenol 
fragments were protected by reaction in the presence of excess acetic 
anhydride and pyridine to give fragments F1, F3-F6 and F10  (Figure 4.1) in 
good yield (60-98%).  
 
Figure 4.1 Protection of phenol fragments. Acetate protection of phenol fragments in the 
presence of acetic anhydride and pyridine gave F1, F3-F6 and F10. 
 
4.1.2  Configuration of a Acetate Deprotection Strategy in Parallel-
Format 
As the phenol/resorcinol moiety is key for fragment binding (Chapter 3), 
the establishment of a simple to implement and mild acetate deprotection 
strategy was established. The use of methoxide, generated from methanol 
and sodium carbonate, was assessed as an acetate deprotection strategy for 
parallel reaction arrays (Table 4.1 and Appendix A). Firstly, an LC-MS and 1H 
(300 MHz) NMR spectrum of the unprotected and protected fragments was 
collected to serve as reference spectra. The use of methoxide was tested in 
flask on ~mmol scale and the successfully deprotected fragment was isolated 
and characterised. The use of methoxide in the flask reactions successfully 
deprotected all the acetate-protected fragments, 1H NMR (300 MHz) spectra 
and LC-MS data shown for unprotected fragment, protected fragment and 
fragment that had successfully been deprotected with methoxide in flask 
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(Table 4.1 and Appendix A), and was therefore assessed in parallel format in 
microscale reaction array format.  
Each fragment (0.01 mmol) was added to a different microvial, followed 
by addition of a MeOH:THF (2:1 75 L) solution and an aqueous sodium 
carbonate solution (25 L, 470 mM). After 24 h the solvent was evaporated 
and the crude mixture analysed by LC-MS to reveal the successfully acetate-
deprotected fragment in parallel format. The use of methoxide in parallel 
format was successful for all six acetate-protected fragments (Table 4.1 and 
Appendix A), and the deprotection conditions were subsequently determined 
to be mild enough not to cause interference in the high-throughput assay. 
Finally, it was proposed the use of the Quadrature BzA resin would 
potentially enable the deprotection of the acetate-protected fragments. Each 
protected fragment (0.01 mmol) was added to a microvial in CH2Cl2  (100 L) 
followed by addition of Quadrapure BzA (30 mg). After 24 h an LC-MS of each 
of the fragments was collected to reveal that the Quadrapure BzA resin could 
successfully deprotect all six fragments (Table 4.1 and Appendix A).  
The deprotection study demonstrated acetate-protected phenol 
fragments could be readily deprotected under mild conditions with methoxide 
or the Quadrapure BzA resin in parallel reaction array format. Given the 
Quadrapure BzA has already been established for the scavenging of metal 
catalysts and Michael acceptors, it was chosen as the deprotection strategy 
to be implemented in the reaction array workflows. The use of a single strategy 
for the scavenging of metal catalysts and Michael acceptors and the acetate 
deprotection of fragments ensured a streamlined and efficient workflow for 
ADS.  
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90/F1 LC-MS Analysis 1H NMR (300 MHz) 
Unprotected 
Start (90) 
Mass Found [MH]+: 224.4  
Protected 
(Purified F1)  
Mass Found [MH]+: 266.4 
 
Deprotected 
(Purified 90) 
 
Mass Found [MH]+: 224.3  
Deprotected 
in Plate 
(crude, 90)  
Mass Found [MH]+: 224.4 
 
Deprotected 
in Plate 
(crude, 90)  
Mass Found [MH]+: 224.4 
 
Table 4.1 LC-MS and 1H NMR (300 MHz) for acetate protection and deprotection of phenol 
containing Hsp90 fragment 90/F1. Protection was performed by reaction of phenol with 
acetic anhydride and pyridine and deprotection was performed with Na2CO3 in 
MeOH:THF:H2O (2:1:1) and LC-MS and 1H NMR (300 MHz) data collected. Deprotection 
was performed in plates with MeOH:THF:H2O (2:1:1) and with Quadrapure BzA resin (30 
mg) and analysed by LC-MS. Calculated mass of unprotected and protected fragment 5/F1 
[MH]+: 224.3 and [MH]+: 266.4 respectively.  
4.2  C-H Functionalisation Reaction Arrays 
A range of C-H functionalisation reaction arrays was performed to 
assess the chemistry as a structure-blind fragment elaboration strategy using 
activity-directed synthesis. Hsp90 fragments were combined with a diverse 
set of substrates, under a range of known C-H functionalisation catalytic 
systems, in a series of room temperature and heated (60 oC) reactions. 
Following reaction (48 h), crude reaction mixtures were scavenged 
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(Quadrapure BzA) and screened directly, without purification, for biological 
activity.  
 
4.2.1  Room Temperature Reaction Arrays 
4.2.1.1  Reaction Array Design 
Room temperature C-H functionalisation reaction arrays were performed 
by combining Hsp90 fragments with a diverse set of substrates under a series 
of reported C-H functionalisation catalytic systems (Figure 4.2). As discussed, 
the ten fragments selected for implementation in ADS, for elaboration with C-
H functionalisation chemistry, were chosen on the basis they demonstrated 
biologically activity with Hsp90 and possessed at least one directing group for 
C-H Functionalisation chemistry.  
For implementation of C-H functionalisation chemistry in microscale 
reaction arrays, a diverse set of C-H functionalisation catalytic systems and 
substrates that can undergo the respective catalyst reaction type were 
selected. Eight catalyst systems, C1-C8 (Figure 4.2) were chosen on the basis 
of their diverse range of possible reactions. Palladium catalysts C1-C4 were 
chosen based upon their ability to undergo a range of C-H arylations and 
alkenylations; C1 (C-H alkenylations),160 C2 (C-H arylations with aryl 
iodides),101 C3 (C-H alkenylations and C-H arylations with aryl boronic 
acids)106 and C4 (C-H alkenylations).94 The rhodium catalyst C5161 and the 
ruthenium catalyst C698 are both able to undergo C-H alkenylation and 
alkynylations and finally iridium catalysts C7 and C8 were chosen on the basis 
they can undergo C-H amination reactions with anilines95 and alkyl amines104 
respectively.  
Finally a set of 33 reaction substrates was chosen which were 
compatible for the C-H functionalisation reaction type of the chosen catalyst 
systems. Substrates were chosen from commercially available libraries 
(Sigma-Aldrich, Fluorochem, Fischer-Scientific and Alfer Asear) and were 
selected on their molecular properties as well as their potential to undergo at 
least one of the chosen C-H functionalisation reaction types. To aid the 
selection of substrates a Pipeline Pilot protocol was established (by Adam 
Nelson), which took databases of commercially available substrates and 
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filtered them for reaction substrate class (alkenes, alkynes, acrylates, 
acrylamides, aryl iodides/bromides, aryl boronic acids, anilines and alkyl 
amines). The filtered database was then filtered again by applying a molecular 
property filter to give a set of substrates, for each reaction substrate class, 
with less than 15 heavy atoms, less than three rotatable bonds and an AlogP 
of 0 ≤ 3. The sets of substrates were then filtered for price and maximised 
diversity to generate a final set of 33 substrates (S1-S33) for implementation 
in ADS (Figure 4.2). 
 
Figure 4.2 Fragments (F1-F10) R=Ac, catalysts (C1-C8) and substrates  (S1-S33) used in 
reaction arrays for potential elaboration of Hsp90 fragments with C-H functionalisation 
chemistry 
- 88 - 
 With the ten fragments, eight catalysts and 33 substrates selected, a 
total of 2640 reactions was in principle possible, enabling the rapid exploration 
of chemical space. However, it was proposed that not all 2640 possible 
reactions would prove productive and impractical to implement due to the 
unlikely reaction of some fragment, substrates and catalyst combinations. It 
was proposed a smaller subset of reactions would be performed to maximise 
reaction array efficiency, by matching two of the three reaction array 
components (in turn) based on literature precedent and then the paired 
components see a broad range of the third component. For instance, catalysts 
were matched to a substrate class (e.g. iridium catalysts matched with 
amines), which then see the full range of fragment chemotypes. For matching 
catalysts and substrates, each of the eight catalysts was paired with three 
substrates of the catalyst reaction type to give 24 catalyst-substrates pairs. 
Each catalyst-substrate pair then underwent reaction with all ten fragments to 
give 240 reaction combinations. This matching was similarly performed by 
pairing fragments and catalysts and pairing fragments and substrates to give 
a total of 720 reaction combinations (Figure 4.3).  
 
Figure 4.3 Design of reaction array combinations by subsequently pairing fragments 
catalysts and substrates to give a diverse array of 720 reactions from a possible 2640.   
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4.2.1.2  Reaction Array Execution 
With the fragments, substrates and catalysts chosen, and the reaction 
array combinations designed, the reaction array itself was implemented. 
Fragments and substrates were prepared as stock solutions at 100 mM and 
200 mM respectively (See component tables, Experimental 6.2.2 for solvent 
details). 100 L of one of each was added to the vial of interest and the solvent 
allowed to evaporate. Catalyst system solutions were prepared at 5 mM in the 
appropriate catalyst reaction solvent (See component tables, Experimental 
6.2.2 for additive concentrations and solvent systems) and 100 L added to 
the vial of interest (Figure 4.4). Vials were capped and reactions left for 48 h, 
reaction solvent left to evaporate and reaction mixtures dissolved in CH2Cl2 
(100 L) followed by addition of Quadrapue BzA (30 mg) to scavenge for metal 
catalysts, Michael acceptors and for acetate deprotections. Reaction mixtures 
were capped and left to scavenge for 24 h, and the mixtures were then filtered, 
solvent allowed to evaporate to air followed by desiccation and finally crude 
reaction mixtures dissolved in DMSO (100 L) to give a final total product 
concentration of 100 mM (with respect to fragment). Crude reaction mixtures 
were then screened against Hsp90 in the established high-throughput 
fluorescence anisotropy assay.  
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Figure 4.4 a) Overview of ADS workflow bi) Room temperature reaction set up bii) 
unsealed and sealed elevated temperature set-up c) Filter plate for removing resin after 
scavenging 
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4.2.1.3  Reaction Array Results 
Following reaction array completion, crude reaction mixtures were 
screened against Hsp90 in the fluorescence anisotropy assay. The reaction 
mixtures were screened in triplicate. Controls of each of the reaction 
components in isolation were also performed, at the same concentration in 
which they were screened in the reaction mixtures, to enable the activity of 
the components to be observed (see Appendix B for component controls). 
Reaction array DMSO stocks (100 mM) were diluted into DMSO and then FA 
assay buffer to give stock solutions at 320 M in 8:92 DMSO:Buffer (four times 
the final assay concentration). 5 L of the DMSO:Buffer (8:92) reaction stocks 
was added to the assay plate followed by 5 L of a 200 nM tracer stock 
solution followed finally by 10 L of a 1 M protein stock solution to give final 
concentration of tracer and protein of 50 nM and 500 nM respectively. The 
room temperature C-H functionalisation reaction arrays were screened at a 
total product concentration of 80 M. 
Each of the 720 C-H functionalisation reaction mixtures was screened at 
a total product concentration of 80 M and the anisotropy data normalised 
relative to the positive control of 10 M geldanamycin (100% activity) and 
negative control of 2% DMSO blank (0% activity). The data was displayed on 
polar charts with the negative control (0%) at the outer edge and the positive 
control (100%) at the centre. The room temperature C-H functionalisation 
reaction arrays were plotted on three charts for each of the component-pairing 
array designs; catalyst-substrate matching (Figure 4.5), catalyst-fragment 
matching (Figure 4.6) and fragment-substrate matching (Figure 4.7). For 
substrates S15 and S25 the activity of the isolated components was observed 
as 46% and 29% respectively in the control points (Appendix B).  
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Figure 4.5 a) Normalised bioactivity data against Hsp90 for the 240 C-H functionalisation 
reaction mixtures with matched catalyst-substrate pairings screened at 80 M. The data 
was normalised  relative to 10 M Geldanamycin (green centre point, 100 %) and blank 
DMSO at the circumference (0%). No significant activity from the reaction mixtures was 
observed. Major sectors show the combinations of fragment and substrate under the eight 
catalyst systems (C1-C8). Each minor sector represents the ten fragments for each 
substrate reacted under each catalyst system (panel b). b) The ten Hsp90 fragments 
implemented in the arrays (R=Ac).See Appendix D for data processing.  
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Figure 4.6 a) Normalised bioactivity data against Hsp90 for the 240 C-H functionalisation 
reaction mixtures with matched catalyst-fragment pairings screened at 80 M. The data 
was normalised  relative to 10 M Geldanamycin (green centre point, 100 %) and blank 
DMSO at the circumference (0%). No significant activity from the reaction mixtures was 
observed but the bioactivity from S25  was observed. Major sectors show the combinations 
of catalyst and fragment under the eight catalyst systems (C1-C8). Each minor sector 
represents the 15 substrates for each fragment reacted under each catalyst system (panel 
b). b) The 15 substrates implemented in the arrays (R=Ac). 
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Figure 4.7 a) Normalised bioactivity data against Hsp90 for the 240 C-H functionalisation 
reaction mixtures with matched fragment-substrate pairings screened at 80 M. The data 
was normalised  relative to 10 M Geldanamycin (green centre point, 100 %) and blank 
DMSO at the circumference (0%). No significant activity from the reaction mixtures was 
observed but the activity from substrates S15 and S25  was observed. Major sectors show 
the combinations of fragment and substrate for each of the ten fragments (F1-F10). Each 
minor sector represents the eight catalyst systems for each combination of fragment and 
substrate (panel b). b) The eight catalyst systems implemented in the arrays (see 
component  table, Experimental 6.2.2).  
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 From the bioactivity data of the 240 catalyst-substrate matched C-H 
functionalisation reactions screened at a total product concentration of 80 M, 
there were no reaction mixtures with significant biological activity (Figure 4.5), 
that stemmed from productive reaction combinations, to design a subsequent 
round of ADS. For the catalyst-fragment matched array (Figure 4.6), increased 
bioactivity was only seen with substrate S25 (~20% activity relative to 
geldanamycin at 10 M) regardless of the fragment and catalyst combination. 
Given the activity of S25 in the control points was observed at ~30%, it was 
deemed the activity from the reaction array mixtures stemmed from the activity 
of the substrate and not a product of the reaction arrays. Similarly for the 
fragment-substrate matched array (Figure 4.7), the increased bioactivity 
observed stemmed from the activity of substrates S15 and S25 and not from 
a product of the reaction array.  
Unfortunately, from the 720 reactions performed, there were no active 
mixtures that could inform the design of a subsequent reaction array. At this 
stage it was not clear the reason for the lack of bioactivity from the reaction 
arrays, but it was proposed that the lack of activity stemmed from poorly 
performing/low yielding reactions. This was likely due the use of non-optimal 
combinations based on the literature precedent. While screening at higher 
concentrations was possible to enable detection of any low yielding products, 
it was probable that the activity of the fragments themselves would be 
observed, making identification of productive reaction mixtures difficult. It was 
therefore proposed, should any reaction have been low yielding, performing a 
reaction array at higher temperature, in the high-temperature set-up 
previously established, would potentially enable an increase in yield of 
products and thus enable detection in the assay.  
 
4.2.2  Heated Reaction Arrays 
4.2.2.1  Reaction Array Design and Execution 
To determine whether poorly performing reactions were the reason for 
the lack bioactive reaction mixtures, a heated (60 oC) array of 130 C-H 
functionalisation reactions was performed using combinations of fragments, 
catalysts and substrates previously selected (Figure 4.2). It was envisaged 
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higher temperatures would increase reaction yields and enable any 
biologically active products to be identified In the assay. The catalysts C2, C4, 
C6 and C8 were chosen as they covered the reaction types (C-H arylation, C-
H alkenylation and C-H aminations) established in parallel array format. 
Reactions combinations were selected based on catalyst-substrate literature 
precedent to potentially enable more productive reaction combinations. The 
catalyst-substrate pairs were then combined with five of the fragments under 
the four chosen catalyst systems.  
Reactions arrays were implemented as described previously from stocks 
solutions of fragment, substrate and catalysts. For the heated array the 
reactions were heated to 60 oC in an Optiblock Parallel Synthesis Reaction 
Block sealed with PTFE-faced Silicone Septa Pads. Following reaction 
completion, reaction mixtures were similarly scavenged, evaporated and 
dissolved in 100 L DMSO (total product concentration 100 mM). 
 
4.2.2.2  Reaction Array Results 
Reaction mixtures were similarly prepared as stock solutions in 
DMSO:Buffer (8:92) and screened in triplicate at a total product concentration 
of 100 M, 50 nM of tracer and 500 nM of protein. The anisotropy data was 
normalised relative to the positive control of 10 M geldanamycin (100% 
activity) and negative control of 2% DMSO blank (0% activity) and plotted on 
a polar chart (Figure 4.8). As for the room temperature array, none of the 
reaction mixtures showed significant biological activity against Hsp90 in the 
fluorescence anisotropy assay and therefore a second round of ADS could 
not be designed.  
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Figure 4.8 a) Normalised bioactivity data against Hsp90 for the 130 C-H functionalisation 
reactions performed at 60 oC. The data was normalised relative to 10 M Geldanamycin 
(green centre point, 100 %) and blank DMSO at the circumference (0%). No significant 
activity from the reaction mixtures was observed. Major sectors show the combinations of 
fragment and substrate under the four catalyst systems (C2, C4, C6 and C8). Each minor 
sector represents five of fragments for each substrate reacted under each catalyst system 
(panel b). b) The seven Hsp90 fragments implemented in the arrays (R=Ac). 
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4.2.3  Matched Chemistry Heated Reaction Arrays 
Given that the crystal structures of the fragments bound to Hsp90 
showed promising elaboration vectors accessible through C-H 
functionalisation chemistry, it is somewhat surprising that an active 
combination was not observed. It was probable the substrate scope of the 
reaction was not producing an active elaborated fragment and a wider array 
of reaction substrates required, or more simply the reactions themselves are 
not robust enough with the range of highly-functionalised substrates selected. 
It was therefore proposed to select a second set of fragments and substrates 
that are more closely aligned to the literature precedent to enable potentially 
productive elaboration vectors to be identified (Figure 4.9). 
 
4.2.3.1  Reaction Array Design and Execution 
From the fragments designed and prepared previously (Chapter 3), six 
fragments that had not been implemented in reaction arrays (F11-F16, Figure 
4.9) were selected on the basis they contained a secondary amide (tert-Butyl 
or cyclopentylamine) as a potential directing group, which is a widely used in 
C-H functionalisations chemistry. These six fragments were chosen along with 
fragments F7 and F8 to give a set of eight fragments which did not possess 
the phenol fragment for Hsp90. While this has been shown as a key moiety 
for Hsp90 binding, the fragments selected all showed biological activity 
towards Hsp90 and would be more compatible for use in C-H 
functionalisations reactions.  
For reaction array implementation, the eight fragments were reacted with 
five of the eight selected catalyst systems. The five catalyst systems had 
previously been established in parallel array format and were chosen to cover 
the range of C-H functionalisation reaction type. For each catalyst system, 64 
reactions were performed with eight substrates (from a range of 37, R1-R37) 
that matched the catalyst reaction type to give a total of 320 reactions. The 
substrates were chosen from the Nelson chemical inventory on the basis they 
possessed the correct functional group for the reaction type of the catalyst 
system, and that the range of substrates for each substrate class was diverse. 
Reaction arrays were performed at 60 oC as previously described, scavenged, 
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evaporated and dissolved in 100 L DMSO, to give a final total product 
concentration of 100 mM. 
 
Figure 4.9  Fragments catalysts and substrates implemented in reaction arrays for high 
temperature C-H functionalisation reaction arrays with literature-matched array design for 
elaboration of Hsp90 fragments.  
 
4.2.3.2  Reaction Array Results 
Reaction mixtures were diluted in DMSO:Buffer (8:92), which were 
screened in the fluorescence anisotropy assay at a total product concentration 
of 100 M, 50 nM of tracer and 500 nM of protein. The anisotropy data was 
normalised relative to 10 M geldanamycin (100% activity) and 2% DSMO 
- 100 - 
blank (0% activity) and the normalised data plotted on a Polar Chart (Figure 
4.10).  
 
Figure 4.10 a) Normalised bioactivity data against Hsp90 for the 320 C-H functionalisation 
reactions performed at 60 oC. The data was normalised relative to 10 M Geldanamycin 
(green centre point, 100 %) and blank DMSO at the circumference (0%). No significant 
activity from the reaction mixtures was observed. Major sectors show the combinations of 
fragment and substrate under the five catalyst systems (C2, C4, C6, C7 and C8). Each 
minor sector represents the eight fragments for each substrate reacted under each catalyst 
system (panel b). b) The eight Hsp90 fragments implemented in the arrays. 
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Unfortunately, there were no reaction mixtures that were identified as 
being biologically active at a total product concentration of 100 M and 
therefore a second round of ADS was not be designed. With 1170 C-H 
functionalisation reactions performed from combinations of 16 fragments, 
eight catalysts and 70 substrates, it was surprising that none of the reaction 
combinations produced biologically active mixtures. It was likely the reactions 
were performing systematically poorly with the choice of fragments and highly 
functionalised and polar substrates. Indeed, the systematic failure of highly-
functionalised and polar substrates in similar reaction classes has been 
reported and that literature reaction methodology studies fail to identify a truly 
broad scope of substrates that would prove beneficial in medicinal chemistry 
workflows.18,26,53 To determine whether it was indeed the poor reaction 
performance with the chosen fragments and substrates that was preventing 
discovery of bioactive reaction mixtures, an LC-MS study was performed to 
identify reactions that had successfully given products in the arrays.  
 
4.2.4  Reaction Array Product Analysis 
An LC-MS study of a random ~10% of the reactions was performed to 
determine the reaction performance of the C-H functionalisation reaction 
arrays. Identification of potential product masses from the reaction indicated 
formation of reaction products. Reaction array stocks (100 mM) were diluted 
into MeCN to give a final total product concentration of 5 mM and analysis of 
the reaction mixture was performed  by LC-MS. LC-MS was performed with a 
positive and negative switching mode with a gradient elution H2O and MeCN 
each plus 0.1% formic acid. The spectra were then analysed by searching for 
potential product masses of the bimolecular reaction (fragment + substrate) 
minus the mass of HX (X = H, Cl, Br, I or B(OH)2.)  
For the room temperature C-H functionalisation reaction arrays, 72 of the 
720 reaction mixtures were analysed by LC-MS (Appendix C.1.1.1). From the 
72 reactions analysed, only 8 reaction mixtures had masses corresponding to 
potential products as a result of a C-H functionalisation reaction indicating only 
~10% of the reactions were successfully undergoing C-H functionalisation 
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reaction highlighting the poor performance of metal-catalysed reactions with 
highly-functionalised substrates.18,53  
 The reaction of fragment F4 with boronic acid substrate S1 under iridium 
catalysis C8 was one example in which a mass of a potential product P1 was 
identified (Figure 4.11), however, the iridium catalysed C-H arylation with aryl 
boronic acids has not been previously reported. Further analysis would be 
required to determine if the reaction had progressed to sufficiently progressed 
and indeed whether a novel transformation had been discovered.  
 
 
F4 
MW: 150.2 
[MH]+: 151.2  ✓ 
S1 No mass found 
P1 
MW: 266.3 
[M2Na]+: 555.03  ✓ 
Figure 4.11 LCMS analysis of crude reaction mixture of fragment F4 with boronic acid 
substrate S1 under iridium catalysis C8 identified an M2Na product mass for potential 
product P1 from the room temperature C-H functionalisation reaction arrays. 
 
Of the 72 reactions, 35 (~50%) still showed presence of fragment and/or 
substrate in the reaction mixture again suggesting that fragment and 
substrates were not going to completion, supporting the poor substrate scope 
of the reactions. It should also be noted that in the all cases in which fragment 
and products could be identified in reaction mixtures, it was the mass of the 
deprotected phenol fragment, supporting the capability of the Quadrapure BzA 
to readily perform acetate deprotections. In the cases in which fragment or 
product was not identified, subsequent analysis did not reveal any 
fragment/product masses which still remained acetate protected. Analysis of 
20 of the 130 C-H functionalisation reactions performed at 60 oC showed only 
one reaction with a potential product mass, further supporting the poor 
substrate scope compatible with the reaction class.  
F4 
P1? 
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Finally, from the LC-MS analysis of 30 of 320 matched-chemistry 60 oC 
C-H functionalisation reaction array, only four reactions with potential product 
masses were identified. Reaction of fragment F11 with acrylamide substrate 
R1 under ruthenium catalysis C6 gave a potential product in the LC-MS, which 
is likely the result of a C-H alkenylation; a well reported transformation under 
ruthenium catalysis (Figure 4.12).98  
 
 
F11 
MW: 219.3 
[MH]+: 219.8  ✓ 
R1 No mass found 
P2 
MW: 288.2 
[MH]+: 288.8  ✓ 
Figure 4.12 LCMS analysis of crude reaction mixture of fragment F11 with  substrate R1 
under iridium catalysis C6 identified an MH product mass for potential product P2 from the 
60 oC matched-chemistry C-H functionalisation reaction arrays. 
 
Of the 122 reactions analysed by LC-MS, only 13 mixtures gave potential 
products as a result of a C-H functionalisation reaction, highlighting the poor 
robustness of the reactions. It was therefore decided the use of C-H 
functionalisation chemistry, with substrates desirable in medicinal chemistry, 
was not compatible for ADS and that alternative chemistry explored as an 
elaboration strategy for Hsp90 fragments. 
4.3  Metal-Catalysed Carbenoid Chemistry with -
Diazoamides Reaction Arrays 
It was proposed that the use of metal-catalysed carbenoid chemistry with 
-diazoamides would provide a more robust and reliable transformation for 
elaboration of Hsp90 fragments. Metal-catalysed carbenoid chemistry is able 
to undergo multiple possible reactions, e.g. C-H, O-H, N-H insertions and 
cyclopropanations (Chapter 1) and so has the potential to elaborate fragments 
in many possible approaches. Two approaches for the use of -diazoamides 
were proposed; firstly to elaborate Hsp90 fragments with a diverse set of -
F11 
P2 
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diazoamides (prepared by Nelson group members via previously reported 
synthetic methods),162,163 and secondly by preparing -diazoamides bearing 
a Hsp90 fragment and reacting them with a range of co-substrates which can 
undergo at least one metal-catalysed carbenoid transformation.  
 
4.3.1  Hsp90 Fragments with -Diazoamides Reaction Array 
For the reaction arrays for the elaboration of Hsp90 fragments with a 
diverse set of -diazoamides, four fragments, two catalysts and 12 
diazoamides were chosen to give a total of 96 possible reactions (Figure 
4.13). The four fragments were chosen on the basis they could undergo at 
least one possible metal-catalysed carbenoid transformation; insertion into 
aromatic C-H, benzylic C-H, C-H next to oxygen or nitrogen, O-H insertion or 
a cyclopropanation. The twelve diazoamides were selected to give a diverse 
set possessing a range of aliphatic and aromatic substituents. The two 
catalysts were chosen based upon their potential to undergo different reaction 
modes (unpublished study by Adam Green, Adam Nelson and co-workers).  
 
Figure 4.13 Fragments (F5, F8, F10 and F17), -diazoamides (D1-D12) and catalysts C9 
and C10 used in reaction arrays for potential elaboration of Hsp90 fragments 
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 All possible 96 reaction combinations were performed by preparing 
stocks of fragment in CH2Cl2 (200 mM), diazoamide in CH2Cl2 (200 mM) and 
catalyst in THF (12.5 mM). To the vial of interest was added one of each of 
fragment (50 L) and catalyst (8 L) and the solvent allowed to evaporate. 
Finally, was added one diazoamide (100 L) and the vials capped to give a 
final reaction concentration of 100 mM fragment, 200 mM diazoamide and 1 
mM catalyst. Following reaction completion, catalysts were scavenged using 
Quadrapure TU (30 mg) for 24 h, reaction mixtures filtered, evaporated and 
dissolved in DMSO (100 L) to give a final total product concentration of 100 
mM. Reaction stocks were diluted into DMSO:Buffer (8:92) to give stocks at 
four times the final assay concentrations (total product concentration: 400 
M), and then screened in triplicate at 100 M in the fluorescence anisotropy 
assay. The anisotropy data was normalised relative to 10 M geldanamycin 
(100% activity) and 2% DSMO blank (0% activity) and the normalised data 
plotted on a Polar Chart (Figure 4.14). 
As for the C-H functionalisation reaction arrays, no significantly 
biologically active reaction mixtures were identified from the metal-catalysed 
carbenoid reaction array. There was slightly increased activity (~15%) for all 
mixtures, regardless of diazoamide and catalyst, with fragment F17. Given 
this fragment has a low micromolar IC50 for Hsp90, the activity observed 
stemmed from the activity of the fragment. Unfortunately on the basis of the 
activity data obtained, a second round of ADS could not be designed. 
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Figure 4.14 a) Normalised bioactivity data against Hsp90 for the 96 metal-catalysed 
carbenoid reactions screened at 100 M. The data was normalised relative to 10 M 
Geldanamycin (green centre point, 100 %) and blank DMSO at the circumference (0%). No 
significant activity from the reaction mixtures was observed. Major sectors show the 
combinations of fragment and catalyst. Each minor sector represents the twelve 
diazoamides reacted with each combination of fragment and catalyst. b) The twelve -
diazoamides implemented in the arrays. 
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4.3.2  -Diazoamides-Fragments with Substrates Reaction Array 
4.3.2.1  Reaction Array Design 
The final array was the use of -diazoamides bearing a Hsp90 fragment 
and performing reactions with a diverse set of co-substrates, in a similar 
approach to previous ADS studies.16,17 Two -diazoamides were selected 
along with two rhodium catalysts C9 and C10 and twenty diverse co-
substrates, CS1-CS20 (Figure 4.15). The two -diazoamides DF1 and DF2 
bearing the Hsp90 fragment, 2-isopropylphenol, required synthesis prior to the 
implementation in the reaction array (Scheme 4.1). The 20 co-substrates were 
chosen to give a diverse set and selected on the basis they possessed a 
functional group for potential reaction with an -diazoamide (e.g. O-H and N-
H insertions, C-H insertions next to O/N and cylcopropanations with 
unsaturated bonds). The two rhodium catalysts were chosen again based on 
their potential to undergo different reaction types (based on an unpublished 
study by Adam Green, Adam Nelson and co-workers).  
 
Figure 4.15 Diazoamide-fragments (DF1 and DF2), co-substrates (CS1-CS20) and 
catalysts C9 and C10 used in reaction arrays for potential elaboration of Hsp90 
diazoamide-fragments 
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4.3.2.2  Synthesis of Hsp90 Fragment -Diazoamides 
The two -diazoamides DF1 and DF2 for implementation in the reaction 
arrays incorporated the TBS protected 2-isopropylphenol moiety, which were 
prepared via known synthetic routes (Scheme 4.1).162,163  The phenol 
fragments were TBS protected, as again they were envisaged as potentially 
dominating reactivity, due to the possibility of undergoing O-H insertions under 
metal-catalysed carbenoid chemistry. A parallel reaction array deprotection 
strategy was subsequently established to reveal the key phenol fragment for 
Hsp90 bioactivity prior to screening in the assay (Section 4.3.2.3).  
The diazoamides were prepared from their respective amines, which 
were themselves synthesised in three and four steps from 2-isopropylphenol 
(Scheme 4.1). Firstly, nitration of 2-isopropylphenol 131 with HNO3 and ZnCl2 
gave a mixture of the 4-mono, 6-mono and 4,6-dinitrated phenol which were 
separated via column chromatography to give the 4-nitro-2-isoproylphenol 
132 in 57% yield. The phenol was readily protected as the tert-
butyldimethylsilane 133 in 74% yield. Reduction of the nitro with H2 and Pd/C 
yielded aniline 134 (78%) which could be methylated with MeB(OH)2 and 
copper (II) acetate to give the methylaniline 135 (58% yield). A mixture of 
mono- and demethylated aniline was produced however separation was 
possible via chromatography using a slow elution gradient. Anilines 134 and 
135 were then used to prepare the two a-diazoamides DF1 and DF2. Firstly 
the toluenesulfonyl hydrazone chloride 136 was prepared from the 
corresponding acid by heating with thionyl chloride in toluene at 90 oC. The 
toluenesulfonyl hydrazone chloride 136 (used as crude material) was coupled 
with each aniline in the presence of DMA at 0 oC, which upon treatment with 
triethylamine gave diazoamides DF1 and DF2 in 50% and 79% yield 
respectively (Scheme 4.1b).  
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Scheme 4.1 Synthesis of anilines 134 and 135 and -diazoamides DF1 and DF2 for 
implementation in ADS reaction arrays. 
 
4.3.2.3  TBS Deprotection in Parallel Array Reaction Format 
To enable reaction products to be screened as the deprotected phenol 
fragment, the key moiety for Hsp90 binding, a simple to implement and mild 
set of TBS deprotection conditions was established in parallel reaction array 
format. Substrate 137 was used as the model substrate for establishing the 
deprotection conditions (Figure 4.16).  
The use of methoxide was assessed for its TBS deprotection 
capabilities; 0.01 mmol of substrate 137 was added to a microvial of interest 
followed 100 L of a sodium methoxide (1.5 eq) solution in MeOD. The 
reaction was left for 6 h, diluted with 400 L of MeOD to enable analysis of 1H 
and 13C NMR spectroscopy. A 1H and 13C NMR spectra of the initial protected 
substrate 137 and the reaction mixture was collected, to reveal the completely 
deprotected substrate 138 under the reaction conditions (Figure 4.16). There 
are no peaks corresponding to the protected substrate 137 (represented by 
blue circles in starting spectra) and there are new peaks corresponding to the 
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formation of 138 (green circles). LC-MS analysis also showed the mass of the 
TBS deprotected substrate 138.  
The use of methoxide (1.5 eq) in MeOH enabled the simple to implement 
deprotection of TBS-protected phenol fragments in microscale reaction 
arrays. An efficient workflow for performing reaction arrays was established; 
reactions are prepared and left to react for 24 h, reaction solvent evaporated 
and TBS-protected phenols deprotected with a solution of methoxide (1.5 eq) 
in methanol (100 L) for 6h and then the metal catalysts scavenged with 
Quadrapure TU (30 mg) resin.  
 
 
 1H NMR (400 MHz) 13C NMR (100 MHz) 
137 
  
138 
 
 
 
Figure 4.16 1H and 13C NMR spectroscopy study showed the use of sodium methoxide 
(1.5 eq) in MeOH could readily as deprotection strategy for TBS-protected fragments in 
parallel reaction array format.  
 
4.3.2.4  Reaction Array Execution and Results 
With the two a-diazoamides bearing the Hsp90 fragment successfully 
prepared and the 20 co-substrates CS1-CS20 and the two catalysts C9 and 
C10 chosen, the 80 possible reactions were performed. Diazoamides and co-
substrate stocks were prepared in CH2Cl2 at 100 mM and 200 mM respectively 
TBS Protected Fragment 
Deprotected Fragment 
MeOD 
Methoxide 
MeO-TBS 
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and catalysts in THF at 12.5 mM. To a vial of interest was added one co-
substrate (100 L) and catalyst (8 L) and the solvent allowed to evaporate. 
Finally, to each vial was added one diazoamide (100 L) to give a final 
concentration of 100 mM diazoamide, 200 mM co-substrate and 1 mM of 
catalyst. Reactions were left for 24 h and then the solvent evaporated. 
Deprotections were performed with sodium methoxide (1.5 eq) in methanol 
(100 L) for 6h, methanol evaporated, mixtures dissolved in CH2Cl2 (100 L) 
and metal catalysts scavenged with Qudrapure TU (30 mg) for 24 h, reaction 
mixtures filtered and solvent evaporated. Reaction mixtures were dissolved in 
DMSO (100 L) to give a final product concentration of 100 mM. Reaction 
mixtures were prepared in DMSO:Buffer (8:92) at four times the assay 
concentration (400 M), and screened at a total product concentration 100 M 
(final DMSO concentration 2%) in the fluorescence anisotropy assay. The 
anisotropy data was normalised relative to 10 M Geldanamycin and plotted 
on a polar chart (Figure 4.17).  
The bioactivity data from the final reaction array (Figure 4.17) 
unfortunately did not reveal any reaction mixtures with significant biological 
activity and therefore a subsequent round of ADS could not be designed. 
Given the success of the approach against the androgen receptor in previous 
ADS studies,16,17 it was somewhat surprising that there were no biologically 
active reaction mixtures. As for the C-H functionalisation reaction arrays, an 
LC-MS study was performed to determine the success of the reactions in the 
array.  
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Figure 4.17 a) Normalised bioactivity data against Hsp90 for the 80 metal-catalysed 
carbenoid reactions screened at 100 M. The data was normalised relative to 10 M 
Geldanamycin (green centre point, 100 %) and blank DMSO at the circumference (0%). No 
significant activity from the reaction mixtures was observed. b) The twenty co-substrates 
implemented in the arrays. 
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4.3.3  Metal-catalysed Carbenoid Reaction Array Product Analysis 
From the two reaction arrays with the metal-catalysed carbenoid 
chemistry, a total of 176 reactions was performed. A total of 20 reactions, from 
the two approaches, were analysed by LC-MS to determine the success rate 
of the reactions. From the LC-MS, the mass of the biomolecular reaction 
minus the mass of nitrogen would indicate the successful formation of 
products in the reaction. For the reactions of fragment and the diverse -
diazoamides, just two of the ten reactions gave masses corresponding to 
possible products, both of which used catalyst C9.  
From the arrays which implemented -diazoamides bearing Hsp90 
fragments and the diverse co-substrates, again just two of the products gave 
masses for potential products. In this case both reaction products were 
observed with diazoamide DF1 and catalyst C10. The reaction of diazoamide-
fragment DF1 with co-substrate CS13 the Rh2(OPiv)4 C10 catalyst gave two 
potential product masses in the LC-MS analysis, which could be a result of a 
cyclopropanation or O-H insertion reaction (Figure 4.18). Both products would 
have identical masses and in this case the same mass was identified in peaks 
with different retention times (0.58 and 0.60 min). This suggests more than 
one possible product was being formed in the reaction, highlighting the 
unpredictable nature of the metal-catalysed carbenoid chemistry.  
 
 
DF1 
MW: 333.3 (protected)  
MW: 219.2 (deprotected)  
S13 
MW: 164.1 
[MH]+: 164.8 ✓ 
P3 
 
P4 
MW: 355.4 
[MH]+: 356.1 ✓, [M-H]-: 354.0 ✓ 
MW: 355.4 
[MH]+: 356.1 ✓ 
Figure 4.18 LCMS analysis of crude reaction mixture of diazo-fragment DF1 with co-
substrate CS13 under rhodium catalysis C10 identified two [MH]+ product mass for 
hypothesised products P3 and P4 from the metal-catalysed carbenoid reaction arrays. 
P3 
P4 
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However, due to the low success rate of reactions in the array, it was 
likely the poorly performing reactions were the reason for no biologically active 
mixtures from the arrays. The lack of bioactivity in the reactions that were 
successful in giving products, was potentially due to low yield and therefore 
not identified in the assay at the screening concentration or simply the product 
itself was simply not biologically active. To enable greater conversion to 
products with the diazoamide-fragments and co-substrates, a broader range 
of catalysts and solvents could be used in future studies.  
4.4  Summary 
It was proposed the use of C-H functionalisation and metal-catalysed 
carbenoid chemistry implemented in ADS would potentially enable the 
elaboration of Hsp90 fragments to discover ligands with increased biologically 
activity. A total of 1170 C-H functionalisation reactions was performed in a 
series of room temperature and 60 oC reaction arrays as well as 176 metal-
catalysed carbenoid reactions. In all cases, none of the reaction mixtures 
demonstrated significant biological activity to design a subsequent round for 
ADS. Around 10% of all the reactions performed were analysed by LC-MS to 
determine the success rate of the reactions. Roughly 10% of the C-H 
functionalisation reactions performed showed masses for possible products, 
and ~20% for the metal-catalysed carbenoid reactions. The poor conversion 
of substrates to products in the arrays was likely the reason for no biologically 
active mixtures being observed. This study demonstrated the poor substrate 
scope, in particular highly-functionalised and polar substrates, in modern 
methodology studies, and is further evidence that a truly reliable and robust 
set of transformations is required for the discovery of biologically active 
ligands in medicinal chemistry workflows (see Chapter 5 for discussion). 
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Chapter 5. 
Summary, Conclusions and Future Work 
5.1  Summary 
Fragments are attractive starting points in drug discovery workflows and 
are typically subjected to structure-guided fragment elaboration cycles to 
develop them into leads.46,47,49,114 However, the synthetic elaboration of 
fragments can be challenging due to the poor accessibility of potentially 
productive elaboration vectors imposed by the limitations of the established 
medicinal chemistry toolkit.18,44,81 To enable the structure-blind and function-
driven elaboration of fragments using ADS, a series of new tools and protocols 
for ADS was established.  
ADS is a function-driven molecular discovery approach, which borrows 
concepts associated from the evolution of biosynthetic pathways found in 
nature.16,17 ADS aims to maximise the diversity of hits that can seed discovery 
programmes, by implementing chemical reactions that are currently 
underutilised in discovery programmes. To assess the potential of the 
structure-blind and function-driven elaboration of fragments using ADS, the 
reported study incorporated two key aspects; firstly, the development of 
underpinning tools for implementation in ADS (section 5.1.1) and secondly, 
the value of these established tools for function-driven fragment elaboration 
was assessed in the context of Hsp90 (Section 5.1.2). 
 
5.1.1  Configuration and Optimisation of a Streamlined Workflow 
for Activity-Directed Synthesis  
To maximise the diversity of hits discovered via activity-directed 
synthesis, the chemical toolkit for ADS was expanded. C-H functionalisation 
was chosen for its potential to synthetically elaborate multiple C-H vectors of 
a fragment. An optimised workflow for ADS was then established for the 
function-driven fragment elaboration using either directed C-H 
functionalisation reactions or metal-catalysed carbenoid chemistry. 
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 A series of reported C-H functionalisation reactions, which covered a 
broad range of reaction types, was configured for implementation in parallel 
microscale reaction arrays at room and elevated (60 oC) temperatures. The 
literature reactions were assessed under conditions that would be amenable 
to ADS. In particular, the reactions were prepared from stock solutions and 
performed in microvials in parallel array format under atmospheric conditions 
without the requirement of agitation. LC-MS analysis of the crude reaction 
mixtures enabled the reactions that were successfully translated into ADS-
format to be identified.  
To minimise potential assay interference from residual components of 
the reaction mixtures, such as metal catalysts and Michael acceptors, a 
scavenging protocol was established for the post reaction work-up of crude 
reaction mixtures. The use of Quadrapure BzA resin was successfully 
demonstrated as an efficient approach for removing metal catalysts and highly 
electrophilic Michael acceptors form crude reaction mixtures prior to biological 
screening. The resin was later also demonstrated to enable the deprotection 
of acetate-protected phenol fragments. The use of the Quadrapure BzA resin 
enabled an efficient post reaction work-up procedure that was simple to 
implement in parallel array format to be configured, ensuring a streamlined 
workflow for ADS.  
Hsp90 was identified as a tractable target to validate C-H 
functionalisation chemistry as a fragment elaboration strategy using ADS. 
Fragment-based discovery had previously been applied in the successful 
discovery of ATP-competitive ligands for Hsp90. The previously reported 
fluorescence anisotropy assay for Hsp90 was adapted to enable the 
development of a high-throughput assay that enabled biologically active 
fragments and reaction array mixtures to be identified. The NTD of Hsp90 was 
successfully expressed and characterised by SDS-page and HRMS. 
BODIPY-labelled geldanamycin was readily synthesised from geldanamycin 
and was used as the tracer for the fluorescence anisotropy assay. The assay 
performance was evaluated by performing a series of control experiments with 
geldanamycin, ATP and ADP.  
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A series of 29 Hsp90 fragments was designed, by analysing known  
fragments and ligands, and successfully prepared. The fragments were 
designed to incorporate as least one potential C-H functionalisation directing 
group. The fragments were screened in dose response to generate IC50 
values, which enabled the selection of a subset of fragments for 
implementation in the reaction arrays. The design, synthesis and screening of 
the small fragment library enabled the discovery of novel analogues of 
previously reported Hsp90 fragments, which were subsequently used as 
substrates in activity-directed synthesis. 15 of the 29 fragments had 
measurable biological activity against Hsp90, seven of which have not been 
previously reported as fragments for Hsp90.  
The phenol containing fragments were acetate-protected, to minimise 
reaction interference, for implementation in the C-H functionalisation reaction 
arrays. The acetate protecting group could be readily removed with the 
Quadrapure BzA resin in parallel array format. A set of -diazoamides which 
incorporated a key Hsp90 fragment was also synthesised, to enable the value 
of the metal-catalysed carbenoid chemistry to be assessed.  
The value of the configured chemistry and established scavenging and 
deprotection protocols was assessed by implementing them in a series of 
reaction arrays. The synthesised Hsp90 fragments served as the substrates 
for ADS and the developed fluorescence anisotropy assay, along with the use 
of LC-MS, was used to assess the biological activity and success rate of the 
crude reaction mixtures (Section 5.1.2). 
 
5.1.2  Reaction Array Implementation and Results for Hsp90 
A series of reaction arrays was performed implementing both the C-H 
functionalisation and metal-catalysed carbenoid chemistry. The value of the 
chemistries for the structure-blind and function-driven elaboration of Hsp90 
fragments was explored. The established protocols (Section 5.1.2) enabled 
reaction arrays to be performed efficiently on microscale in parallel reaction 
array format, metal catalysts and Michael acceptors to be scavenged, 
fragment protecting groups to be removed, and the biological activity and 
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reaction success rate be determined by using the established high-throughput 
assay and LC-MS.  
A total of 1346 reactions was performed using the C-H functionalisation 
and metal-catalysed carbenoid chemistry in a series of reaction arrays (Table 
5.1). The reaction arrays were also assessed to identify the optimal method 
for designing reaction combinations. For the arrays that harnessed C-H 
functionalisation chemistry, a total of 1170 reactions was performed at room 
and at elevated temperatures (60 oC) and the method for designing reaction 
combinations was also assessed. For the metal-catalysed carbenoid 
chemistry, all combinations of reaction components were assessed in both of 
the arrays performed. The carbenoid arrays were designed and implemented 
in two approaches; by reaction of Hsp90 fragments with a diverse set of -
diazoamides and by reaction of -diazoamides bearing an Hsp90 core 
fragment with a diverse set of co-substrates.  
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Chemistry 
Implemented 
Reaction 
Array 
Temperature 
Total Number 
of Possible 
Combinations 
Array Design 
Number of 
Reactions 
Performed 
C-H 
Functionalisation 
rt 2640 
Matched: 
Fragment-
Substrate Pairs 
240 
Matched: 
Fragment-
Catalyst Pairs 
240 
Matched: 
Catalyst-
Substrate Pairs 
240 
rt 924 
Matched: 
Catalyst-
Substrate Pairs 
130 
60 oC 1480 
Matched: 
Catalyst-
Substrate Pairs 
320 
Metal-Catalysed 
Carbenoid 
rt 96 
Exhaustive: 
Fragments + 
diazoamides 
96 
rt 80 
Exhaustive: 
Diazoamide-
fragments +     
co-substrates 
80 
Table 5.1 Summary of reaction arrays implemented in activity-directed synthesis to assess 
C-H functionalisation chemistry and metal-catalysed carbenoid chemistry as function-
driven fragment elaboration strategies. 
 
From the bioactivity data of the screened array mixtures using both sets 
of chemistry, there were no productive reaction combinations that informed 
the design of a subsequent array. Observed bioactivity from the reaction 
mixtures stemmed from unreacted reaction components with low levels of 
bioactivity. This provided evidence that hits from the workflow would have 
been identified provided reaction combinations had been productive. 
To determine the lack of hits from the reaction mixtures an LC-MS study 
was performed to assess the success rate of the reactions in the arrays. 10% 
of the reaction mixtures from the C-H functionalisation and metal-catalysed 
carbenoid reaction mixtures were analysed, which revealed poorly performing 
reactions. Reaction mixtures were analysed by searching for potential product 
masses and roughly 10% of those analysed had masses of potential  
intermolecular products. The poorly performing reactions in the arrays was 
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likely a key contributing factor for the lack of biologically active mixtures, 
provided successful reactions would have indeed led to products with 
increased bioactivity. 
5.2  Discussion and Conclusions 
The interest in C-H functionalisation chemistry from the synthetic 
community has grown rapidly over the last few decades,82–84 with multiple C-
H functionalisation methodology papers reported on a weekly basis. Synthetic 
methodology papers typically report the substrate scope of the transformation, 
by varying the positions, sterics and electronics of the various R groups on 
each of the reaction partners, under the optimal reaction conditions.53 The 
substrate scope is typically accompanied by a practical application of the 
transformation, to demonstrate the potential of the transformation and drive 
the uptake of the transformation in molecular discovery. Indeed, C-H 
functionalisation chemistry is often highlighted for its potential to revolutionise 
molecular discovery by enabling access to disconnections of a target molecule 
that were not previously possible.85–87,164,165  
 Given the unprecedented era for new synthetic methodologies, the 
slow uptake of these methodologies in medicinal chemistry workflows for the 
discovery of novel bioactive molecules is remarkable.18,53 Indeed, the range 
of chemical reactions implemented in medicinal chemistry workflows has 
remained roughly constant (although very slowly increasing) for the last 30 
years.20 This is due, in part, to the requirement for reliable and robust synthetic 
transformations implemented in discovery workflows to maximise productivity. 
While new synthetic methodologies report a broad substrate scope under 
idealised reaction conditions, they often fail to validate the chemistry with 
highly-functionalised and polar substrates, which are often required for the 
preparation of drug-like compounds.18,26,53 Drug molecules typically contain 
amines, N-heterocycles and unprotected polar groups.18 Indeed, such 
reactions with highly-functionalised substrates systematically fail under the 
model reaction conditions, leading to logP drift, in which the final synthesised 
library of molecular compounds is typically more lipophilic than the initially 
deigned library.27  
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The poor performance of synthetic methodologies with highly-
functionalised substrates has led to the development and implementation of 
high-throughput nano/microscale reaction optimisation into medicinal 
chemistry workflows.60 Exemplar studies have seen the reaction optimisation 
of palladium  cross-couplings (C-C, C-O, C-N and C-S) with highly-
functionalised substrates in batch57 and flow-based58 systems. Multiple 
reaction parameters were explored, such as catalyst, base, reagent 
stoichiometry and catalyst loading, to enable a broader scope of substrates to 
be used, enabling a greater number of compounds to be successfully 
prepared thus increasing the value of the specific reaction class. This is 
highlighted in the nanoscale synthesis and affinity ranking of CHK1 inhibitors, 
in which under a single reaction condition (per reaction class) just 158 of 384 
target compounds were successfully prepared.68 By exploring four sets of 
reactions conditions (per reaction class) 345 of the 384 target compounds 
were prepared. For reactions to be successful with highly-functionalised 
substrates, a range of catalyst systems and reaction conditions typically need 
to be investigated for each combination of substrate.  
 Studies have also been performed that enable sufficiently robust 
reactions that are fit for purpose to be identified. Robustness screens allow 
the functional group tolerance of a reaction to be assessed by the use of 
additives under the standard reaction conditions.53 Reporting a robustness 
screen alongside the publication of new synthetic methodologies can enable 
sufficiently robust transformation to be identified and adopted. It is clear from 
the ADS study with C-H functionalisation chemistry, significant optimisation of 
reaction conditions for each combination of substrate would be required. For 
future or novel synthetic transformations to be adopted and harnessed in the 
discovery of novel bioactive small molecules within in such discovery 
platforms, the chemical methodology itself must robust and be tolerant to a 
broad range of functional groups.  
5.3  Outlook for Future Activity-Directed Syntheses  
While the reaction arrays themselves failed to deliver reaction mixtures 
with significant biological activity that would have enabled the discovery of 
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new bioactive ligands against Hsp90, the study lead to a series of positive 
outcomes which could prove useful for future studies. Firstly, an optimised 
workflow for performing high-throughput parallel reaction arrays was 
established. The adoption of microvials has enabled parallel reactions to be 
performed at room and elevated temperatures, demonstrated by the 
successful replication of literature C-H functionalisation reactions in 
microscale format.  The use of scavenger resins, in particular Quadrapure 
BzA, can be used for the parallel removal of metal catalysts and Michael 
acceptors from reaction mixtures. The study also demonstrated that if 
protection of polar groups is required to minimise potential reaction 
interference, the deprotection in parallel can readily be performed. The 
optimised workflow could be readily transferred for alternative reaction classes 
in activity-directed synthesis, which can be used in the discovery of novel 
bioactive small molecules against a range of biological targets.  
The discovery of novel ligands of Hsp90 through ADS proved 
challenging, however a series of novel analogues of previously reported 
fragments was identified from the fragment screen. The high-throughput 
assay was readily established and enabled the identification of bioactivity, all 
be it from the unreacted reaction components, from crude reaction mixtures.  
To enable Hsp90 ligands to be discovered in activity-directed synthesis, 
alternative chemistry could be implemented, such as the use of photoredox 
chemistry. The use of photoredox-mediated C-H functionalisation for fragment 
elaboration has been reported in high-throughput format.31 The study 
demonstrated the cross dehydrogenative heteroarylation of cyclic amines. As 
a strategy for the discovery of novel ligands of Hsp90, a fragment screen of 
heteroarenes could be performed (heteroarenes could potentially mimic the 
binding mode of the ADP/ATP core) to identify novel Hsp90 fragments which 
can then be coupled in high-throughput to a broad range of cyclic amines, 
which upon screening in the assay, enable the identification of productive 
reaction combinations (Figure 5.1).  
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Figure 5.1 Potential future study implementing photoredox C-H functionalisation of 
heteroarenes with cyclic amines for Hsp90 ligand discovery in activity-directed synthesis. 
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Chapter 6. 
Experimental 
6.1  General Information and Instrumentation 
Commercially available starting materials were obtained from Sigma−Aldrich, 
Acros, Fluorochem, Alfa Aesar, Fisher Scientific, Enamine BB (EU), SLS 
(Scientific Laboratory Supplies) and Insight Biotechnology. All non-aqueous 
reactions were performed under a nitrogen atmosphere unless otherwise 
stated. Water-sensitive reactions were performed in anhydrous solvents in 
oven-dried glassware and cooled under nitrogen before use. Anhydrous 
dichloromethane (DCM), anhydrous tetrahydrofuran (THF), anhydrous 
toluene, anhydrous diethyl ether, anhydrous ethanol, anhydrous methanol 
and anhydrous acetonitrile were obtained from a PureSolv MD5 Purification 
System. Anhydrous dimethyl sulfoxide (DMSO), anhydrous 1,2-
dichloroethane, anhydrous dimethylformamide (DMF) and anhydrous 1,4-
dioxane were obtained from SureSeal bottles from Sigma−Aldrich. All other 
solvents used were of chromatography or analytical grade. Petrol refers to 
petroleum spirit (b.p. 40–60 °C) and ether refers to diethyl ether. Solvents 
were removed under reduced pressure using a Büchi rotary evaporator and 
Vacuubrand PC2201 Vario diaphragm pump.   
  
Thin layer chromatography (TLC) was performed using aluminium backed 
silica (Merck silica gel 60 F254) plates obtained from Merck. Ultraviolet light 
(λmax = 254 nm) and KMnO4 were used for visualization. Flash column 
chromatography was performed using silica gel 60 (35-70 μm particles) 
supplied by Merck. Infrared spectra were recorded using a Bruker Alpha-P 
ATR FR-IR Spectrometer. Absorptions are reported in wavenumbers (cm–1). 
 
Analytical LCMS was performed using two systems. An Agilent 1200 series 
LC system comprising a Bruker HCT Ultra ion trap mass spectrometer, a high 
vacuum degasser, a binary pump, a high performance autosampler and a 
micro well plate autosampler, an autosampler thermostat, a thermostated 
column compartment and a diode array detector. The system used a 
Phenomenex Luna C18 50 x 2 mm 5 micron column with two solvent systems: 
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MeCN/H2O + 0.1% formic acid or MeCN/H2O. Secondly, an Ultimate3000 
HPLC instrument with a Bruker Amazon Speed MS Detector with electrospray 
ionization. The system ran with a positive and negative switching mode and 
UV diode array detector using a Phenomenex Kinetex C18 column (2.6 
micron, 2.1x50mm) and gradient elution H2O and MeCN each plus 0.1% 
formic acid. Accurate mass spectrometry was performed using electrospray 
ionisation on a Bruker MaXis Impact spectrometer.  
 
Proton (1H) and carbon (13C) NMR data was collected on Bruker 300, 400, 
500 or 500-CP(cryoprobe) MHz spectrometers using an internal deuterium 
lock. Data was collected at 300 K unless otherwise stated. Chemical shifts (δ) 
are given in parts per million (ppm) and referenced to the residual solvent 
peak. Coupling constants (J) are reported in Hertz (Hz) and splitting patterns 
are reported in an abbreviated manner: app. (apparent), s (singlet), d 
(doublet), t (triplet), q (quartet), sext. (sextet), hept. (heptet), m (multiplet) and 
br (broad). NMR data was reported in the format: ppm (number of protons, 
splitting pattern, coupling constant (Hz), proton ID). Assignment of signals was 
aided by the use of DEPT 135, COSY, HMQC, HMBC and NOESY.  
6.2  Chemistry 
6.2.1  General Procedures 
General Procedure (A) for Evaluation of Reported C-H Functionalisation 
Microscale Reactions in parallel format 
Reactions were performed using 0.75 mL borosilicate glass vials (8 x 30 mm, 
Chemglass #CV-7000-0830). Substrates refers to the reactant bearing the 
directing group for C-H functionalisation and co-substrate refers to the 
functionalisation reaction partner. Substrates and co-substrates stocks were 
prepared in CH2Cl2 at 100 mM and 200 mM respectively and 100 L of one of 
each was added to the vial of interest and the solvent allowed to evaporate. 
Catalyst-system stock solutions were prepared at 5 mM, with respect to 
catalyst, in the appropriate solvent system with reaction additives prepared in 
the same ratio to catalyst as reported (Table 6.3). 100 L of the catalyst-
system solution was added to the vial of interest, to give final concentration of 
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substrate, co-substrate and catalyst of 100 mM, 200 mM and 5 mM 
respectively and the reactions sealed and allowed to react at rt for 24 h. 
Reaction mixtures were analysed via LC-MS, by preparing 5 mM stock 
solutions in MeCN.  
 
General Procedure (B) for Evaluation of Heated Parallel Microscale 
Reactions 
Reactions were performed sealed using 0.75 mL borosilicate glass vials (8 x 
30 mm, Chemglass #CV-7000-0830) and sealed using an OptiBlock Parallel 
Synthesis Reaction Block (Chemglass #OP-5000-01) and PTFE-Faced 
Silicone Septa Pads (Chemglass #OP-5000-60). Substrates and co-
substrates stocks were prepared in CH2Cl2 at 100 mM and 200 mM 
respectively and 100 L of one of each was added to the vial of interest and 
the solvent allowed to evaporate. Catalyst-system stock solutions were 
prepared at 5 mM, with respect to catalyst, in the appropriate solvent system 
with reaction additives prepared in the same ratio to catalyst as reported 
(Table 6.3). 100 L of the catalyst-system solution was added to the vial of 
interest, to give final concentration of substrate, co-substrate and catalysts of 
100 mM, 200 mM and 5 mM respectively and the reactions sealed and heated 
at 60 oC for 24 h. Reaction mixtures were analysed via LC-MS by preparing 5 
mM stock solutions in MeCN.  
 
General Procedure (C) for Michael Acceptor Scavenging Screen 
The scavenging capabilities of the functionalised solid-support resins was 
determined by performing a screen on a model set of Michael acceptors with 
varying electrophilicities. A stock solution of the corresponding Michael 
acceptor (0.15 mmol) and an internal standard, 2,4,5-trichloro-
methoxybenzene (0.15 mmol) in CDCl3 (5 mL) was prepared and aliquoted (5 
x 1 mL, 0.03 mmol of Michael acceptor and 0.03 mmol of standard per 1 mL). 
The 1H NMR spectrum of one aliquot was recorded to serve as the 
unscavenged reference spectrum. To the remaining four aliquots was added 
one of the functionalised resins (2-3 eq. depending on resin loading) and left 
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to scavenge for 24 h. The reaction mixtures were filtered and a 1H NMR 
spectrum of the filtrate recorded. The peaks for the Michael acceptor in the 
unscavenged and scavenged were integrated relative to the internal standard 
to determine the amount of Michael acceptor scavenged from solution.  
 
General Procedure (D) for Metal Catalyst Scavenging Screen 
The metal scavenging capabilities of the Quadrapure BzA solid-supported 
resin was assessed by performing a screen against a range of metal catalysts. 
5mM stock solutions of each of the appropriate metal catalysts (see Section 
3.1.3.2) were prepared, 2.5 moles in 500 μL of CH2Cl2, and aliquoted (5 x 100 
μL). To each solution was added increasing amounts of the Quadrapure BzA 
resin (0 mg, 10 mg, 20 mg, 30 mg and 40 mg) and left to scavenge for 24 h. 
Reaction solutions were filtered, washed with CH2Cl2 (5 x 100 μL), left to 
evaporate overnight and then desiccated for a further 24 h. Scavenged 
mixtures were screened in the biological assay to determine the effect of 
residual metal catalysts in the assay.   
 
General Procedure (E) for Literature Reaction Scavenging 
The scavenging capabilities of the Quadrapure BzA solid-supported resin was 
tested on a model C-H functionalisation reaction as followed. A solution of 
nButyl acrylate (14.3 μL, 100 mM), 3-methylacetanilide (15.0 mg, 100 mM), 
1,4-benzoquinone (5.50 mg, 50.0 mM), para-toluenesulphonic acid (9.50 mg, 
50.0 mM), Pd(OAc)2 (1.10 mg, 5.00 mM) and 2,4,5-trichloro-methoxybenzene 
(4.20 mg, 20.0 mM) in CDCl3 (986 μL) was left to react at rt for 24 h. Aliquots 
(5 x 100 μL) were taken and to each was added increasing amounts of 
Quadrapure BzA (0 mg, 10 mg, 20 mg, 30 mg or 40 mg) and left to scavenge 
for 48 h at rt. The aliquoted reaction mixtures were each filtered, washed with 
CDCl3 (5 x 100 μL) and the samples analysed by 1H NMR (300 MHz) 
spectroscopy. 
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General Procedure (F) for Amide Couplings 
To a solution of benzoic acid, DIPEA (2.00 eq.), TBTU (2.00 eq.) in CH2Cl2 
(10 mL/mmol) was added amine (2.00 eq.) and the reaction mixture stirred at 
rt overnight. The reaction mixture was diluted with H2O (10 mL/mmol), 
extracted with CH2Cl2 (3 x 10 mL) washed with brine (3 x 10 mL), dried 
(MgSO4) and concentrated under reduced pressure. The crude residue was 
purified using column chromatography. 
 
General Procedure (G) for Acetylation of Phenols 
A solution of phenol (1.00 eq.) in Ac2O (26.0 eq.) and pyridine (31.0 eq.) was 
stirred at rt for 18 h.  The reaction mixture was evaporated under reduced 
pressure by addition of toluene (3X). The crude mixture was dissolved in 
CH2Cl2: 10% (w/v) copper (II) sulphate solution (50:50) and stirred for 10 min. 
The aqueous layer was extracted with CH2Cl2, dried (MgSO4) and 
concentrated to give the acetate protected phenol.  
 
General Procedure (H) for Deacetylation of Phenols 
To a stirred solution of acetate protected phenol (0.2 mmol) in MeOH:THF 
(2:1, 1.5 mL), was added a solution of sodium carbonate (25 mg) in H2O (0.5 
mL) and stirred overnight. The reaction mixture was concentrated under 
reduced pressure and the residue partitioned between EtOAc and H2O, the 
organics washed with brine, dried (MgSO4) and concentrated under reduced 
pressure to yield the deprotected phenol.  
 
General Procedure (I) for Deacetylation of Phenols in Parallel Arrays 
To a vial charged with acetate protected phenol (0.01 mmol) was added 
MeOH:THF (2:1, 75.0 L), followed by addition of sodium carbonate solution 
(25.0 L, 470 mM). The reaction mixture was left for 24 h, left open to the air 
to evaporate for 24 h and then desiccated for 24 h. Subsequent analysis by 
LC-MS and 1H NMR (300 MHz) spectroscopy revealed the deprotected 
phenol. 
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General Procedure (J) for Deacetylation of Phenols in Parallel Arrays 
To a vial charged with acetate protected phenol (0.01 mmol) in chloroform 
(100 L) was added Quadrapure BzA resin (30.0 mg) and the solution left  for 
24 h. Subsequent analysis by LC-MS and 1H NMR (300 MHz) spectroscopy 
revealed the deprotected phenol. 
 
General Procedure (K) for LCMS Analysis of Crude Reaction Arrays 
Mixtures 
Crude reaction array mixtures (100 mM in DMSO) were analysed by LC-MS 
by preparing 5 mM stocks in MeCN (100 L) and ran with a positive and 
negative switching mode and UV diode array detector using a Phenomenex 
Kinetex C18 column (2.6 micron, 2.1x50mm) and gradient elution H2O and 
MeCN each plus 0.1% formic acid. Reactions were analysed for conversion 
to products by searching for the bimolecular reaction mass minus the mass of 
H-X (X = H, Cl, Br, I or B(OH)2). 
 
6.2.2  Implementation of Reaction Arrays 
6.2.2.1  C-H Functionalisation Reaction Arrays 
Reaction arrays were performed in 0.75 mL borosilicate glass vials (8 x 30 
mm, Chemglass #CV-7000-0830) in 96-vial (12 x 8) array format and sealed 
with PTFE snap plugs. Fragments, substrates and catalyst stock solutions 
were prepared as shown in Tables 6.1, 6.2 and 6.3 respectively. To each vial 
was added one fragment (100 L) and one substrate (100 L) and the solvent 
allowed to evaporate. Catalyst-system stock solutions (100 L) were added to 
the vial of interest and capped, to give a final reaction concentration of 100 
mM fragment, 200 mM substrate and 5 mM of catalyst (see Table 6.3 for 
additive concentrations) and reactions left at rt for 48 h. After 48 h the reaction 
solvent was allowed to evaporate open to air for 24 h, CH2Cl2 (200 L) was 
added along with Quadrapure BzA resin (30.0 mg), reaction mixtures capped 
and left to scavenge for 24 h. Reaction mixtures were filtered, washed with 
CH2Cl2 (3 x 100 L), CH2Cl2 evaporated open to air followed by desiccation 
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and finally reaction mixtures dissolved in DMSO (100 L) to give a final total 
product concentration (with respect to fragment) of 100 mM.  
For heated reaction arrays, stock components and reactions were prepared 
and performed identically as described, except the reactions were sealed 
using an OptiBlock Parallel Synthesis Reaction Block (Chemglass # OP-5000-
01) and PTFE-Faced Silicone Septa Pads (Chemglass #OP-5000-60) and 
heated to 60 oC, scavenged, filtered and dissolved in DMSO (100 L) to give 
a final total product concentration (with respect to fragment) of 100 mM.  
Reaction Array Components Implemented in Room Temperature Array and 
Heated Array 1: 
 
Fragments (Set 1) (Prepared in CH2Cl2) 
Fragment MW Stock Conc. (mM) Fragment MW Stock Conc. (mM) 
 
F1 
265.1 100 
 
F2 
219.2 100 
 
F3 
257.0 100 
 
F4 
192.1 100 
 
F5 
266.1 100 
 
F6 
202.1 100 
 
F7 
187.1 100 
 
F8 
189.1 100 
 
F9 
197.1 100 
 
F10 
262.1 100 
Table 6.1 Fragment stock concentrations prepared in CH2Cl2 implemented in ADS reaction 
arrays 
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Substrates (Set 1) 
Substrate MW 
Stock 
Conc. 
(mM) 
Solvent Substrate MW 
Stock 
Conc. 
(mM) 
Solvent 
 
S1 
162.0 200 MeOH 
 
S2 
179.0 200 MeOH 
 
S3 
185.0 200 MeOH 
 
S4 
212.1 200 Insoluble* 
 
S5 
207.0 200 Acetone 
 
S6 
200.1 200 Acetone 
 
S7 
224.1 200 Acetone 
 
S8 
279.5 200 CH2Cl2 
 
S9 
285.1 200 Insoluble* 
 
 
S10 
274.1 200 CH2Cl2 
 
S11 
163.1 200 Acetone 
 
S12 
101.1 - 
Not 
Prepared† 
 
S13 
198.7 200 CH2Cl2 
 
S14 
152.6 200 Acetone 
 
S15 
134.2 200 Acetone 
 
S16 
161.2 200 Acetone 
 
S17 
204.0 200 CH2Cl2 
 
S18 
138.2 200 Acetone 
 
S19 
212.1 200 Acetone 
 
S20 
173.2 200 Acetone 
 
S21 
199.3 200 Insoluble*  
S22 
105.1 200 Acetone 
 
S23 
71.1 200 Acetone 
 
S24 
169.2 200 Acetone 
 
S25 
200.1 200 CH2Cl2 
 
S26 
173.2 200 Acetone 
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S27 
151.1 200 Acetone 
 
 
S28 
56.1 200 Acetone 
 
S29 
135.2 200 Acetone 
 
S30 
163.2 200 Acetone 
 
S31 
99.1 200 Acetone 
 
S32 
141.1 200 Acetone 
 
S33 
86.1 200 Acetone 
 
Table 6.2 Substrate stock concentrations prepared in MeOH, Acetone or CH2Cl2 
implemented in ADS reaction arrays (*Insoluble in CH2Cl2, Acetone, MeOH, MeCN, 
Toluene, EtOAc, DCE, Ether and Pentane, † Volatile) 
 
Catalysts 
Catalyst System Component MW Stock Conc. (mM) Solvent 
C1160 
Pd(OAc)2 
(NH4)2S2O8 
224.5 
228.2 
5  
200 
TFA 
C2101 
Pd(OAc)2 
Ac-Ile-OH 
Ag2CO3 
CsCO3 
224.5 
173.2 
275.7 
325.8 
5 
5 
50 
50 
HFIP 
C3106 
Pd(OAc)2 
Benzoquinone 
224.5 
108.1 
5 
200 
CH2Cl2:
iPrOH 
(50:50) 
C494 
Pd(OAc)2 
Benzoquinone 
TsOH 
224.5 
108.1 
172.2 
5 
100 
50 
AcOH:Toluene 
(2:1) 
C5161 
[Cp*RhCl2]2 
CsOAc 
HOAc 
618.1 
192.0 
60.1 
5 
25 
120 
MeOH 
C698 
[Ru(p-cymene)Cl2]2 
AgSbF6 
Cu(OAc)2.H2O 
612.4 
343.6 
181.6 
5 
200 
200 
Dioxane 
C795 
IrCp*(OAc)2 
AgNTf2 
Cu(OAc)2.H2O 
446.0 
338.0 
181.6 
5 
200 
50 
1,2-DCE 
C8104 
[Cp*IrCl2]2 
AgNTf2 
Cu(OAc)2.H2O 
796.7 
388.0 
181.6 
5 
200 
50 
1,2-DCE:HFIP 
(50-:50) 
Table 6.3 Catalyst system stock concentrations prepared in reaction solvent implemented 
in ADS reaction arrays 
 
Reaction Array Components Implemented in Chemistry-Targeted Heated 
Array 2 (Fragments F7 and F8 were prepared and used as described 
previously along with fragments F11-F16, Catalyst systems C2, C4, C6, C7 
and C8 which were matched with substrates (R1-R37) below based on 
literature reactions): 
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Fragments (Set 2) (Prepared in CH2Cl2) 
Fragment MW Stock Conc. (mM) Fragment MW Stock Conc. (mM) 
 
F11 
219.3 100 
 
F12 
219.3 100 
 
F13 
249.3 100 
 
F14 
243.3 100 
 
F15 
255.3 100 
 
F16 
219.3 100 
 
F7 
187.1 100 
 
F8 
189.1 100 
Table 6.4 Fragment stock concentrations prepared in CH2Cl2 implemented in ADS heated 
reaction arrays at 60 oC 
 
Substrates (Set 2) 
Substrate MW 
Stock 
Conc. 
(mM) 
Solvent Substrate MW 
Stock 
Conc. 
(mM) 
Solvent 
Substrates for C4 
 
R1 
71.1 200 CH2Cl2  
R2 
57.1 200 CH2Cl2 
 
R3 
178.2 200 CH2Cl2 
 
R4 
152.2 200 CH2Cl2 
 
R5 
134.2 200 CH2Cl2  
R6 
100.1 200 CH2Cl2 
 
R7 
139.2 200 CH2Cl2  
R8 
86.1 200 CH2Cl2 
Substrates for C6 
 
R1 
71.1 200 CH2Cl2 
 
R9 
163.2 200 CH2Cl2 
 
R10 
86.1 200 CH2Cl2 
 
R7 
139.2 200 CH2Cl2 
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R11 
128.2 200 CH2Cl2 
 
R12 
86.1 200 CH2Cl2 
 
R13 
115.1 200 CH2Cl2 
 
R14 
119.2 200 CH2Cl2 
Substrates for C7 
 
R15 
156.3 200 CH2Cl2  
R2 
57.1 200 CH2Cl2 
 
R16 
105.1 200 CH2Cl2  
R17 
75,1 200 CH2Cl2 
 
R18 
73.1 200 CH2Cl2  
R19 
91.1 200 CH2Cl2 
 
R20 
167.2 200 CH2Cl2  
R21 
71.1 200 CH2Cl2 
Substrates for C2 
 
R22 
272.9 200 CH2Cl2  
R23 
158.0 200 CH2Cl2 
 
R24 
182.2 200 CH2Cl2 
 
R25 
196.1 200 CH2Cl2 
 
R26 
187.0 200 CH2Cl2 
 
R27 
200.0 200 CH2Cl2 
 
R28 
176.0 200 CH2Cl2  
R29 
272.0 200 CH2Cl2 
Substrates for C8 
 
R30 
161.1 200 CH2Cl2 
 
R31 
118.1 200 CH2Cl2 
 
R32 
134.2 200 CH2Cl2 
 
R33 
123.2 200 CH2Cl2 
 
R34 
162.0 200 CH2Cl2  
R35 
150.2 200 CH2Cl2 
 
R36 
94.1 200 CH2Cl2  
R37 
137.1 200 CH2Cl2 
Table 6.5 Substrates (R1-R37) prepared at the final reaction concentration for 
implementation in ADS reaction arrays. Substrates were matched to their respective 
catalysts based on known literature reactions.  
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6.2.2.2  Fragment and -Diazoamide Reaction Arrays 
Reaction arrays for the proposed elaboration of fragments with -diazoamides 
under rhodium catalysis were performed by preparing fragment and 
diazoamide stocks at 200 mM in CH2Cl2 and catalysts stocks at 12.5 mM in 
THF. To the reaction vial of interest was added one fragment (50.0 L) and 
catalyst (8.00 L) and the solvent allowed to evaporate. Finally one 
diazoamide was added (100 L) to each reaction vial to give a final 
concentration of fragment (100 mM), -diazoamide (200 mM) and catalyst 
(1.00 mM). Reaction vials were capped and left for 24 h at rt, followed by 
addition of Quadrapure TU (30.0 mg) to each vial and reaction mixtures left to 
scavenge at rt for 24 h. Reaction mixtures were filtered, solvent allowed to 
evaporate open to air followed by desiccation and reaction mixtures dissolved 
in DMSO (100 L) to give a final total product concentration (with respect to 
fragment) of 100 mM.  
Fragments (Set 3) (Prepared in CH2Cl2) 
Fragment MW 
Stock Conc. 
(mM) 
Fragment MW Stock Conc. (mM) 
 
89 
182.2 200 
 
90 
235.3 200 
 
91 
189.2 200 
 
92 
 
220.3 
 
200 
Table 6.6 Fragment stock concentrations prepared in CH2Cl2 implemented in ADS metal-
catalysed carbenoid reaction arrays. 
 
Rhodium Catalysts (Prepared in THF) 
Catalyst MW 
Stock Conc. 
(mM) 
Catalyst MW Stock Conc. (mM) 
[(CF3CF2CF2CO2)2Rh]2 
 
C9 
1057.9 12.5 
Rh2(OPiv)4 
 
C10 
610.3 12.5 
Table 6.7 Catalysts stock concentrations prepared in CH2Cl2 implemented in ADS metal-
catalysed carbenoid reaction arrays 
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-Diazoamide Substrates (Prepared in CH2Cl2 From Nelson library, prepared by Nelson group members) 
-Diazoamide MW Stock Conc. (mM) -Diazoamide MW Stock Conc. (mM) 
 
D1 
251.7 200 
 
D2 
215.3 200 
 
D3 
183.2 200 
 
D4 
180.2 200 
 
D5 
215.3 200 
 
D6 
155.2 200 
 
D7 
169.2 200 
 
D8 
161.2 200 
 
D9 
220.6 200 
 
D10 
229.2 200 
 
D11 
175.2 200 
 
D12 
162.2 200 
Table 6.8 -Diazoamide substrates stock concentrations prepared in CH2Cl2 implemented 
in ADS metal-catalysed carbenoid reaction arrays. 
 
6.2.2.3  -Diazoamide-Fragment and Co-Substrate Reaction Arrays 
Reaction arrays for the proposed elaboration of -diazoamides bearing an 
Hsp90 motif with a range of co-substrates under rhodium catalysis were 
performed by preparing -diazoamide and co-substrate stocks at 100 mM and 
200 mM in CH2Cl2 respectively and catalysts stocks at 12.5 mM in THF. To 
the reaction vial of interest was added one co-substrate (100 L) and catalyst 
(8.00 L) and the solvent allowed to evaporate. Finally one -diazoamide 
fragment was added (100 L) to each reaction vial to give a final concentration 
-diazoamide fragment (100 mM), co-substrate (200 mM) and catalyst (1.00 
mM). Reaction vials were capped and left for 24 h at rt, followed by addition 
of Quadrapure TU (30.0 mg) to each vial and reaction mixtures left to 
scavenge at rt for 24 h. Reaction mixtures were filtered, solvent allowed to 
evaporate open to air followed by desiccation and reaction mixtures dissolved 
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in DMSO (100 L) to give a final total product concentration (with respect to 
fragment) of 100 mM. 
-Diazoamide fragments prepared in CH2Cl2 
-Diazoamide 
Fragment 
MW Stock Conc. (mM) 
-Diazoamide 
Fragment 
MW Stock Conc. (mM) 
 
DF1 
333.5 100 
 
DF1 
347.5 100 
Table 6.9 -Diazoamide fragments stock concentrations prepared in CH2Cl2 implemented 
in ADS metal-catalysed carbenoid reaction arrays 
 
Co-Substrates prepared in CH2Cl2 
Co-Substrate MW Stock Conc. (mM) Co-Substrate MW Stock Conc. (mM) 
 
CS1 
152.1 200  
CS2 
185.1 200 
 
CS3 
69.1 200 
 
CS4 
191.1 200 
 
CS5 
134.2 200  
CS6 
84.02 200 
 
CS7 
84.02 200 
 
CS8 
151.0 200 
 
CS9 
100.1 200 
 
CS10 
173.1 200 
 
CS11 
132.1 200 
 
CS12 
161.1 200 
 
CS13 
164.1 200 
 
CS14 
175.2 200 
 
CS15 
179.2 200 
 
CS16 
146.1 200 
 
CS17 
137.1 200 
 
CS18 
204.1 200 
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CS19 
173.1 200 
 
CS20 
186.1 200 
Table 6.10 Co-substrate stock concentrations prepared in CH2Cl2 implemented in ADS 
metal-catalysed carbenoid reaction arrays 
 
 
6.2.3  Compound Data 
Butyl (2E)-3-(2-acetamido-4-methylphenyl)prop-2-enoate, 68 
 
nButyl acrylate (0.42 mL, 3.00 mmol) in toluene (2.25 mL) was added at rt 
to a suspension of 3-methylacetanilide (448 mg, 3.00 mmol), Pd(OAc)2 
(15.0 mg, 0.06 mmol), benzoquinone (324 mg, 3.00 mmol) and p-toluene 
sulfonic acid monohydrate (286 mg, 3.00 mmol) in acetic acid (4.5 mL) and 
the mixture stirred at rt overnight. After 16 h the reaction mixture was diluted 
with diethyl ether (15 mL) and neutralised with aqueous NaOH solution (2.0 
M). The aqueous phase was extracted with diethyl ether (3 × 15 mL) and 
the combined organic phases washed with water (3 × 15 mL), dried 
(MgSO4), and concentrated under reduced pressure to give the crude 
product which was purified by flash column chromatography eluting with 
50:50 petroleum ether-ethyl acetate to give the enoate 6894 (452 mg, 55%) 
as a colourless solid, Rf = 0.31 (50:50, Petroleum ether−ethyl acetate); δH 
(500 MHz; CDCl3) 7.84 (1H d, J 15.8, 3-H), 7.65 (1H, s, phenyl 3-H), 7.53 
(1H, d, J 8.0, phenyl 6-H), 7.21 (1H, br s, NH) 7.09 (d, J 8.0, phenyl 5-H), 
6.44 (1H, d, J 15.8, 2-H), 4.27 (2H, t, J 6.7, butyl 1-H2), 2.43 (3H, s, 
acetamide-H3), 2.30 (3H, s, methylphenyl-H3), 1.75 (2H, p, J 6.7, butyl 2-
H2), 1.50 (2H, h, J 7.4, butyl 3-H2) and 1.03 (3H, t, J 7.4, butyl 4-H3); δC (125 
MHz; CDCl3) 168.7, 167.0, 141.5, 139.0, 135.7, 127.0, 125.7, 125.1, 124.8, 
119.6, 64.6, 30.8, 24.2, 21.5, 19.2 and 13.7; vmax/cm-1 (film) 3269, 2957, 
2931, 2871, 1709, 1657, 1626, 1570 and 1534; HRMS Found MH+: 
276.1601. (C16H21NO3 requires MH, 276.1600). 
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Butyl 2-(3,3-dimethyl-2,3-dihydro-1H-isoindol-1-yl)acetate, 44 
 
Cumylamine (68.0 mg, 0.5 mmol) and nbutyl acrylate (128 mg, 1.0 mmol) 
were added at rt to a suspension of [Ru(p-cymene)Cl2]2 (15.0 mg, 0.025 
mmol), silver hexafluoroantimonate (35.0 mg, 0.10 mmol) and copper (II) 
acetate monohydrate (200 mg, 1.00 mmol) in dioxane (3 mL). The mixture 
was stirred for 6 h under nitrogen atmosphere at rt. The mixture was diluted 
with saturated aqueous sodium bicarbonate solution (40 mL) containing 
ethylenediamine (1 mL) and then extracted with ethyl acetate (2 × 40 mL). 
The combined organic layers were dried (Na2SO4) and concentrated under 
reduced pressure to give the crude product which was purified by flash 
column chromatography, eluting with 50:50 hexane-ethyl acetate to give the 
acetate 4498 (37.0 mg, 28%) as a colourless viscous oil, Rf = 0.21 (50:50, 
hexane−ethyl acetate); δH (500 MHz; CDCl3) 7.26-7.20 (2H, m, isoindolyl 6-
H and 7-H), 7.16-7.11 (2H, m, isoindolyl 5-H and 8-H), 4.83 (1H, dd, J 8.9 
and 4.2, isoindolyl 1-H), 4.16-4.08 (2H, m, butyl 1-H2), 2.88 (1H, dd, J 16.0 
and 4.2, acetate 2-HA), 2.60 (1H, dd, J 15.9 and 8.9, acetate 2-HB), 2.23 
(1H, br s, NH), 1.65-1.57 (2H, m, butyl 2-H2), 1.48 (3H, s, Me), 1.42-1.33 
(2H, m, butyl 3-H2), 1.38 (3H, s, Me) and 0.93 (3H, t, J 7.4, butyl 4-H3); δC 
(125 MHz; CDCl3) 172.3, 149.7, 141.8, 127.5, 126.9, 121.9, 121.3, 64.5, 
62.9, 57.4, 41.8, 30.7, 29.9, 19.2 and 13.7; vmax/cm-1 (film) 2960, 2933, 
2872, 1728, 1667 and 1606; HRMS Found MH+: 262.1809. (C16H23NO2 
requires MH 262.1808).  
The reaction was repeated as stated but under atmospheric conditions to 
yield the crude product which was purified by flash chromatography, eluting 
with 50:50 hexane-ethyl acetate to give the acetate 44 (100 mg, 76%) as a 
colourless viscous oil with spectroscopically identical data to that obtained 
previously.  
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tert-Butyl 2-[(1E)-3-butoxy-3-oxoprop-1-en-1-yl]-1H-pyrrole-1-
carboxylate, 56 
 
Pd(OAc)2 (48.0 mg, 0.20 mmol), nbutyl acrylate (286 μL, 2.00 mmol), N-boc 
pyrrole (670 μL, 4.00 mmol), and benzoquinone (218 mg, 2.00 mmol) were 
added to a mixture of acetic acid/dioxane/DMSO (3:9:1, 10 mL) in a round-
bottom flask and stirred at rt under atmospheric conditions for 96 h. The 
reaction mixture was diluted with diethyl ether (50 mL), water (20 mL) and 
filtered through a plug of celite and the organic phase dried (MgSO4) and 
concentrated under reduced pressure to yield the crude product which was 
purified using flash column chromatography eluting with 75:25, 
hexane−diethyl ether to yield the carboxylate 5690 as a colourless oil (150 
mg, 26%), Rf = 0.25 (75:25 hexane−diethyl ether); δH (500 MHz; CDCl3) 8.27 
(1H, d, J 15.9, propenyl 1-H), 7.39 (1H, d, J 3.5, pyrrole 5-H), 6.69 (1H, d, J 
3.5, pyrrole 3-H), 6.21 (1H, d, J 15.9, propenyl 2-H), 6.21 (1H, t, J 3.5, 
pyrrole 3-H), 4.18 (2H, t, J  7.0, Butyl 1-H2), 1.66 (3H, quin, J 7.0, butyl 2-
H2), 1.62 (s, 9H, tert-butyl H9), 1.42 (sext, J 7.4, butyl 3-H2) and 0.95 (3H, t, 
J  7.4, butyl 4-H3); δC (125 MHz; CDCl3) 167.2, 149.0, 134.9, 131.1, 124.8, 
116.6, 114.8, 111.4, 84.9, 64.2, 30.8, 28.0, 19.2 and 13.7; vmax/cm-1 (film) 
2963, 2876, 1742, 1701 and 1624; HRMS Found MH+: 294.1703. 
(C16H23NO4 requires MH, 294.1705). 
 
Iridium pentamethylcyclopentadienyl diacetate      
   
[IrCp*(OAc)]2 
 
A suspension of [IrCp*Cl2]2 (50.0 mg, 0.06 mmol) and AgOAc (45.0 mg, 0.27 
mmol) in dry toluene (2.5 mL) was stirred at rt under an atmosphere of argon 
for 3h. The yellow solution was filtered from a residue of silver chloride and 
excess silver acetate and the filtrate was evaporated under reduced 
pressure to give IrCp*(OAc)2 as an orange powder (45 mg, 80%), δH (500 
MHz; CDCl3) 1.93 (6H, s, acetate-H3) and 1.57 (15H, s, Cp*-methyl).95 
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N-tert-Butyl-5-methyl-2-{[4-(trifluoromethyl)phenyl]amino}benzamide, 
70 
 
N-tert-Butyl-3-methylbenzamide (38.2 mg, 0.20 mmol), 4-
(trifluoromethyl)aniline (32.0 mg, 0.20 mmol), IrCp*(OAc)2 (10.0 mg, 0.02 
mmol), Silver(I) Bis(trifluoromethanesulfonyl)imide (232 mg, 0.60 mmol) and 
copper (II) acetate monohydrate (20.0 mg, 0.10 mmol) were added to a 
round-bottom flask at rt. 1,2-Dichloroethane (0.66 mL) was added and the 
mixture stirred under atmospheric conditions at rt for 24 h. The reaction was 
then filtered through a pad of celite, diluted with CH2Cl2 (10 mL) and a 
saturated solution of NH4OH (10 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 10 mL), the combined organic layers were dried (MgSO4), 
filtered and concentrated under reduced pressure. The resulting crude 
residue was purified using flash column chromatography eluting with 50:50 
hexane−EtOAc to yield benzamide 7095 as a pale yellow oil (41.0 mg, 58%), 
Rf = 0.32 (50:50 hexane−EtOAc); δH (500 MHz; CDCl3) 9.00 (1H, br s, NH), 
7.41 (2H, d, J 8.5, phenyl 2’-H and 6’-H), 7.28 (1H, d, J 8.5, phenyl 4-H), 
7.13 (1H, s, phenyl 6-H), 7.08 (3H, m, phenyl 3-H, 3’-H and 5’-H), 5.91 (1H, 
br NH), 2.25 (3H, s, methyl), 1.38 (9H, s, tert-Butyl); δC, (125 MHz; CDCl3) 
168.8, 145.9, 140.2, 132.3, 129.7, 128.0, 126.5 (q, J 3.7), 122.4 (q, J 270.1), 
122.2 (q, J 32.5), 117.9, 117.2, 29.7, 28.9 and 20.6; vmax/cm-1 (film); 3446, 
3326, 1644 and 1588; HRMS Found MH+: 351.1675 (C19H21F3N2O requires 
MH, 351.1684). 
 
N-(pivaloyloxy)benzamide, 73 
 
Benzylhydroxamic acid (1.00 g, 7.30 mmol), pivaloyl chloride (0.87 mL, 7.30 
mmol), triethylamine (0.87 mL, 7.30 mmol) in THF (40 mL) were stirred at rt 
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for 16 h. The reaction mixture was diluted with EtOAc (50 mL) and washed 
with HCl (1N 50 mL), water (2 × 50 mL) and brine (50 mL), the organic layer 
dried (MgSO4) and concentrated under reduced pressure. The crude 
product was crystallised from Et2O-pentane to give a colourless 
microcrystalline powder, N-(pivaloyloxy)benzamide 73 (1.40 g, 87%); δH 
(500 MHz, CDCl3), 9.30 (1H, br s, NH), 7.81 (2H, d, J 8.0, 2-H and 6-H), 
7.54 (1H, t, J 8.0, 4-H), 7.42 (1H, t, J 8.0, 3-H and 5-H), 1.35 (9H, s, tert-
butyl H9); δC, (125 MHz, CDCl3) δ 177.1, 166.8, 132.6, 130.9, 128.8, 127.5, 
38.5 and 27.0; vmax/cm-1 (film) 3205, 2976, 1778, 1660 and 1581; HRMS 
Found MNa+: 244.0943 (C12H15NO3Na requires MNa, 244.0950). 
 
[2-(morpholin-4-yl)phenyl]formamido 2,2-dimethylpropanoate, 75 
 
[RhCp*Cl2]2 (15.5 mg, 0.02 mmol), CsOAc (191 mg, 1.00 mmol), N-
pivaloyloxybenzamide 73 (112 mg, 0.50 mmol) and PivOH (24.0 mg, 0.03 
mmol) was added to a dried round-bottom flask and flushed with nitrogen. 
Dry MeOH (2.5 mL) was added followed by addition of N-chloromorpholine 
(125 mg, 1.00 mmol) and the solution was stirred at rt under an atmosphere 
of nitrogen for 16 h. The reaction mixture was diluted with EtOAc (2 mL), 
filtered through silica, washed with EtOAc (3 x 5 mL) and filtrate evaporated 
under reduced pressure. The resulting residue was purified by flash column 
chromatography eluting with 85:15 pentane−ethyl acetate to yield 
propanoate 75105 (104 mg, 68%) as a colourless solid; Rf = 0.23 (85:15 
pentane−ethyl acetate); δH, (500 MHz, CDCl3) 8.11 (1 H, dd, J 7.8 and 1.7, 
phenyl 3-H), 7.46 (1 H, ddd, J 8.2, 7.3 and 1.7, phenyl H5), 7.30 – 7.23 (2 
H, m, phenyl 4-H and 6-H), 3.92–3.80 (4 H, m, morpholine 2-H2 and 6-H2), 
3.03–2.88 (4H, m, morpholine 3-H2 and 5-H2) and 1.31 (9 H, s, tert-butyl); 
δC, (100 MHz, CDCl3) 176.2, 164.1, 150.7, 133.1, 131.6, 126.8, 126.4, 
121.9, 67.1, 53.8, 38.5 and 27.2; vmax/cm-1 (film) 2975, 2852, 1772, 1681 
and 1598; HRMS Found MH+: 307.1659 (C16H22N2O4 requires MH, 
307.1658). 
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The reaction was repeated as stated at rt under an atmospheric conditions 
to yield the crude product which was purified by flash chromatography, 
eluting with 50:50 hexane-ethyl acetate to give the propanoate 75 (94.0 mg, 
61%) with spectroscopically identical data to that obtained previously.  
 
4-methoxy-N-(2-phenylcyclohexyl)aniline, 76 
 
2-phenylcyclohexanone (500 mg, 2.90 mmol), p-methoxyaniline (354 mg, 
2.90 mmol) and acetic acid (173 μL, 2.88 mmol) were stirred in 1,2-
dichloroethane (15 mL) for 1 h at rt. Sodium triacetoxyborohydride (0.92g, 
4.32 mmol) was added and the solution stirred for 18h at rt. Saturated 
aqueous sodium bicarbonate solution (20 mL) was added and the organic 
phase was dried (MgSO4) and concentrated under reduced pressure to yield 
the crude product which was purified by flash column chromatography using 
95:5, petroleum ether−ethyl acetate to give the aniline 76 (339 mg, 42%) as 
a pale yellow oil, Rf = 0.44 (95:5 Petroleum Ether−EtOAc); δH (500 MHz; 
CDCl3) 7.28-7.22 (4H, m, aniline 2-H, 3-H, 5-H and 6-H), 7.17-7.13 (1H, m, 
phenyl 4-H), 6.67-6.62 (2H, m, phenyl 2-H and 6-H), 6.39-6.32 (2H, m, 
phenyl 3-H and 5-H), 3.70 (1H, m, cyclohexyl 1-H), 3.65 (3H, s, methoxy-
H3), 3.37 (1H, br s, NH), 2.96 (1H, dt, J  12.2 and 3.6, cyclohexyl 2-H), 2.10-
2.04 (1H, m, cyclohexyl-H), 1.97-1.85 (2H, m, cyclohexyl-H2), 1.86-1.78 (1H, 
m, cyclohexyl-H) and 1.63-1.50 (3H, m, cyclohexyl-H3); δC (125 MHz; 
CDCl3) 151.9, 144.2, 142.4, 128.4, 127.8, 126.3, 115.1, 114.8, 55.9, 54.9, 
46.5, 30.4, 26.1, 25.9 and 20.5; vmax/cm-1 (film) 3412, 2932, 2857 and 1617 
and 1602; HRMS Found MH+: 282.1857. (C19H23NO requires MH, 
282.1858). 
 
 
 
 
 
- 144 - 
4-methoxy-N-[2-(2-phenylphenyl)cyclohexyl]aniline, 78 
 
Pd(OAc)2 (9.00 mg, 0.04 mmol), benzoquinone (43.2 mg, 0.40 mmol), 
phenylboronic acid (49.0 mg, 0.40 mmol) and CH2Cl2 (1.5 mL) were added 
at rt to a flask, followed by a solution of aniline 76 (57.0 mg, 0.20 mmol) in 
isopropanol (0.3 mL). The mixture was stirred at rt for 24 h and then diluted 
with CH2Cl2 (15 mL), washed with saturated aqueous sodium bicarbonate 
solution (3 x 20 mL), the combined aqueous layers extracted with CH2Cl2 (3 
x 20 mL) and the combined organic layers were dried (MgSO4) and then 
concentrated under reduced pressure to give the crude product which was 
purified by flash column chromatography eluting with 99:1 petroleum ether-
ethyl acetate to give the aniline 78106 (51.0 mg, 76%) as a pale yellow oil, Rf 
= 0.31 (50:50 petroleum ether−ethyl acetate); δH (500 MHz; CDCl3) 7.43-
7.36 (4H, m, phenyl-H4), 7.31-7.26 (1H, m, phenyl-H), 7.24-7.15 (4H, m, 
phenyl-H4), 7.11 (1H, td, J 7.4 and 1.3, phenyl-H), 6.57-6.51 (2H, m, phenyl-
H2), 6.20-6.13 (2H, m, phenyl-H2), 3.61 (3H, s, methyl), 3.35 (1H, br s, NH), 
3.25 (1H, d, J 3.3, cyclohexyl 1-H), 3.08 (1H, dt, J 12.8 and 3.3, cyclohexyl 
2-H), 1.92-1.81 (1H, m, cyclohexyl-H), 1.80-1.69 (2H, m, cyclohexyl-H2), 
1.66-1.57 (1H, m, cyclohexyl-H), 1.43-1.34 (2H, m, cyclohexyl-H2), 1.28-
1.16 (1H, m, cyclohexyl-H) and 1.12-1.00 (1H, m, cyclohexyl-H); δC (125 
MHz; CDCl3) 151.7, 142.6, 141.4, 137.1, 136.3, 132.7, 130.2, 129.3, 128.6, 
128.1, 127.4, 126.8, 125.8, 114.9, 55.8, 53.5, 42.5, 30.6, 26.2, 26.1 and 
20.1; vmax/cm-1 (film) 3408, 3058, 3025, 2929, 2855, 1600 and 1510; HRMS 
Found MH+: 358.2182. (C25H27NO requires MH, 358.2171). 
 
N-[2-(3,4-dimethylphenyl)-5-methylphenyl]acetamide, 80 
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Ammonium persulfate (228 mg, 1.00 mmol), 3-methyl acetanilide (75.6 mg, 
0.50 mmol) and Pd(OAc)2 (11.6 mg, 0.05 mmol) was added to a round-
bottom flask at rt. TFA (0.74 mL, 10.0 mmol) and o-xylene (1.22 mL, 10.0 
mmol) were added and the reaction mixture stirred at rt for 24 h. The mixture 
was then diluted with CH2Cl2 (10 mL), filtered through a celite pad and 
washed with CH2Cl2 (10 mL). The filtrate was concentrated under reduced 
pressure and the resulting crude product purified by flash column 
chromatography eluting with 2:1 petroleum ether−EtOAc to give the 
acetamide 80107 as a yellow oil (60.0 mg, 52%), Rf = 0.32 (2:1 petroleum 
ether−EtOAc); δH (500 MHz; CDCl3) 8.10 (1H, br s, NH), 7.27-7.18 (2H, m, 
phenyl-H2), 7.14-7.07 (3H, m, phenyl-H3), 6.97 (1H, d, J 7.7, phenyl 5-H), 
2.40 (3H, s, acetamide-methyl), 2.33 (3H, s, methyl), 2.32 (3H, s, methyl), 
2.02 (3H, s, methyl); δC (125 MHz; CDCl3) 168.2, 138.1, 137.4, 136.2, 135.7, 
134.6, 130.6, 130.2, 129.9, 129.4, 126.6, 125.1, 122.0, 24.7, 21.5, 19.9 and 
19.5; vmax/cm-1 (film) 3415, 3293, 2864, 1681 and 1620; HRMS Found MH+: 
254.1544. (C17H19NO requires MH, 254.1545). 
 
1-methyl-2-phenyl-1H-indole, 60 
 
Pd(OAc)2 (11.2 mg, 0.05 mmol), Ag2O (174 mg, 0.75 mmol), 2-nitrobenzoic 
acid (251 mg, 1.50 mmol), iodobenzene (224 μL, 2.00 mmol) and N-
methylindole (128 μL 1.00 mmol) were added to a round-bottom flask at rt. 
Anhydrous DMF (2 mL) was added and the reaction mixture stirred at rt 
under atmospheric conditions for 24 h. The reaction mixture was filtered 
through a plug of silica and then concentrated under reduced pressure and 
the resulting crude product was purified using flash column chromatography 
eluting with 98:2 hexane−EtOAc to yield the indole 6091 as a colourless, 
amorphous solid (57.0 mg, 27%), Rf = 0.32 (98:2 hexane−EtOAc); δH (500 
MHz; CDCl3) 7.68 (1H, d, J 7.9, 7-H), 7.59-7.52 (2H, m, phenyl 2-H and 6-
H), 7.51 (2H, t, J 8.0, phenyl 3-H and 5-H), 7.48-7.40 (1H, m, 6-H), 7.40 (1H, 
d, J 8.0, 8-H), 7.30 (1H, td, J 7.2 and 1.1, 4-H), 7.19 (1H, td, J 8.0 and 1.1, 
5-H), 6.61 (1H, s, 3-H) and 3.78 (3H, s, methyl); δC (125 MHz; CDCl3) 141.6, 
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138.4, 132.9, 129.4, 128.5, 128.0, 127.9, 121.7, 120.5, 119.9, 109.7, 101.7 
and 31.2; vmax/cm-1 (film) 3054, 2918 and 1601; HRMS Found MH+: 
208.1119. (C15H13N requires MH, 208.1126). 
 
N-tert-Butyl-2-(cyclohexylamino)-5-methylbenzamide, 72 
 
N-tert-Butyl-3-methylbenzamide (38.2 mg, 0.20 mmol), cyclohexylamine 
(19.8 mg, 0.20 mmol), [IrCp*Cl2]2 (8.00 mg, 0.01 mmol), Silver(I) 
Bis(trifluoromethanesulfonyl)imide (232 mg, 0.60 mmol), copper (II) acetate 
monohydrate (20.0 mg, 0.10 mmol) were added to a round-bottom flask. A 
solution of 1,2-dichloroethane and hexafluoroisopropanol (50:50, 0.66 mL) 
was added and the reaction heated under atmospheric conditions at 60 oC 
overnight. The reaction was then filtered through a pad of celite, diluted with 
CH2Cl2 (10 mL) and a saturated solution of NH4OH (10 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 10 mL), the combined organic layers 
dried (MgSO4), filtered and concentrated under reduced pressure. The 
resulting crude residue was purified using flash column chromatography 
eluting with 50:50 hexane−ethyl acetate to yield benzamide 72104 as a pale 
yellow oil, (28.0 mg, 49%), Rf = 0.6 (50:50 hexane−EtOAc); δH (300 MHz; 
CDCl3) 7.08-7.01 (2H, m, phenyl 4-H and 6-H), 6.62 (1H, d, J 8.2, phenyl 3-
H), 5.88 (1H, br s, NH), 3.27 (1H, m, cyclohexyl 1-H), 2.22 (3H, s, methyl), 
2.02 (2H, m, cyclohexyl 2-HA and 6-HA), 1.75 (2H, m, cyclohexyl 2-HB and 
6-HB), 1.45 (9H, s, tert-butyl) and 1.41-1.20 (6H, m, cyclohexyl 3-H2, 4-H2 
and 5-H2); δC; (100 MHz, CDCl3) δ 169.6, 146.2, 132.8, 127.8, 123.4, 117.4, 
112.7, 51.4, 33.1, 29.0, 26.0, 25.0 and 20.3, vmax/cm-1 (film); 3442, 3346, 
2931, 2856, 1644, 1608 and 1577, HRMS Found MH+: 289.2293 
(C18H28N2O requires MH, 289.2280).  
The reaction was repeated as stated at rt to yield the crude product which 
was purified by flash chromatography, eluting with 50:50 hexane-ethyl 
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acetate to give the benzamide 72 (22.0 mg, 38%) with spectroscopically 
identical data to that obtained previously.  
 
Tris(propan-2-yl)(2-(propan-2-yl)phenoxy)silane, 118 
 
To a solution of 2-isopropylphenol (3.00 g, 22.0 mmol) and triisopropylsliane 
chloride (6 mL, 27.0 mmol) in dry CH2Cl2 (30 mL) at 0 oC was added 
imidazole (3.70 g, 55.0 mmol) and the solution stirred at 0 oC for 18 h. The 
reaction mixture was quenched with H2O (20 mL), extracted with EtOAc (3 
x 15 mL) and the combined organic layers washed with brine (3 x 20 mL), 
dried (MgSO4) and concentrated under reduced pressure. The resulting 
colourless oil was purified using flash column chromatography eluting with 
hexane to yield silane 118 (4.70 g, 74%). Rf = 0.56 (hexane); δH, (400 MHz, 
CDCl3) 7.07 (1H, dd, J 7.7 and 1.8, 6-H), 6.89 (1H, td, J 7.7 and 1.8, 5-H), 
6.77 (1H, td, J 7.7 and 1.3, 4-H), 6.64 (1H, dd, J 7.7 and 1.3, 3-H), 3.25 (1H, 
hept, J 6.9, propan-2-yl 2-H), 1.24-1.14 (3H, m, tris-propan-2-yl 2-H3), 1.08 
(6H, d, J 6.9, propan-2-yl 1-H3 and 3-H3) and 0.99 (18H, d, J 7.4, tris-propan-
2-yl 1-H9 and 3-H9); δC, (100 MHz, CDCl3) 152.3, 141.0, 129.3, 128.9, 119.4, 
113.1, 26.9, 22.6, 18.1 and 13.1; vmax/cm-1 (film) 3031, 2893, 1598 and 
1580; HRMS (no mass found on positive or negative mode).  
 
4-Bromo-2-(propan-2-yl)phenoxytris(propan-2-yl)silane, 119 
 
To a solution of silane 118 (3.00 g, 10.0 mmol) in THF (25 mL) was added 
N-bromosuccinimide (1.80 g, 10.0 mmol) and the reaction solution was 
stirred at rt for 6 h. The reaction mixture was washed with saturated aqueous 
sodium thiosulphate solution (3 x 20 mL), the combined aqueous layers 
extracted with EtOAc (3 x 20 mL), the combined organic layers washed with 
brine (3 x 20 mL), dried (MgSO4) and concentrated under reduced pressure 
to yield crude silane 119 as a pale yellow oil (3.00 g, 81%), Rf = 0.59 
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(hexane); δH, (400 MHz, CDCl3) 7.14-7.13 (1H, m, 3-H), 6.99 (1H, d, J 8.5, 
5-H), 6.51 (1H, d, J 8.5, 6-H), 3.19 (1H, h, J 6.9, propan-2-yl 2-H), 1.24-1.11 
(3H, m, tris-propan-2-yl 2-H3), 1.06 (6H, d, J 6.9, propan-2-yl 1-H3 and 3-H3) 
and 0.98 (18H, d, J 7.4, tris-propan-2-yl 1-H9 and 3-H9); δC, (100 MHz, 
CDCl3) 152.3, 141.0, 129.3, 128.9, 119.4, 113.1, 26.9, 22.6, 18.1 and 13.1; 
vmax/cm-1 (film): 2944, 2865, 1777 and 1706. 
 
N,N‐Dimethyl‐3‐(propan‐2‐yl)‐4‐{[tris(propan‐2‐yl)silyl]oxy}benzamide, 
120 
 
To a solution of silane 119 (1.00 g, 2.70 mmol) in THF (20 mL) under an 
atmosphere of nitrogen at -78 oC was added dropwise nBuLi (1.40 M in 
hexanes, 2.5 mL, 3.50 mmol) and stirred for 3 h. Dimethyl carbamoyl 
chloride (750 L, 8.10 mmol) was added at the reaction mixture allowed to 
warm to rt and stirred for 24 h. The reaction mixture was quenched with H2O 
(20 mL), extracted with EtOAc (3 x 15 mL) and organics washed with 
saturated aqueous sodium bicarbonate (3 x 15 mL), brine (3 x 15 mL), dried 
(MgSO4) and concentrated under reduced pressure. The residue was 
purified by column chromatography eluting with hexane–EtOAc (80:20) to 
yield the benzamide 120 (0.40 g, 40%) as a colourless solid, Rf = 0.14 
(hexane–EtOAc, 80:20); δH (400 MHz, CDCl3); 7.16 (1H, d, J 2.3, 2-H), 7.00 
(1H, dd, J 8.2 and 2.3, 6-H), 6.58 (1H, d, J 8.2, 5-H), 3.19 (1H, hept, J 6.9, 
propan-2-yl 2-H1), 3.00 (6H, br s, dimethyl H6), 1.18 (3H, hept, J 7.4, tris-
propn-2-yl 2-H3) 1.10 (6H, d, J 6.9, propan-2-yl 1-H3 and 3-H3) and 1.00 
(18H, d, J 7.4, tris-propan-2-yl 1-H9 and 3-H9); δC (100 MHz, CDCl3); 172.0, 
155.8, 135.0, 127.9, 126.4, 126.0, 116.0, 44.5, 26.9, 22.6, 18.0 and 14.1; 
vmax/cm-1 (film); 3160, 2940, 2916, 2879, 1725, 1610 and 1589; HRMS 
Found MH+: 364.3675 (C21H38NO2Si requires MH, 364.2672). 
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N,N‐Diethyl‐3‐(propan‐2‐yl)‐4‐{[tris(propan‐2‐yl)silyl]oxy}benzamide, 
121 
 
To a solution of silane 119 (1.00 g, 2.70 mmol) in THF (20 mL) under an 
atmosphere of nitrogen at -78 oC was added dropwise nBuLi (1.40 M in 
hexanes, 2.5 mL, 3.5 mmol) and stirred for 3 h. Diethyl carbamoyl chloride 
(1.0 mL, 8.10 mmol) was added at the reaction mixture allowed to warm to 
rt and stirred for 24 h. The reaction mixture was quenched with H2O (20 
mL), extracted with EtOAc (3 x 15 mL) and organics washed with saturated 
aqueous sodium bicarbonate (3 x 15 mL), brine (3 x 15 mL), dried (MgSO4) 
and concentrated under reduced pressure. The residue was purified by 
column chromatography eluting with hexane–EtOAc (80:20) to yield the 
benzamide 121 (0.47 g, 44%) as a colourless solid, Rf = 0.16 (hexane–
EtOAc, 80:20); δH (400 MHz, CDCl3) 7.14 (1H, d, J 2.2, 2-H), 6.96 (1H, dd, 
J 8.2 and 2.2, 6-H), 6.51 (1H, d, J 8.2, 5-H), 3.32 (4H, very br d (rotameric) 
ethyl CH2), 3.18 (1H, h, J 6.9, propan-2-yl 2-H1), 1.56 (3H, br s, ethyl CH3), 
1.18 (3H, hept, J 7.6, tris-propan-2-yl 2-H3), 1.16 (6H, d, J 6.9, propan-2-yl 
1-H3 and 3-H3), 1.14 (3H br s, ethyl CH3) and 0.99 (18H, d, J 7.6, tris-propan-
2-yl 1-H9 and 3-H9); δC (100 MHz, CDCl3) 179.6, 155.9, 134.0, 127.6, 125.2, 
125.1, 116.4, 42.3, 26.8, 22.1, 18.0, 15.5 and 13.8; vmax/cm-1 (film); 3060, 
2981, 2972, 1625 and 1580; HRMS Found MH+: 392.2980 (C23H42NO2Si 
requires MH, 392.2985). 
 
4-hydroxy-N,N-dimethyl-3-(propan-2-yl)benzamide, 104 
 
Benzamide 120 (0.40 g, 1.10 mmol) was dissolved in TFA:H2O (50:50, 10 
mL), potassium fluoride (174 mg, 3.30 mmol) added and heated to 80 oC 
overnight. The reaction mixture was diluted with H2O (10 mL), extracted with 
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EtOAc (3 x 10 mL) and organics washed with saturated aqueous sodium 
bicarbonate (3 x 10 mL), brine (3 x 10 mL), dried (MgSO4) and concentrated 
under reduced pressure. The resiude was purified by column 
chromatography eluting with hexane–EtOAc (50:50) to yield the benzamide 
104 (28.0 mg, 12%) as a colourless solid, Rf = 0.10 (hexane–EtOAc, 50:50); 
δH (400 MHz, CDCl3) 7.18 (1H, d, J 2.2, 2-H), 6.97 (1H, dd, J 8.2 and 2.2, 
6-H), 6.53 (1H, d, J 8.2, 5-H), 3.16 (1H, hept, J 6.9, propanyl 2-H1), 2.99 
(6H, br s dimethyl) and 1.12 (6H, d, J 6.9 propanyl H6); δC (100 MHz, CDCl3) 
172.8, 155.3, 134.6, 127.0, 126.1, 125.9, 115.0, 26.8 and 22.4; vmax/cm-1 
(film) 3118, 2960, 2928, 1726, 1613 and 1600; HRMS Found MH+: 208.1332 
(C12H18NO2 requires MH, 208.1338).  
 
N,N-diethyl-4-hydroxy-3-(propan-2-yl)benzamide, 90 
 
Benzamide 121 (0.40 g, 1.00 mmol) was dissolved in TFA:H2O (50:50, 10 
mL), potassium fluoride (174 mg, 3.30 mmol) added and heated to 80 oC 
overnight. The reaction mixture was diluted with H2O (10 mL), extracted with 
EtOAc (3 x 10 mL) and organics washed with saturated aqueous sodium 
bicarbonate (3 x 10 mL), brine (3 x 10 mL), dried (MgSO4) and concentrated 
under reduced pressure. The residue was purified by column 
chromatography eluting with hexane–EtOAc (50:50) to yield the benzamide 
90 (65.0 mg, 27%) as a colourless solid, Rf = 0.24 (hexane–EtOAc 50:50); 
δH (500 MHz, CDCl3); 7.12 (1H, d, J 2.1, 2-H), 6.93 (1H, dd, J 8.1 and 2.1, 
6-H), 6.52 (1H, d, J 8.1, 5-H), 3.34 (4H, very br d (rotameric) ethyl CH2), 
3.16 (1H, h, J 6.9, propanyl 2-H1), 1.57 (3H, br s, ethyl CH3), 1.14 (6H, d, J 
6.9, propanyl 1-H6) and 1.14 (3H, br s, ethyl CH3); δC (75 MHz, DMSO-d6); 
170.5, 155.2, 133.8, 127.7, 125.0, 124.5, 114.4, 41.3, 26.2, 22.3 and 15.6; 
vmax/cm-1 (film); 3062, 2980, 2948, 1610 and 1594; HRMS Found MH+: 
236.1650 (C14H22NO2 requires MH, 236.1651).  
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Sodium [(1E)-2-oxocyclopentylidene]methanolate, 124 
 
To a suspension of NaH (60% in mineral oil, 1.20 g, 0.03 mol) in hexane (20 
mL) was added dropwise a mixture of ethyl formate (2.40 mL, 0.03 mmol) 
and -butyrolactone (2.20 mL, 0.03 mmol). After addition of 10% of the 
mixture, ethanol absolute (1 mL) was added to initiate the reaction, followed 
by the dropwisde addition of the remaining mixture. The mixture was 
refluxed for 2 h and the resulting precipitate filtered and washed with cold 
hexane (3 x 10 mL) and dried to give the methanolate 124153 (4.00 g, 99%) 
as a colouress amorphous solid. δH, (400 MHz, MeOH-d4) 8.56 (1H, m, 
methanolate H1), 4.24 (2 H, dd, J 8.4 and 7.6, oxocyclopentyl 3-H2) and 2.81 
(2 H, dd, J 8.4 and 7.6, oxocyclopentyl 4-H2); δC, (100 MHz, DMSO-d6) 
175.7, 173.5, 167.3, 63.4 and 26.1; vmax/cm-1 (film); 3300, 2937, 2855, 1708 
and 1561; HRMS Found M+: 136.0497 (C5H5NaO3 requires M, 136.0136).  
 
(3E)-3-[(phenylamino)methylidene]oxolan-2-one, 91 
 
To a solution of sodium salt 124 (2.00 g, 15.0 mmol) in methanol (50 mL), 
was added aniline hydrochloride (4.00 g, 31.0 mmol) and the mixture 
refluxed overnight. The reaction mixture was concentrated under reduced 
pressure, diluted with H2O (30 mL), the combined organics extracted with 
CH2Cl2 (3 x 10 mL), organics washed with HCl (3 x 10 mL), saturated 
aqueous sodium bicarbonate (3 x 10 mL) and brine (3 x 10 mL). The 
organics were concentrated under reduced pressure and crude product 
purified by flash column chromatography eluting with hexane–EtOAc 
(50:50) to yield oxolanone 91153 (2.60 g, 73%) as a colourless solid, Rf = 
0.2; δH (400 MHz, DMSO-d6) 9.04 (1H, d, J 13.0, NH), 7.66 (1H, dt, J 13.0 
and 2.3, methylidene 2-H1), 7.29 (2H, apparent t J 7.7, phenyl 3-H and 5-
H), 7.16 (2H, d, J 7.7, phenyl 2-H and 6-H), 6.95 (1H, tq, J 7.7 and 1.0, 
phenyl 4-H1), 4.30 (2H, t, J 7.8, oxolanone 5-H2) and 2.88 (2H, td, J 7.8 and 
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2.3, oxolanone 4-H2), δC (75 MHz, DMSO-d6) 172.9, 141.6, 134.8, 129.4, 
121.6, 115.1, 95.5, 64.6, and 24.7; vmax/cm-1 (film); 3277, 2978, 1722, 1622 
and 1600; HRMS Found MNa+: 262.0680 (C11H11NO2Na requires MNa, 
262.0688)  
 
6-(2-bromophenyl)-1,3,5-triazine-2,4-diamine, 101 
 
2-Bromobenzonitrile (3.70 g, 20.0 mmol), dycyanodiamide (2.50 g, 30.0 
mmol) and potassium hydroxide (0.20 g, 3.60 mmol) were stirred in 
diethylene glycol dimethyl ether (37 mL) at 100 oC for 8 h. Additonal 
dycanodiamide (1.25 g, 0.15 mmol) was added and stirred at 100 oC for a 
further 8 h. The mixture was cooled to rt, diluted with water (20 mL) and the 
resulting precipitate collected by filtration and washed with cold water (3 x 
10 mL) to afford the diamine 101154 (4.50 g, 85%); δH, (400 MHz, DMSO-d6) 
7.66 (1H, dt, J 7.9 and 1.1, 3-H), 7.47 (1 H, dd, J 7.6 and 1.9, 6-H), 7.43 
(1H, dt, J 7.6 and 1.1, 5-H), 7.33 (1H, d, J 7.9 and 1.9, 4-H), 6.84 (4H, br s, 
NH); δC, (100 MHz, DMSO) δ 173.7, 167.4, 140.4, 133.2, 130.7, 130.5, 
127.8 and 120.5; vmax/cm-1 (film) 3515, 3401, 3116, 1630 and 1537. HRMS 
Found MH+: 266.0029 (C9H8BrN5 requires MH, 266.0041). 
 
2-(cyclohexylamino)benzonitrile, 127 
 
To a microwave vial was added 2-bromobenzonitrile (1.00 g, 5.50 mmol), 
Pd(OAc)2 (62.0 mg, 0.03 mmol), dppf (300 mg, 0.55 mmol) and NaOtBu 
(1.60 g, 16.5 mmol). The vial was degassed and flushed with nitrogen. To a 
separate crimped vial was added cyclohexylamine (1.90 mL, 16.5 mmol), 
which was degassed, flushed with nitrogen followed by addition of toluene 
(5 mL) and the solution transferred to the microwave vial, followed by 
addition of toulene (10 mL). The reaction mixture was heated under 
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microwave irradiation to 130 oC for 1.5 h. The reaction mixture was diluted 
with toluene (10 mL), partitioned with H2O (3 x 10 mL), aqueous layers 
extracted with EtOAc (3 x 10 mL), combined organics washed with saturated 
aqueous sodium bicarbonate solution (3 x 10 mL), brine ( 3 x 10 mL), dried 
(MgSO4) and concentrated under reduced pressure. The crude residue was 
purified using flash column chromatography eluting with hexane–EtOAc 
(90:10), to yield the benzonitrile 127 (800 mg, 72%) as a pale brown oil, Rf 
= 0.40 (hexane–EtOAc 90:10); δH (300 MHz, CDCl3) 7.42 – 7.31 (2H, m, 6-
H and 4-H), 6.68 (1H, d, J 8.5, 3-H), 6.63 (1H, td, J 7.5 and 1.0 5-H), 4.46 
(1H, d, J 7.3, NH), 3.37 (1H, ddq, J 10.4, 7.3 and 4.0, cychlohexyl 1-H), 2.12 
– 1.95 (2H, m, cylohexyl 2-HA and 6-HA), 1.82 (2H, dt, J 12.4 and 4.0 
cyclohexyl 2-HB and 6-HB), 1.75 – 1.63 (1H, m, cylohexyl 4-H), 1.48 – 1.16 
(5H, m, cyclohexyl 3-H2, 4-H and 5-H2); δC (75 MHz, Chloroform-d) 149.4, 
134.1, 132.9, 118.1, 115.9, 111.0, 95.5, 51.4, 33.0, 25.6 and 24.8; vmax/cm-
1 (film); 3404. 2930, 2854, 2229, 1709, 1604 and 1576; HRMS Found MNa+: 
223.1205 (C13H16N2Na requires MNa, 223.1211). 
 
2-(cyclohexylamino)benzamide, 113 
 
To an oven-dried dry flask charged with benzonitrile 127 (500 mg, 2.50 
mmol) and potassium tert-butoxide (842 mg, 7.50 mmol) was added dry tert-
butanol (10 mL). The reaction mixture was stirred under an atmosphere of 
nitrogen at 100 oC overnight. The reaction mixture was cooled to rt, 
quenched with H2O (10 mL), organics washed with brine (3 x 10 mL), dried 
(MgSO4) and concentrated under reduced pressure. The crude material was 
purified using flash column chromatography eluting with hexane–EtOAc 
(70:30) to yield the benzamide 113 (270 mg, 50%); Rf = 0.30 (hexane–
EtOAc 70:30); δH (300 MHz, CDCl3), 7.78 (1H, s, NH), 7.29 (1H, dd, J 8.0 
and 1.1, 6-H), 7.25 – 7.16 (1H, m 4-H), 6.64 (1H, d, J 8.0 3-H), 6.44 (1H, 
ddd, J 8.0, 7.0 and 1.1 5-H), 5.58 (2H, br s, NH2), 3.28 (1H, br s, cyclohexyl 
1-H), 1.93 (2H, dd, J 10.2 and 4.0, cyclohexyl 2-HA and 6-HB), 1.81 – 1.49 
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(4H, m, cyclohexyl 2-HB, 3-H, 5-H and 6-HB) and 1.42 – 1.13 (4H, m, 
cyclohexyl, 3-H, 4-H2 and 5-H); δC (75 MHz, CDCl3) 212.2, 172.2, 160.4, 
133.7–132.5 (m), 128.5, 113.7, 112.3, 50.6, 32.8, 25.9 and 24.7; vmax/cm-1 
(film); 3453, 3347, 3168, 2931, 2855, 1632 and 1612; HRMS Found MH+: 
219.1497 (C13H19N2O requires MH, 219.1497). 
 
N,N-Diethyl-3-(propan-2-yl)benzamide, 109 
 
To a solution of 3-isopropylbenzoic acid (1.00 g, 6.00 mmol), DIPEA (5.2 
mL, 30.0 mmol), TBTU (4.50 g, 14.0 mmol) in CH2Cl2 (20 mL) was added 
diethylamine (6.20 mL, 60.0 mmol), and the reaction mixture stirred at rt 
overnight. The reaction mixture was diluted with H2O (15 mL), extracted with 
pentane (3 x 10 mL) washed with brine (3 x 10 mL), dired (MgSO4) and 
concentrated under reduced pressure. The crude residue was purified using 
column chromatography eluting with pentane–EtOAc (80:20) to yield the 
benzamide 109 as a yellow oil (1.20 g, 96%) ; Rf = 0.25 (pentane–EtOAc 
80:20); δH (300 MHz, CDCl3) 7.24 – 7.12 (3H, m, phenyl H3), 7.07 (1H, dt, J 
7.1 and 1.6, phenyl H), 3.30 (4H, very br d, (rotameric) ethyl CH2), 2.82 (1H, 
h, J 6.9, propanyl 2-H1), 1.16 (6H, d, J 6.9 propanyl H6), 1.16 (3H, very br s, 
(rotameric) ethyl CH3), and 1.06 (3H, very br s, (rotameric) ethyl CH3); δC 
(75 MHz, CDCl3); 171.7, 149.1, 137.3, 128.3, 127.2, 124.3, 123.6, 43.2, 
39.2, 34.0, 23.9, 14.2 and 12.9; vmax/cm-1 (film); 2962, 2933, 2873, 1628 and 
1583; HRMS Found MNa+: 242.1546 (C14H21NONa requires MNa, 
242.1421). 
 
N‐tert‐butyl‐3‐(propan‐2‐yl)benzamide, 110 
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According to general procedure F, 3-isopropylbenzoic acid (0.50 g, 3.00 
mmol) and tert-butylamine (630 L, 6.00 mmol) gave a crude material which 
was purified using column chromatography using hexane–EtOAc (80:20) to 
yield the benzamide 110 as  a white solid (438 mg, 67%); Rf = 0.30 
(hexane–EtOAc 80:20); δH (300 MHz, CDCl3) 7.58 – 7.54 (1H, m, 6-H), 7.39 
(1H, app. ddd, J 4.5, 3.8 and 2.1, 2-H), 7.30 – 7.22 (2H, m, 4-H and 5-H), 
2.88 (1H, hept, propanyl 2-H1), 1.41 (9H, s, tert-butyl H9) and 1.20 (6H, d, J 
7.0, propanyl 1-H3 and 3-H3); δC (100 MHz, CDCl3) 167.2, 149.4, 136.0, 
129.3, 128.4, 125.2, 123.8, 51.6, 34.2, 28.9 and 23.9; vmax/cm-1 (film); 3295, 
2970, 1655, 1586, 1514 and 1487; HRMS Found MH+: 220.1645 (C14H22NO 
requires MH, 220.1696). 
 
 
N‐tert‐butyl‐3‐methoxybenzamide, 105 
 
According to general procedure F, 3-methoxybenzoic acid (0.50 g, 3.30 
mmol) and tert-butylamine (693 L, 6.60 mmol) gave a crude material which 
was purified using column chromatography eluting with hexane–EtOAc 
(80:20) to yield the benzamide 105 as a white solid (609 mg, 89%); Rf = 
0.40 (hexane–EtOAc 80:20); δH (300 MHz, CDCl3) 7.26 (1H, app. t, J 2.0, 
6-H), 7.23 (1H, app. t, J 8.0, 5-H), 7.14 (1H, app dt, J 6.5 and 1.0, 2-H), 6.94 
(1H, ddd, J 8.0, 2.6 and 1.0, 4-H), 3.78 (3H, s, methoxy H3) and 1.40 (9H, 
s, tert-butyl H9); δC (100 MHz, CDCl3) 166.7, 159.8, 137.4, 129.4, 118.4, 
117.3, 112.1, 55.4, 51.6 and 28.9; vmax/cm-1 (film); 3298, 3010, 2971, 1636, 
1587, 1530 and 1488; HRMS Found MH+: 208.1275 (C12H18NO2 requires 
MH, 208.1288). 
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N‐tert‐butyl‐4‐(1H‐pyrazol‐1‐yl)benzamide, 115 
 
According to general procedure F, 4‐(pyrazol‐1‐yl)benzoic acid (0.50 g, 2.70 
mmol) and tert-butylamine (560 L, 5.40 mmol) gave a crude material which 
was purified using column chromatography eluting with hexane–EtOAc 
(70:30) to yield the benzamide 115 as a white solid (527 mg, 81%); Rf = 
0.20 (hexane–EtOAc 70:30); δH (300 MHz, CDCl3) 7.91 (1H, d, J 2.4, 
pyrazol-1-yl 5-H), 7.78 – 7.65 (5H, m, 2-H, 3-H, 5-H, 6-H and pyrazol-1-yl 3-
H), 6.45 – 6.41 (1H, m, pyrazol-1-yl 4-H), 5.88 (1H, br s, NH) and 1.42 (9H, 
s, tert-butyl H9); δC (100 MHz, CDCl3) 165.9, 142.0, 141.7, 133.6, 128.2, 
126.8, 118.5, 108.3, 51.8 and 28.9; vmax/cm-1 (film); 3312, 2969, 1654, 1609, 
1586, 1590 and 1500; HRMS Found MH+: 244.1384 (C14H18N3O requires 
MH, 244.1440). 
 
N‐cyclopentyl‐3‐methoxybenzamide, 106 
 
According to general procedure F, 3-methoxybenzoic acid (0.50 g, 3.30 
mmol) and cyclopentylamine (652 L, 6.60 mmol) gave a crude material 
which was purified using column chromatography eluting with hexane–
EtOAc (70:30) to yield the benzamide 106 as a white solid (583 mg, 81%); 
Rf = 0.26 (hexane–EtOAc 70:30); δH (400 MHz, CDCl3) 7.27 (1H, app dd, J 
2.5 and 1.7, 6-H), 7.23 (1H, app t, J 5.9, 2-H), 7.19 – 7.15 (1H, m, 5-H), 6.95 
(1H, ddd, J 8.2, 2.6 and 1.0, 4-H), 4.52 – 4.20 (1H, m, cyclopentyl 1-H), 2.20 
– 1.87 (2H, m, cyclopentyl 2-H and 5-H), 1.82 – 1.56 (4H, m, cyclopentyl 2-
H, 3-H, 4-H and 5-H) and 1.50 – 1.28 (2H, m, cyclopentyl 3-H and 4-H); δC 
(100 MHz, CDCl3) 167.0, 159.8, 136.5, 129.5, 118.5, 117.4, 112.3, 55.5, 
51.8, 33.3 and 23.8; vmax/cm-1 (film); 3245, 3073, 2957, 2869, 2828, 1631, 
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1602. 1586 and 1536; HRMS Found MH+: 220.1354 (C13H18NO2 requires 
MH, 220.1338). 
 
N‐cyclopentyl‐3,4‐dimethoxybenzamide, 107 
 
According to general procedure F, 3,4-dimethoxybenzoic acid (0.50 g, 2.80 
mmol) and cyclopentylamine (543 L, 5.50 mmol) gave a crude material 
which was purified using column chromatography eluting with hexane–
EtOAc (50:50) to yield the benzamide 107 as a white solid (604 mg, 88%); 
Rf = 0.10 (hexane–EtOAc 50:50); δH (300 MHz, CDCl3) 7.35 (1H, d, J 2.0, 
2-H), 7.15 (1H, dd, J 8.3 and 2.0, 6-H), 6.77 (1H, d, J 8.3, 5-H), 5.93 (1H, br 
s, NH), 4.39 – 4.24 (1H, m, cyclopentyl 1-H), 3.86 (3H, s, 4-methoxy), 3.84 
(3H, s, 3-methoxy), 2.09 – 1.96 (2H, m, cyclopentyl 2-H and 5-H), 1.71 – 
1.52 (4H, m, cyclopentyl 2-H, 3-H, 4-H and 5-H) and 1.51 – 1.34 (2H, m, 
cyclopentyl 3-H and 4-H); δC (100 MHz, CDCl3) 166.8, 151.5, 148.9, 127.6, 
119.2, 110.7, 110.2, 56.0, 51.7, 33.2 and 23.9; vmax/cm-1 (film);3313, 2960, 
2870, 2839, 1629, 1603, 1583, 1541 and 1502; HRMS Found MH+: 
250.1437 (C14H20NO3 requires MH, 250.1438). 
 
N‐cyclopentyl‐4‐methoxybenzamide, 108 
 
According to general procedure F, 4-methoxybenzoic acid (0.50 g, 3.30 
mmol) and cyclopentylamine (652 L, 6.60 mmol) gave a crude material 
which was purified using column chromatography eluting with hexane–
EtOAc (70:30) to yield the benzamide 108 as a white solid (625 mg, 86%); 
Rf = 0.25 (hexane–EtOAc 70:30); δH (400 MHz, CDCl3) 7.67 – 7.61 (2H, m, 
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2-H and 6-H), 6.88 – 6.80 (2H, m, 3-H and 5-H), 4.37 – 4.27 (1H, m, 
cyclopentyl 1-H), 3.77 (3H, s, methoxy H), 2.08 – 1.93 (2H, m, cyclopentyl 
2-H and 5-H), 1.81 – 1.52 (4H, m, cyclopentyl 2-H, 3-H, 4-H and 5-H) and 
1.48 – 1.33 (2H, m, cyclopentyl 3-H and 4-H); δC (100 MHz, CDCl3) 166.7, 
162.0, 128.6, 127.3, 113.7, 55.4, 51.6, 33.3 and 23.8; vmax/cm-1 (film); 3291, 
2962, 2869, 1645, 1607, 1577, 1531 and 1496; HRMS Found 
MH+:220.1283 (C13H18NO2 requires MH, 220.1288). 
 
N‐cyclopentyl‐4‐(1H‐pyrazol‐1‐yl)benzamide, 116 
 
According to general procedure F, 4‐(pyrazol‐1‐yl)benzoic acid (0.50 g, 2.70 
mmol) and cyclopentylamine (525 L, 5.40 mmol) gave a crude material 
which was purified using column chromatography eluting with hexane–
EtOAc (70:30) to yield the benzamide 116 as a white solid (527 mg, 81%); 
Rf = 0.20 (hexane–EtOAc 70:30); δH (300 MHz, CDCl3) 7.91 (1H, d, J 2.5, 
pyrazol-1-yl 5-H1), 7.81 – 7.75 (2H, m, 2-H and 6-H), 7.74 – 7.66 (3H, m, 3-
H, 5-H and pyrazol-1-yl 3-H), 6.67 – 6.26 (1H, m, pyrazol-1-yl 4-H), 5.97 
(1H, br s, NH), 4.76 – 4.02 (1H, m, cyclopentyl 1-H), 2.13 – 1.96 (2H, m, 
cyclopentyl 2-H and 5-H), 1.77 – 1.54 (4H, m, cyclopentyl 2-H, 3-H, 4-H and 
5-H) and 1.50 – 1.36 (2H, m, cyclopentyl 3-H and 4-H); δC (100 MHz, CDCl3) 
166.2, 142.2, 141.7, 132.6, 128.3, 126.8, 118.6, 108.3, 51.8, 33.3 and 23.9; 
vmax/cm-1 (film); 2961, 1650, 1601, 1520 and 1500;  HRMS Found MH+: 
256.1375 (C15H18N3O requires MH, 256.1400). 
 
N-ethyl-1,2-oxazole-3-carboxamide, 112 
 
A solution of isoxazole-3-carboxylic acid (1.00 g, 8.50 mmol), TBTU (6.00 
g, 18.0 mmol) and DIPEA (3.10 mL, 18.0 mmol) in CH2Cl2 (20 mL) was 
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stirred at rt for 1 h. Ethylamine hydrochloride was added (4.50 g, 44.0 
mmol), and the reaction mixture stirred at rt overnight. The reaction mixture 
was diluted with H2O (15 mL), extracted with EtOAc (3 x 10 mL) washed 
with a saturated sodium bicarbonate solution (3 x 10 mL), brine (3 x 10 mL), 
dired (MgSO4) and concentrated under reduced pressure. The crude 
residue was purified using column chromatography eluting with hexane–
EtOAc (50:50) to yield the oxazole 112 as a yellow solid (0.60 g, 48 %); Rf 
= 0.46 (hexane–EtOAc 50:50); δH (400 MHz, CDCl3) 8.48 (1H, d, J 1.7 5-
H), 6.84 (1H, d, J 1.7 4-H), 3.51 (2H, q, J 7.3 ethyl CH2) and 1.27 (3H, t, J 
7.3, ethyl CH3);δC (100 MHz, CDCl3) 159.7, 158.5, 157.9, 104.4, 34.5 and 
14.7; vmax/cm-1 (film); 3157, 3124, 2981, 1789, 1676 and 1654; HRMS 
Found MNa+: 163.0475 (C6H8N2O2Na requires MNa, 163.0483). 
 
4-(1H-pyrazol-1-yl)benzamide, 114 
 
A solution of ammonium chloride (0.28 g, 1.07 mmol) in distilled water (4 
mL) was covered with a thin layer of toluene (3 mL) and cooled to 0 oC. A 
solution of NaOH (0.42 g, 2.2 mmol) in distilled water (3 mL) was added 
directly to the aqueous layer followed by a solution of 4-(1H-pyrazol-1-
yl)benzyl chloride (1.0 g, 4.85 mmol) in toluene (20 mL). The biphasic 
mixture was stirred overnight at rt and then cooled to 0 oC and the resulting 
precipitate was filtered, washed with cold water (3 x 20 mL) and toluene (3 
x 20 mL) to yield the benzamide 114 as a colourless solid (491 mg, 55%); 
δH, (400 MHz, DMSO-d6) 8.60 (1H, d, J 2.2, pyrazol-1-yl 3-H), 8.01 (2H, d, 
J 8.6, phenyl 2-H and 6-H), 7.94 (2H, d, J 8.6, phenyl 3-H and 5-H), 7.80 
(1H, d, J 2.2, pyrazol-1-yl 5-H), 7.40 (1H, br s, NH) and 6.59 (1H, t, J 2.2, 
pyrazol-1-yl 4-H); δC, (100 MHz, DMSO) 167.5, 142.0, 132.1, 129.5, 128.5, 
118.1 and 108.8; vmax/cm-1 (film): 3414, 3156, 3107, 1752 and 1654; HRMS 
Found MH+: 188.0816 (C10H9N3O requires MH,188.0824). 
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1-benzoyl-4-methylpiperazine, 97 
 
To a solution of methyl piperazine (925 μL, 8.00 mmol) in 50:50 CH2Cl2-
ether (10 mL) was added dropwise a solution of benzoyl chloride (923 μL, 
8.00 mmol)  in CH2Cl2-ether (2 mL) and stirred overnight at rt. The resulting 
precipitate was filtered, washed with cold ether (2 x 10 mL) to yield the 
piperazine 97 a colourless amorphous solid (1.47 g, 90%), δH, (400 MHz, 
DMSO-d6) 7.57–7.37 (5H, m, phenyl H5), 3.39 (4H, appearing as v. broad 
m, piperazine 2-H2 and 6-H2), 3.19 (4H, s appearing as v. broad m, 
piperazine 3-H2 and 5-H2), 2.75 (3H, s, methyl); δC, (100 MHz, DMSO) 
169.7, 135.2, 130.5, 129.0, 127.6, 52.4, 49.7 and 42.5; vmax/cm-1 (film): 
3340, 2954 1625 and1575; HRMS Found MH+: 205.1337 (C12H16N2O 
requires MH, 205.1341). 
BODIPY-labeled Geldanamycin, 130 
 
A solution of BODIPY FL EDA (2.50 mg, 0.07 mmol), Geldanamycin (8.00 
mg, 0.014 mmol) and DIPEA (7.50 μL, 0.042 mmol) in CH2Cl2 was stirred at 
rt for 24 h.  The mixture was was purified by column chromatography eluting 
with 75:25 CH2Cl2-acetone to yield GM-BODIPY 130156 (5.00 mg 86%). Rf 
= 0.38 (75:25 CH2Cl2-acetone); δH  (500 MHz, CDCl3) 9.13 (1H, s), 7.20 (1H, 
s), 7.05 (1H, s), 6.95 (1H, d, J 11.7), 6.83 (1H, d, J 4.1), 6.62-6.54 (2H, m), 
6.25 (1H, d, J 4.1), 6.13 (1H, s), 5.91 (1H, d, J 9.5), 5.86 (1H, t, J 10.5), 5.18 
(1H, s), 4.76 (2H, br NH), 4.31 (2H, d, J 9.9), 3.65-3.41 (5H, m), 3.35 (3H, 
s), 3.27 (3H, s), 3.25 (2H, d, J 7.3), 2.73 (3H, dtd, J 14.5, 7.1 and 2.1), 2.55 
(3H, s), 2.30 (1H, dd, J 14.0 and 10.7), 2.25 (3H, s), 2.03 (2H, s), 1.80 (3H, 
d, J 1.3), 1.78 (2H, t, J 3.8), 1.73-1.65 (1H, m), 1.00 (3H, d, J 6.9), 0.94 (3H, 
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d, J 6.7); δC, (100 MHz, DMSO-d6) 183.9, 180.3, 173.1, 168.3, 156.2, 156.0, 
145.6, 140.8, 135.8, 135.0, 133.9, 132.7, 128.1, 126.6, 123.9, 120.7, 117.3, 
109.0, 81.8, 81.5, 81.3, 72.6, 69.5, 57.1, 56.7, 53.8, 53.4, 46.9, 39.2, 35.6, 
35.0, 34.2, 32.3, 31.7, 29.7, 29.3, 24.7, 22.8, 15.0, 12.8, 12.6, 12.3, 11.4 
and 1.0; vmax/cm-1 (film); 3456, 2249 and 1620; HRMS Found MNa+: 
885.4149 (C44H57BF2N6O9 requires MNa, 885.4156).  Data consistent with 
literature.156 
 
4-(1H-pyrazol-5-yl)phenyl acetate, F6 
 
General Procedure A yielded acetate F6 as a pale yellow oil (0.22 g, 98%); 
δH (300 MHz, CDCl3) 8.21 (1H, d, J 2.8, pyrazolyl 4-H), 7.82 (2H, dt, J 8.7 
and 2.0, 2-H and 6-H), 7.11 (2H, dt, J 8.7 and 2.0, 3-H and 5-H), 6.67 (1H, 
d, J 2.8, pyrazolyl 5-H) and 2.25 (3H, s, OAc); δC (100 MHz, CD3OD) 169.7, 
157.2, 150.5, 126.9, 126.4, 121.8, 115.5 and 19.5; vmax/cm-1 (film); 3150, 
2918, 1739 and 1606; HRMS Found MH+: 203.0823 (C11H11N2O2 requires 
MH, 203.0821)  
 
4-(Diethylcarbamoyl)-2-methoxyphenyl acetate, F1 
 
General Procedure A yielded acetate F1 as a pale yellow oil (0.60 g, 98%); 
δH (300 MHz, CDCl3) 6.97 (1H, d, J 8.1, 6-H), 6.95 (1H, d, J 1.9, 3-H), 6.86 
(1H, dd, J 8.1 and 1.9, 5-H), 3.77 (3H, s, methoxy), 3.35 (4H, very br d 
(rotameric) ethyl CH2), 2.25 (3H, s, OAc) and 1.28 – 0.97 (6H, m, ethyl CH3); 
δC (75 MHz, CDCl3) 170.7, 168.8, 151.2, 140.4, 135.5, 122.7, 118.5, 111.1, 
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56.0, 43.4, 39.5 and 20.6; vmax/cm-1 (film); 2980, 2254, 1762, 1713 and 
1617; HRMS Found MH+: 266.1418 (C14H20NO4 requires MH, 266.1392)   
 
4-(4-methylpiperazine-1-carbonyl)phenyl acetate, F10 
 
General Procedure A yielded acetate F10 as a pale yellow oil (39.0 mg, 6%); 
δH (300 MHz, CDCl3) 7.38 (2H, d, J 8.6, 2-H AND 6-H), 7.08 (2H, d, J 8.6, 
3-H and 5-H), 3.78 (4H, br s piperazine 2-H2 and 6-H2), 2.76 (4H, s, 
piperazine 3-H2 and 5-H2), 2.49 (3H, s, OAc) and 2.25 (3H, s, N-Me). δC 
(100 MHz, CDCl3) 169.1, 158.5, 129.4, 128.6, 121.8, 115.4, 54.0, 44.9, 44.6 
and 21.1; vmax/cm-1 (film);  2929, 2798, 1754, 1713 and 1607; HRMS Found 
MH+: 263.1398 (C14H19N2O3 requires MH, 263.1396).  
 
4-propanoylphenyl acetate, F4 
 
General Procedure A yielded acetate F4 as a pale yellow oil (0.70 g, 98%); 
δH (300 MHz, CDCl3) 7.93 (2H, d, J 8.8, 2-H and 6-H), 7.12 (2H, d, J 8.8, 3-
H and 5-H), 2.92 (2H, q, J 7.2, propanoyl 2-H2), 2.26 (3H, s, OAc) and 1.16 
(3H, t, J 7.2, propanoyl 3-H2); δC (100 MHz, CD3OD) 171.7, 169.1, 146.4, 
129.3, 123.5, 121.6, 31.2, 19.5 and 7.1; vmax/cm-1 (film); 2979, 1753, 2939, 
1680 and 1592.  
 
Methyl 2-[3,5-bis(acetyloxy)phenyl]acetate, F5 
 
General Procedure A yielded acetate F5 as a pale yellow oil (0.66 g, 90%); 
δH (300 MHz, CDCl3) 6.87 (2H, d, J 2.1, phenyl 2-H1 and 6-H1), 6.79 (1H, t, 
J 2.1, phenyl 4-H1), 3.62 (3H, s, methoxy), 3.54 (2H, s, acetate 2-H2) and 
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2.20 (6H, s, OAc); δC (75 MHz, CD3OD) 172.9, 170.6, 152.5, 137.9, 121.1, 
115.4, 52.5, 41.0 and 20.8; vmax/cm-1 (film); 2955, 1765. 1733, 1616 and 
1593; HRMS Found MNa+: 289.0699 (C13H14O6Na requires MNa 289.0688).  
 
Methyl 3,5-bis(acetyloxy)benzoate, F3 
 
General Procedure A yielded acetate F3 as a pale yellow oil (0.70 g, 94%); 
δH (300 MHz, CDCl3), 7.59 (2H, d, J 2.2, 2-H and 6-H), 7.07 (1H, t, J 2.2, 4-
H), 3.84 (3H, s, methoxy) and 2.23 (6H, s, OAc); δC (75 MHz, CD3OD), 
172.9, 170.6, 152.5, 137.9, 121.1, 115.4, 52.5 and 41.0; vmax/cm-1 (film); 
3082, 2963, 1767, 1713 and 1590; HRMS Found MNa+: 275.0549 
(C12H12O6Na requires MNa 275.0531)  
 
3-phenyl-5H-1,4,2-dioxazol-5-one, S12 
 
To a stirred solution of benzohydroxamic acid (0.50 g, 3.70 mmol) in CH2Cl2 
(40 mL) was added carbonyldiamidazole (0.60 g, 3.70 mmol) and the 
reaction stirred at rt for 0.5 h. The reaction was quenched with HCl (1N, 20 
mL), extracted with CH2Cl2 (3 x 20 mL), dried (MgSO4) and concentrated 
under reduced pressure to afford the dioxazolone S12 as a white solid (0.55 
g); Rf = 0.5 (hexane–EtOAc 90:10); δH (400 MHz, CDCl3) 7.92 – 7.85 (2H, 
m, 2-H and 6-H), 7.72 – 7.64 (1H, m, 4-H) and 7.62 – 7.53 (2H, m, 3-H and 
5-H); δC (100 MHz, CDCl3) 1635, 153.8, 133.8, 129.4, 126.6 and 120.2; 
vmax/cm-1 (film); 2980, 1893, 1862, 1616 and 1590 
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4‐Nitro‐2‐(propan‐2‐yl)phenol, 132 
 
According to a modified procedure,166 70% HNO3 (2.5 mL) was added to a 
solution of 2-isopropylphenol (5.00 g, 37.0 mmol) in EtOAc (25 mL) at 0 oC. 
ZnCl2 (5.00 g, 37.0 mmol) was added and the mixture sonicated at rt for 1 h 
and then stirred at rt overnight. The reaction mixture was diluted with H2O 
(25 mL) and the organics washed with H2O (3 x 20 mL), saturated aqueous 
sodium bicarbonate solution (3 x 20 mL) and brine (3 x 20 mL), dried 
(MgSO4) and concentrated under reduced pressure. The crude orange oil 
was purified using flash column chromatography eluting with a gradient of 
hexane–EtOAc (95:5 to 0:100) to yield the phenol 132 as a bright yellow oil 
(3.50 g, 57%); Rf = 0.19 (hexane–EtOAc 80:20); δH (400 MHz, CDCl3) 8.05 
(1H, d, J 2.8, 3-H), 7.92 (1H, dd, J 8.8 and 2.8, 5-H), 6.79 (1H, d, J 8.8, 6-
H), 3.21 (1H, hept, J 6.9, propan-2-yl 2-H) and 1.21 (6H, d, J 6.9, propan-2-
yl 1-H3 and 3-H3); δC (100 MHz, CDCl3) 159.7, 142.0, 136.4, 123.7, 123.4, 
115.7, 27.5 and 22.6; vmax/cm-1 (film); 3204, 2967, 2872, 1607, 1541 
and1452; LC-MS Found MH+:182.2 (C9H12NO3 requires MH, 182.1). 
 
Tert‐butyldimethyl[4‐nitro‐2‐(propan‐2‐yl)phenoxy]silane, 133 
 
To a solution of tert-butyldimethylsilyl chloride (2.90 g, 19/0 mmol) and 
imidazole (1.30 g, 19.0 mmol) in CH2Cl2 (50 mL) was added 4‐Nitro‐2‐
(propan‐2‐yl)phenol 132 (3.50 g, 19.0 mmol) and the reaction stirred at rt 
overnight. The reaction mixture was diluted with H2O (25 mL), the aqueous 
extracted with CH2Cl2 (3 x 20 mL) and the combined organics washed with 
saturated aqueous sodium bicarbonate solution (3 x 20 mL) and brine (3 x 
20 mL), dried (MgSO4) and concentrated under reduced pressure. The 
crude product was purified using flash column chromatography eluting with 
hexane–EtOAc (80:20) to yield the silane 133 as an orange oil (4.10 g, 
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74%); Rf = 0.5 (hexane–EtOAc 80:20); δH (400 MHz, CDCl3) 8.11 (1H, d, J 
2.8, 3-H), 7.98 (1H, dd, J 8.9 and 2.8, 5-H), 6.82 (1H, d, J 8.9, 6-H), 3.31 
(1H, hept, J 6.9, propan-2-yl 2-H), 1.23 (6H, d, J 6.9, propan-2-yl 1-H3 and 
3-H3), 1.03 (9H, s, tert-butyl H9) and 0.30 (6H, s, dimethyl H6); δC (101 MHz, 
CDCl3) 158.8, 141.9, 140.3, 122.8, 122.6, 117.9, 26.9, 25.7, 22.5, 18.3 and 
-4.1; vmax/cm-1 (film); 2960, 2931, 2860, 1608, 1584,1514 and 1486; HRMS 
Found MH+: 296.1688 (C15H26NO3Si requires MH, 296.1682). 
 
4‐[(Tert‐butyldimethylsilyl)oxy]‐3‐(propan‐2‐yl)aniline, 134 
 
To a solution of tert‐butyldimethyl[4‐nitro‐2‐(propan‐2‐yl)phenoxy]silane 133 
(2.00 g, 6.80 mmol) in EtOAc (75 mL) was added 10% Pd/C (2.00 g). The 
flask was flushed with nitrogen and then repeatedly evacuated and flushed 
with hydrogen and the reaction left to stir under a hydrogen atmosphere at 
rt overnight. The reaction flask was purged with nitrogen and filtered through 
a short plug of celite and the celite washed with EtOAc (3 x 15 mL). The 
filtrate was concentrated under reduced pressure and the crude product 
purified using flash column chromatography eluting with hexane–EtOAc 
(70:30) to yield the aniline 134 as an orange-brown oil (1.40 g, 78%); Rf = 
0.15 (hexane–EtOAc 70:30); δH (400 MHz, CDCl3) 6.40 (1H, d, J 8.4, 5-H), 
6.39 (1H, d, J 2.9, 2-H), 6.22 (1H, dd, J 8.4 and 2.9, 6-H), 3.19 (2H, br s, 
NH2), 3.06 (1H, hept, J 6.9, propan-2-yl 2-H), 0.97 (6H, d, J 6.9, propan-2-
yl 1-H3 and 3-H3), 0.82 (9H, s, tert-butyl, H9) and 0.00 (6H, s, dimethyl H6); 
δC (100 MHz, CDCl3) 145.5, 140.0, 139.8, 118.9, 113.8, 113.2, 26.6, 26.2, 
22.9, 18.3 and -4.2; vmax/cm-1 (film); 3385, 2966, 2972, 1612, 1588, 1520 
and 1492; HRMS Found M2Na+: 553.3414 (C30H54N2O2Si2Na requires 
M2Na, 553.3622). 
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4‐[(Tert‐butyldimethylsilyl)oxy]‐N‐methyl‐3‐(propan‐2‐yl)aniline, 135 
 
By modification of an existing procedure,167 copper acetate (1.80 g, 9.80 
mmol) was added to a solution of 4‐[(Tert‐butyldimethylsilyl)oxy]‐3‐(propan‐
2‐yl)aniline 134 (1.00 g, 3.80 mmol) and pyridine (1.00 mL, 13.3 mmol) in 
dioxane (50 mL) and the reaction mixture stirred at rt for 0.25 h. To the 
reaction mixture was added methyl boronic acid (0.50 g, 8.30 mmol) and the 
reaction mixture heated to 100 oC for 3 h. The reaction mixture was filtered 
through celite, concentrated under reduced pressure, diluted with EtOAc (30 
mL), washed with H2O (3 x 10 mL), saturated aqueous sodium bicarbonate 
solution (3 x 10 mL) and brine (3 x 10 mL), dried (MgSO4) and concentrated 
under reduced pressure. The crude product was purified using flash column 
chromatography eluting with a gradient of hexane–EtOAc (100:0 to 50:50) 
to give the aniline 135 as an orange-brown solid (0.56 g, 53%); Rf = 0.4 
(hexane–EtOAc 80:20); δH (400 MHz, CDCl3) 6.65 (1H, d, J 8.5, 5-H1), 6.51 
(1H, d, J 2.9, 2-H), 6.35 (1H, dd, J 8.5 and 2.9, 6-H), 3.41 (1H, s, br NH H1), 
3.26 (1H, hept, J 6.9, propan-2yl 2-H1), 2.80 (3H, s, Methyl H3), 1.18 (6H, d, 
J 6.9, propan-2-yl 1-H3 and 3-H3), 1.01 (9H, s, tert-butyl H9) and 0.19 (6H, s 
dimethyl H6); δC (100 MHz, CDCl3) 144.8, 143.8, 139.7, 118.9, 111.3, 109.9, 
31.6, 26.7, 25.9, 22.9, 18.3 and -4.2; vmax/cm-1 (film); 2960, 2930, 2859, 
1612, 1588 and 1499; HRMS Found MH+:280.2043 (C16H30NOSi requires 
MH, 280.2097). 
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N‐{4‐[(Tert‐butyldimethylsilyl)oxy]‐3‐(propan‐2‐yl)phenyl}‐2‐
diazoacetamide, DF1 
 
p-Toluenesulfonylhydrazone acid chloride (700 mg, 2.70 mmol) was 
dissolved in CH2Cl2 (10 mL), flushed with nitrogen and cooled to 0 °C. A 
solution of aniline 134 (500 mg, 1.90 mmol) in CH2Cl2 (5 mL) and 
dimethylaniline (350 L, 2.70 mmol) were slowly added and the reaction 
mixture stirred for 2 h before dropwise addition of triethylamine (1.20 mL, 
8.10 mmol). The reaction mixture was allowed to return to rt and the 
resulting red solution stirred for a further 0.5 h. The reaction mixture was 
washed with 10% (w/v) aqueous citric acid solution (3 x 10 mL), the 
combined organics dried (Na2SO4) and concentrated under reduced 
pressure. The crude product was purified using flash column 
chromatography eluting with pentane–ether (50:50) to yield the 
diazoacetamide DF1 as a yellow solid (333 mg, 50%); Rf = 0.20 (Pentane–
ether 50:50); δH (500 MHz, Acetone-d6) 8.72 (1H, br s, NH), 7.42 (1H, d, J 
2.6, 2-H), 7.37 (1H, dd, J 8.6 and 2.6, 6-H), 6.77 (2H, d, J 8.6, 5-H), 5.36 
(1H, s, diazoacetamide 2-H), 3.33 (1H, hep, J 6.9, propan-2-yl 2-H), 1.18 
(6H, d, J 6.9 propan-2-yl 1-H3 and 3-H3), 1.04 (9H, s, tert-butyl H9) and 0.25 
(6H, s, dimethyl H6); δC (125 MHz, Acetone-d6) 164.1, 149.2, 139.8, 134.7, 
119.3, 118.4, 118.3, 48.4, 27.5, 26.3, 23.3, 19.0 and -3.9;  vmax/cm-1 (film); 
3279, 3085, 2959, 2929, 2886, 2858, 2101, 1622, 1602, 1550, 1490 and 
1471; HRMS Found MH+: 334.1949 (C17H28N3O2Si requires MH, 334.1951). 
 
N‐{4‐[(tert‐butyldimethylsilyl)oxy]‐3‐(propan‐2‐yl)phenyl}‐2‐diazo‐N‐
methylacetamide, DF2 
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p-Toluenesulfonylhydrazone acid chloride (700 mg, 2.70 mmol) was 
dissolved in CH2Cl2 (10 mL), flushed with nitrogen and cooled to 0 °C. A 
solution of aniline 135 (500 mg, 1.80 mmol) in CH2Cl2 (5 mL) and 
dimethylaniline (350 L, 2.70 mmol) were slowly added and the reaction 
mixture stirred for 2 h before dropwise addition of triethylamine (1.20 mL, 
8.10 mmol). The reaction mixture was allowed to return to rt and the 
resulting red solution stirred for a further 0.5 h. The reaction mixture was 
washed with 10% (w/v) aqueous citric acid solution (3 x 10 mL), the 
combined organics dried (Na2SO4) and concentrated under reduced 
pressure. The crude product was purified using column chromatography 
eluting with pentane–ether (80:20) to yield the diazoacetamide DF2 as a 
yellow solid (500 mg, 79%); Rf = 0.40 (Pentane–ether 80:20); δH (500 MHz, 
Acetone-d6) 7.15 (1H, d, J 2.7, 2-H), 7.00 (1H, dd, J 8.5 and 2.7, 6-H), 6.91 
(1H, d, J 8.5, 5-H), 4.77 (1H, s, diazoacetamide 2-H), 3.35 (1H, hept, J 6.9, 
propan-2-yl 2-H), 3.21 (3H, s, methyl H3), 1.21 (6H, d, J 6.9, propan-2-yl 1-
H3 and 3-H3), 1.05 (9H, s, tert-butyl H9) and 0.29 (6H, s, dimethyl H6); δC 
(125 MHz, Acetone-d6) 166.0, 153.0, 141.3, 137.8, 126.4, 126.4, 120.0, 
47.3, 37.4, 27.7, 26.3, 23.2, 19.0 and -3.9; vmax/cm-1 (film); 3280, 3085, 
2959, 2930, 2859, 2101, 1622, 1602, 1549 and 1491; HRMS Found MH+: 
348.2112 (C18H30N3O2Si requires MH, 348.2107). 
 
 
 
 
 
 
 
 
 
- 169 - 
6.3  Biology 
6.3.1  Protein Expression 
6.3.1.1  Cell Lines, Media and Buffers 
Bacterial Strains and Plasmids: 
E. coli DH5α cells:  – For plasmid Cloning  
E. coli BL21 (DE3): – For Protein Production 
pET-28a (Kanr) plasmid: contains the His6-Hsp90-NTD(D9-E236) gene. 
 
Media: 
Luria-Bertani Broth  – 25 g/L 
For 100 mL of Luria-Bertani broth (25 g/L) 2.50 g of Luria-Bertani medium was 
added to dH2O (100 mL) and autoclaved (20 min, 121 °C) and stored at rt.  
Kanamycin 1000x stock – 25 mg/mL 
For 5 mL 1000X Kanamycin, 125 mg of Kanamycin was added to dH2O (5 
mL), sterile filtered (0.22 μM syringe filter) and stored at -20 °C (1 mL aliquots). 
 
Isopropyl β-d-1-thiogalactopyranoside (IPTG) 1000x stock – 238 mg/mL 
For 3 mL 1000X IPTG, 714 mg of IPTG was added to dH2O (3 mL) sterile 
filtered (0.22 μM syringe filter) and stored at -20 °C (1 mL aliquots). 
 
Luria-Bertani Agar with Kanamycin (25 μg/mL) Plates 
For 400 mL Luria Bertani/Agar solution containing 25 g/L LB and 15 g/L Agar, 
10 g Luria Bertani medium and 6 g Agar was added to dH2O (400 mL) and 
autoclaved (20 min, 121 °C). Once the solution had reached 50 °C, 1000x 
Kanamycin (400 μL) was added and the solution poured into plates (25 
mL/plate). The plates were left to harden at rt and stored at 4 °C.  
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Buffers: 
Buffer A (40 mM HEPES, pH 8, 300 mM NaCl, 5 mM DTT) 
For 2000 mL of Buffer A, 1M HEPES (80 mL), 4M NaCl (150 mL) and 1M DTT 
(10 mL) was added to dH2O (1600 mL), adjusted to pH 8, volumed to       2000 
mL by addition of dH2O, filter sterilised and stored at 4 °C.  
 
Buffer B (40 mM HEPES, pH 8, 300 mM NaCl, 5 mM DTT, 1M Imidazole) 
For 300 mL of Buffer B, Imidazole (20.4 g) was added to Buffer A (300 mL), 
filter sterilised and stored at 4 °C. 
 
Wash Buffer B1 (40 mM HEPES, pH 8, 300 mM NaCl, 5 mM DTT, 10 mM 
Imidazole) 
For 300 mL Buffer B1, mix Buffer A (297 mL) and Buffer B (3 mL) and store 
at 4 °C.  
 
Wash Buffer B2 (40 mM HEPES, pH 8, 300 mM NaCl, 5 mM DTT, 20 mM 
imidazole) 
For 300 mL Buffer B2, mix Buffer A (294 mL) and Buffer B (6 mL) and store 
at 4 °C.  
 
Elution Buffer B3 (40 mM HEPES, pH 8, 300 mM NaCl, 5 mM DTT, 250 mM 
Imidazole) 
For 300 mL Buffer B3, mix Buffer A (225 mL) and Buffer B (75 mL) and store 
at 4 °C.  
 
Storage Buffer (20 mM, pH 7.5) 
For 200 mL NaPi Buffer (20 mM) add 0.5 M Na2HPO4 to dH2O (192 mL) and 
adjust pH 7.5 with 0.5 M NaH2PO4.  
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Fluorescence Anisotropy (FA) HEPES Buffer (pH 7.3) 
To dH2O was added 20 mM HEPES (pH 7.3), 50 mM KCl, 5mM MgCl2, 20mM 
Na2MoO4, 0.01% Np40 (Tergitol) followed by fresh addition before use of 0.1 
mg/mL Bovine Gamma Globulin (BGG) and 2mM 1,4-Dithiothreitol (DTT). 
 
4XSB Buffer (SDS-Gel) 
For 1 mL of 4XSB buffer add 4xlaemelli (900 μL) to 2-mercaptoethanol (100 
μL) and stored at 4 °C. 
 
6.3.1.2  Transformations for Plasmid Stocks and Sequencing 
pET-28a (Kanr) plasmid containing His6-Hsp90-NTD(D9-E236) (2 μL) was 
transformed into an aliquot of DH5α cells (25-50 μL) by incubating the plasmid 
with the cells on ice for 30 min. The transformation mixture was subjected to 
a heat shock (42 °C) for 45 sec. Luria-Bertani Media (500 μL) was added to 
the transformation mixture and then incubated for 1 h (37 °C, 250 rpm). The 
mixture was centrifuged (3000 rpm, 2 min), the supernatant discarded, the 
pellet re-suspended and then plated onto LB Agar with kanamycin (25 μg/mL). 
The plates were incubated (37 °C) overnight (maximum of 16 h). A single 
colony was picked from the plate and incubated in LB media (5 mL) containing 
Kanamycin (5 μL, 30 °C, 250 rpm) overnight. The plasmid was then isolated 
and purified using a PureLink® Quick Plasmid Miniprep Kit as described in the 
manufacturer’s instructions. Plasmid stocks were stored at –20 °C.  
 
6.3.1.3  Protein Expression 
For protein expression transformations were carried out as above into BL21 
(DE3) E. coli cells. Following incubation overnight, a single colony was picked 
from the plate and incubated in Luria-Bertani media (5 mL) containing 
kanamycin (5 μL) for ca. 4 h or until the optical density (OD) at 600 nm had 
reached ~1.00 (37 °C, 250 rpm). This starter culture (2 mL) was transferred 
into pre-warmed Luria-Bertani media (50 mL, starting OD600 ~ 0.1) and 
incubated ca. 2 h or until the optical OD600 ~1.00 (37 °C, 250 rpm). The culture 
mixture was then transferred to pre-warmed Luria-Bertani media (450 mL, 
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starting OD600 ~ 0.1) and incubated ca. 2 h or until the optical OD600 ~1.00 (37 
°C, 250 rpm). Protein expression was induced by adding 1 mM IPTG (500 μL 
of IPTG 1000X stock per 500 mL of culture) and incubated overnight (20 °C, 
250 rpm). Cells were harvested by centrifugation (5000 rpm, 20 min, 4 °C), 
the supernatant discarded, the pellet re-suspended in buffer A (35 mL) and 
stored at -80 °C.  
 
6.3.1.4  Cell Lysis 
The bacterial pellet was removed from the -80 °C and allowed to thaw to rt.  
and inverted slowly to allow gentle mixing. Lysozyme (20 mg/mL) and one 
protease inhibitor P8849 tablet (Roche complete EDTA free) dissolved in 
buffer A (1 mL) was added to the thawed pellet. The pellet was incubated on 
ice for 0.5 h. The pellet was then sonicated (6 sec. on/6 sec. off × 10 cycles) 
at 4 °C. The sonicated pellet was centrifuged (20,000 rpm, 20 min, 4 °C). The 
supernatant was sterile filtered (0.45 μm syringe filter) and kept on ice ready 
for purification. 
 
6.3.1.5  Purification of His6-Hsp90-NTD(D9-E236) 
The cell lysate containing His6-Hsp90-NTD(D9-E236) was loaded onto a Ni-
packed column (GE Healthcare Life Sciences) using buffer A (10 mL), washed 
with buffer B1 (10 mL) and buffer B2 (10 mL), and protein eluted with buffer 
B3 (20 mL). Following elution the fractions containing His6-Hsp90-NTD(D9-
E236) were collected and combined and then dialysed against NaPi buffer (pH 
7.3) overnight at 4 °C. Protein purification was analysed by SDS PAGE and 
by HRMS. 
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6.4 Fluorescence Anisotropy Assay 
6.4.1  Measurement of Anisotropy 
Fluorescence Anisotropy measurements were carried out on an EnvisionTM 
2013 multilabel plate reader (PerkinElmer) using the following optics: 
 Manufacturer’s 
Description 
Wavelength 
(nm) 
Bandwidth 
(nm) 
Dichromoic 
Mirror 
FITC FP D505 
Single Mirror 
505  
Excitation 
Filter 
FITC FP 485 485 14 
Emission 
Filter 1: 
FITC FP P-pol 535 535 40 
Emission 
Filter 2: 
FITC FP S-pol 535 535 40 
Assays were performed using black 384 well plates (Corning #4514 or #3676). 
The reading protocol was optimised (instrument gain, read height) using the 
instrument software to ensure that the detector was not saturated. 150 flashes 
were used per measurement.  
The anisotropy (r) was calcuated using equation 1. 
𝑟 = 1000 × 
𝑠 − 𝑔𝑝
𝑠 + 𝑔2𝑝
    𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏 
The total fluorescence intensity (I) was calculated using equation 2. 
𝐼 = 𝑆 + 𝑔2𝑝    𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐 
Where s in the intensity of light emitted with the same polarisation as the 
excitation light, p is the light emitted with perpendicular polarisation to the 
excitation light, g is the grating factor which accounts for the responsiveness 
of an instrument to light with differing polarisations. In these assays this was 
set to 0.91 as part of the optimisation process.  
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Blank corrections were performed by subtracting the average of the 
appropriate blank in the s and p channels prior to calculations of the 
anisotropy.  
The BODIPY-labelled Geldanamycin was stored as stock solutions at 190 
M in DMSO at – 20 oC. All stock solutions were kept on ice at all times. 
 
6.4.2  Determination of Limits of Anisotropy 
To rows A-F, wells 1-24 was added 10 L of FA buffer. 10 L of a protein stock 
solution (60 M, 4x final concentration) was added to well 1 in each of the 
rows A-F, and the contents of the well agitated with a pipette. Following 
addition and agitation 10 L of the contents of well 1 in rows A-F was 
transferred to well 2, agitated, then 10 L transferred to well 3. The process 
was repeated across the entire series to well 23 across rows A-F, where after 
agitation 10 L was removed and discarded. 10 L of 100 nM BODIPY-
Geldanamycin (final concentration 50 nM) was added to all well in rows A, C 
and E and 10 L of FA buffer added to all wells in rows B, D, and F to serve 
as blanks. Plates were incubated at 4 oC for 20 h (optimal incubation time) 
and the anisotropy of each well was measured and the average intensities 
measured in the wells containing no tracer (rows B, D and F) were used to 
provide a blank correction for each protein concentration. The anisotropy was 
plotted against protein concentration with the standard deviation of the 
replicates used as the error. The data was fitted to a logistic function (equation 
3) to find the lower and upper limits of the anisotropy rmax, rmin  which reflect the 
anisotropy of the tracer when in the unbound and bound state state 
respectively.  
𝑟 =  
𝑟𝑚𝑖𝑛 − 𝑟𝑚𝑎𝑥
1 + (𝑥 𝑥0⁄ )
𝑝
+  𝑟𝑚𝑎𝑥     𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟑 
Average values were calculated to be rmax  = 139  rmin  = - 4 and these values 
were used throughout subsequent assays. This data was also used to 
calculate the change in quantum yield between the bound and free states of 
the assay by checking for any variation in total intensity over the course of the 
titration (𝜆 = 2.39). 
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6.4.3  Determination of the Dissociation Constant of the 
Fluorescent Tracer 
A serial dilution by a ½ of protein (stock concentration 60 M, 4x final 
concentration) across a series, rows A-F, well 1-24 was performed as 
described above, followed by addition of 10 L of tracer (100 nM, final 
concentration 50 nM) to wells 1-24 in rows A, C and E and 10 L of buffer to 
wells 1-24 in rows B, D and F to serve as blanks. The anisotropy in each well 
was calculated and converted to the fraction of tracer bound using equation 4 
and finally into the amount of tracer bound by multiplying by the total 
concentration of tracer in the well of interest (50 nM).  
𝐿𝐵
𝐿𝑇
=  [
𝜆(𝑟𝑚𝑎𝑥 − 𝑟)
(𝑟 −  𝑟min)
+ 1]
−1
  𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟒 
The data was plotted and fitted to equation 5 using a non-linear least squares 
fitting algorithm in Originpro to determine the Kd of the tracer for the protein. 
The error in Kd was obtained from the fitting error within the procedure.  
𝐿𝐵 =  
(𝐿𝑇 + 𝑃𝑇 + 𝐾𝑑) −  √(𝐿𝑇 + 𝑃𝑇 + 𝐾𝑑)2 − 4𝐿𝑇𝑃𝑇
2
   𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟓 
LB is the concentration of fluorescent tracer bound to protein, LT is the total 
tracer concentration, PT is the total concentration of protein.  
 
6.4.4  Competition Experiments to Determine the Dissociation 
Constant of Unlabelled Ligands 
Dissociation constants for unlabelled control ligands; geldanamycin, ATP and 
ADP, and all subsequent unlabelled ligands were determined as described. 
Stocks of unlabelled ligand were prepared in DMSO (500 mM) and diluted in 
FA buffer (50 mM) prior to addition to the assay plate. 10 L of buffer was 
added to wells 1-24 in rows A-D. 10 L of unlabelled ligand was added to well 
1 in each of the four rows and diluted by ½ across the entire series. 5 L of 
tracer (200 nM) was added to all wells in rows A-C and 5 L of buffer to all 
well in row D. Finally, 5 L of protein (2 M) was added to all wells in rows A-
D. The plates were incubated at 4 oC for 20 h and the anisotropy for all wells 
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measured and calculated by subtracting the intensities of the s and p channels 
in the blank wells from the well of interest. The anisotropy in each well was 
converted into the fraction of tracer bound using equation 4, and finally into 
the amount of tracer bound by multiplying by the final tracer concentration (50 
nM). The bound amount was plotted against the log10 of the competitor 
concentration and the data fitted to a single site competition model (Equation 
6) in OriginPro. The error in IC50 was taken from the fitting error of the data.  
𝐿𝐵 = 𝑀𝑖𝑛 +  
(𝑀𝑎𝑥 − 𝑀𝑖𝑛)
1 + 10(𝑥−𝐿𝑜𝑔𝐼𝐶50)
  𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟔 
Where x is the Log10 of the unlabelled ligand concentration. Max and Min are 
the upper and lower asymptotes of the curve.  
The IC50 values were then converted into Ki of the competitor ligand by 
combination with Kd of the protein using the method of Nicolovska-Coleska.168  
As the error in the final Ki involves components from the error in the 
measurement of the Kd of the tracer and the IC50 of the inhibitor, the error was 
assessed using simulation. A series of simulations were run with a simulated 
value of Kd and IC50 generated around the observed mean, the probability of 
the value occurring was based upon a normal distribution with standard 
deviation equal to the fitting error of each value. The simulated value was then 
propagated to give a simulated Ki. 2000 simulations were performed with the 
final error estimated from the standard deviation of the simulated results. 
 
6.4.5  Fragment Screen 
Fragment stocks were prepared in DMSO at 500 mM and subsequently 
diluted to 50 mM in FA buffer prior to addition to the assay plate. Screening of 
individual compounds was performed in triplicate, with a single blank recorded 
for each concentration of ligand. 10 L of FA buffer was added to wells 1-24 
across four rows of the plate. To the first well in each row was added 10 L of 
50 mM fragment (4X stock) and was diluted by ½ across each well in the row 
to well 23, where after the final addition and agitation 10 L was removed and 
discarded. To all wells in three rows was added 5 uL of tracer (200 nM, 4X 
stock) and to all wells in the fourth row was added 5 uL of FA buffer (serves 
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as blank). Finally, to all wells in all four rows was added 5 L of protein (2 M, 
4X stock). The plates were incubated at 4 oC for 20 h, and the anisotropy 
measured for each well in the series.  
 
6.4.6  Screening Crude Reaction Array Mixtures 
Crude reaction mixtures were stored as 100 mM DMSO stocks and were 
diluted accordingly into DMSO and then DMSO:Buffer (8:92) at four times the 
final assay concentration prior to addition into the assay plate. Reaction array 
mixtures were screened in triplicate and with a single blank (no tracer) as a 
control. 5 L of the reaction array mixtures in DMSO:Buffer (8:92) were added 
to the well of interest followed by 5 L of a 200 nM tracer solution (5 L of 
buffer for the blank). Finally 10 L of a 1 M protein stock solution was added 
to all wells to give a final concentration of 50 nM tracer and 500 nM protein. 
The final DMSO concentration in all wells was 2%. Assay plates were 
incubated at 4 oC for 20 h. The anisotropy in each well was calculated and the 
anisotropy data normalised relative to the positive (10 M geldanamycin) and 
negative (2% DMSO) controls.  
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Appendix A 
Protection and Deprotection of Phenol Containing Hsp90 
Fragments for C-H Functionalisation Reaction Arrays 
A series of LC-MS and 1H NMR (300 MHz) studies were performed to 
determine the deprotection of acetate-protected phenol Hsp90 fragments in 
parallel-based reaction format.  
A.1  Acetate Protections and Deprotections 
A.1.1  Fragment 92/F10 
92/F10 LC-MS Analysis 1H NMR (300 MHz) 
Unprotected 
Start (92) 
 
Mass Found [MH]+: 221.3  
Protected 
(Purified F10) 
 
Mass Found [MH]+: 263.4  
Deprotected 
(Purified 92) 
 
Mass Found [MH]+: 221.3  
Deprotected in 
Plate (crude, 
92)  
Mass Found [MH]+: 221.3  
Table A1.1 LC-MS and 1H NMR (300 MHz) for acetate protection and deprotection of 
phenol containing Hsp90 fragment F10. Protection was performed by reaction of phenol 
with acetic anhydride and pyridine and deprotection was performed with Na2CO3 in 
MeOH:THF:H2O (2:1:1) and LC-MS and 1H NMR (300 MHz) data collected. Deprotection 
was performed in plates with Quadrapure BzA resin (30 mg) and analysed by LC-MS. 
Calculated mass of unprotected 92 and protected F10 fragment  [MH]+: 221.3 and  [MH]+: 
263.3 respectively. 
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A.1.2  Fragment 88/F3 
88/F3 LC-MS Analysis 1H NMR (300 MHz) 
Unprotected 
Start (88) 
 
Mass Found [M-H]-: 167.3  
Protected 
(Purified F3)  
Mass Found [MH]+: 253.3  
Deprotected 
(Purified 88) 
 
Mass: 1. [M-H]-: 167.3 and 2. [MH]+ 169.4  
Deprotected 
in Plate 
(crude, 88)  
Mass Found [M-H]-: 167.3  
Deprotected 
in Plate 
(crude, 88)  
Mass Found [M-H]-: 167.3  
Table A1.2 LC-MS and 1H NMR (300 MHz) for acetate protection and deprotection of 
phenol containing Hsp90 fragment F3. Protection was performed by reaction of phenol with 
acetic anhydride and pyridine and deprotection was performed with Na2CO3 in 
MeOH:THF:H2O (2:1:1) and LC-MS and 1H NMR (300 MHz) data collected. Deprotection 
was performed in plates with MeOH:THF:H2O (2:1:1) and with Quadrapure BzA resin (30 
mg) and analysed by LC-MS. Calculated mass of unprotected 88 and protected F3 
fragment [M-H]-: 167.1 or [MH]+: 169.2  and [MH]+: 253.2 respectively. 
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A.1.3  Fragment 89/F5 
89/F5 LC-MS Analysis 1H NMR (300 MHz) 
Unprotected 
Start (89) 
Mass Found [M-H]-: 181.3 
 
Protected 
(Purified F5) 
 
Mass Found [MH]+: 267.3  
Deprotected 
(Purified 89) 
 
Mass Found [M-H]-: 181.3  
Deprotected 
in Plate 
(crude, 89)  
Mass Found [M-H]-: 181.3  
 
Deprotected 
in Plate 
(crude, 89)  
Mass Found [M-H]-: 181.3 
 
Table A1.3 LC-MS and 1H NMR (300 MHz) for acetate protection and deprotection of 
phenol containing Hsp90 fragment F5. Protection was performed by reaction of phenol with 
acetic anhydride and pyridine and deprotection was performed with Na2CO3 in 
MeOH:THF:H2O (2:1:1) and LC-MS and 1H NMR (300 MHz) data collected. Deprotection 
was performed in plates with MeOH:THF:H2O (2:1:1) and with Quadrapure BzA resin (30 
mg) and analysed by LC-MS. Calculated mass of protected F5 and unprotected fragment 
89 [MH]+: 267.3 and [M-H]-: 181.2 respectively. 
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A.1.4  Fragment 94/F4 
94/F4 LC-MS Analysis 1H NMR (300 MHz) 
Unprotected 
Start (94) 
Mass Found [MH]+: 151.5 
 
Protected 
(Purified F4)  
Mass Found [M2H]
+: 385.2 
 
Deprotected 
(Purified 94) 
 
 
Mass Found [MH]+: 151.5  
Deprotected 
in Plate 
(crude, 94)  
Mass Found [MH]+: 151.4 
 
Deprotected 
in Plate 
(crude, 94)  
Mass Found [MH]+: 151.4  
Table A1.4 LC-MS and 1H NMR (300 MHz) for acetate protection and deprotection of 
phenol containing Hsp90 fragment F4. Protection was performed by reaction of phenol with 
acetic anhydride and pyridine and deprotection was performed with Na2CO3 in 
MeOH:THF:H2O (2:1:1) and LC-MS and 1H NMR (300 MHz) data collected. Deprotection 
was performed in plates with MeOH:THF:H2O (2:1:1) and with Quadrapure BzA resin (30 
mg) and analysed by LC-MS. Calculated mass of protected F4 and unprotected fragment 
94 [M2H]+: 385.4 and [MH]+: 151.2 respectively. 
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A.1.5  Fragment 111/F6 
111/F6 LC-MS Analysis 1H NMR (300 MHz) 
Unprotected 
Start (111) 
 
Mass Found [MH]+: 161.4 
 
Protected 
(Purified F6) 
 
Mass Found [MH]+: 203.4 
 
Deprotected 
(Purified 
111)  
Mass Found [MH]+: 161.4 
 
Deprotected 
in Plate 
(crude, 111)  
Mass Found [MH]+: 161.4 
 
Deprotected 
in Plate 
(crude, 111)  
Mass Found [MH]+: 161.4 
 
Table A1.5 LC-MS and 1H NMR (300 MHz) for acetate protection and deprotection of 
phenol containing Hsp90 fragment F6. Protection was performed by reaction of phenol with 
acetic anhydride and pyridine and deprotection was performed with Na2CO3 in 
MeOH:THF:H2O (2:1:1) and LC-MS and 1H NMR (300 MHz) data collected. Deprotection 
was performed in plates with MeOH:THF:H2O (2:1:1) and with Quadrapure BzA resin (30 
mg) and analysed by LC-MS. Calculated mass of protected F6 and unprotected fragment 
111 [MH]+: 203.2 and [MH]+: 161.2 respectively.  
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Appendix B 
Reaction Array Component Assay Controls 
B.1  C-H functionalisation Reaction Arrays 
B.1.1  Room Temperature Arrays 
Component 
Biological Activity, % (Relative 
to 10 M Geldanamycin)  
Component 
Biological Activity, % (Relative to 
10 M Geldanamycin) 
Screened at 80 M 
 
Screened at 80  
Catalyst 1 0.44  Catalyst 2 -2.79 
Catalyst 3 -1.96  Catalyst 4 -1.86 
Catalyst 5 0.44  Catalyst 6 -1.65 
Catalyst 7 -0.42  Catalyst 8 -2.55 
F1 -1.95  F2 -1.13 
F3 -2.88  F4 -0.04 
F5 -2.21  F6 -3.12 
F7 -2.10  F8 -6.88 
F9 0.75  F10 -4.48 
S1 -0.15  S2 -1.42 
S3 -0.76  S4  
S5 2.60  S6 0.31 
S7 -2.12  S8 -1.81 
S9 0.43  S10  
S11 -0.35  S12 - 
S13 -1.83  S14 -1.86 
S15 46.09  S16 -1.96 
S17 -2.18  S18 -4.73 
S19 -1.76  S20 0.18 
S21 -  S22 -0.60 
S23 0.64  S24 2.53 
S25 29.30  S26 -2.41 
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S27 -3.32  S28 1.43 
S29 -3.63  S30 -4.51 
S31 -2.44  S32 -1.35 
S33     
 
B.1.2  Heated Arrays 
Component 
Biological Activity, % (Relative 
to 10 M Geldanamycin)  
Component 
Biological Activity, % (Relative to 
10 M Geldanamycin) 
Screened at 100 M 
 
Screened at 100  
F11 -8.44  F12 -7.67 
F13 -7.75  F14 -8.35 
F15 -8.87  F16 -4.93 
R1 -5.64  R2 -4.86 
R3 -5.50  R4 -7.16 
R5 -2.93  R6 -5.29 
R7 -6.08  R8 -2.68 
R9 0.09  R10 -2.92 
R11 -0.50  R12 -0.16 
R13 2.39  R14 -3.07 
R15 -9.70  R16 -4.88 
R17 -10.10  R18 -5.29 
R19 -14.74  R20 -10.88 
R21 -5.51  R22 -1.71 
R23 -6.00  R24 -5.05 
R25 -9.72  R26 -1.93 
R27 -4.26  R28 -0.93 
R29 -1.97  R30 -1.64 
R31 -4.49  R32 -12.85 
R33 -6.63  R34 -2.11 
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R35 -7.47  R36 -4.95 
R37 -3.68    
 
B.2  Metal-Catalysed Carbenoid -Diazoamide Reaction 
Arrays 
Component 
Biological Activity, % (Relative 
to 10 M Geldanamycin)  
Component 
Biological Activity, % (Relative to 
10 M Geldanamycin) 
Screened at 100 M 
 
Screened at 100  
C9 1.33  C10 0.45 
D1 1.78  D2 -1.14 
D3 -0.68  D4 -0.49 
D5 0.70  D6 -1.11 
D7 -0.60  D8 -0.41 
D9 -1.10  D10 -0.71 
D11 -0.35  D12 -0.29 
DF1 2.55  DF2 3.15 
CS1 3.26  CS2 -0.26 
CS3 1.85  CS4 -1.44 
CS5 -2.38  CS6 -1.35 
CS7 0.23  CS8 3.72 
CS9 0.96  CS10 -5.56 
CS11 -3.84  CS12 -8.54 
CS13 -3.70  CS14 -4.30 
CS15 2.79  CS16 4.30 
CS17 4.73  CS18 -3.28 
CS19 3.84  CS20 8.98 
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Appendix C 
Analysis of Crude Reaction Array Mixtures by LCMS for 
Detection of Elaborated Hsp90 Fragments 
C.1  C-H Functionalisation Reaction Array Product Analysis 
C.1.1  Reaction Array LCMS Analysis 
Crude reaction array mixtures were analysed by LCMS (Experimental 6.2) by 
diluting reaction arrays stocks (100 mM, DMSO) into MeCN to give a final 
product concentration of 5 mM. LC-MS spectra were analysed by searching 
for the mass of the starting fragment (with deprotection of acetate), substrate 
and bimolecular reaction products ([F+S] – [H+X], F= Fragment, S = substrate 
and X = H, Cl, Br, I or B(OH)2). The catalyst is listed to show the full reaction 
mixture but masses of catalysts and additives were not searched for. For each 
component, the component number is given, the molecular weight and 
whether the mass was (✓) or was not () detected. For reactions where more 
than one possible reaction is possible, multiple masses are given. 10% of the 
reaction array mixtures were analysed. 
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C.1.1.1  Room Temperature Reaction Array  
Fragment Substrate Catalyst Product  Fragment Substrate Catalyst Product 
F4 S3 C3 
289.3 
 
F7 S1 C3 303.3 
347.1 150.2 185.0 - 187.2 162.0 - 
  N/A  ✓  N/A  
F2 S14 C8 335.5 
369.9  
F7 S31 C6 
284.3 
219.3 448.8 - 187.2 99.1 - 
✓  N/A  ✓  N/A  
F1 S2 C3 356.4 
400.2  
F8 S24 C5 
356.4 
223.3 179.0 - 189.2 169.2 - 
✓  N/A  ✓  N/A  
F4 S27 C5 
299.3 
 
F7 S32 C1 
326.4 
150.2 151.1 - 187.2 141.1 - 
✓  N/A  ✓  N/A  
F3 S5 C5 
294.3 
 
F9 S30 C1 
358.4 
168.2 207.0 - 197.2 163.2 - 
  N/A  ✓  N/A  
F4 S19 C7 360.8 
326.4  
F9 S19 C7 407.9 
373.5 150.2 212.7 - 197.2 212.7 - 
  N/A  ✓  N/A  
F2 S23 C6 
288.4 
 
F10 S9 C2 503.3 
377.5 219.3 71.1 - 220.3 285.1 - 
✓  N/A   ✓ N/A ✓ 
F3 S33 C4 
252.2 
 
F10 S23 C5 
289.4 
168.2 86.1 - 220.3 71.1 - 
  N/A    N/A  
F4 S1 C3 266.3 
310.1  
F5 S1 C1 342.1 
298.3 150.2 162.0 - 182.2 162.0 - 
  N/A    N/A ✓ 
F3 S18 C7 
304.3 
 
F7 S11 C3 
306.3 
168.2 136.2 - 187.2 163.1 - 
 ✓ N/A  ✓  N/A  
F5 S32 C1 
321.4 
 
F9 S6 C4 395.5 
316.4 182.2 141.2 - 197.2 200.1 - 
  N/A  ✓  N/A  
F5 S17 C7 305.3 
384.2  
F9 S8 C5 440.2 
348.8 182.2 204.0 - 197.2 279.5 - 
  N/A  ✓  N/A  
F7 S8 C2 338.8 
430.2  
F6 S6 C2 358.2 
279.3 187.2 279.5 - 160.2 200.1 - 
  N/A    N/A  
F5 S24 C5 
349.4 
 
F4 S8 C7 393.2 
301.7 182.2 169.2 - 150.2 279.5 - 
  N/A ✓ ✓  N/A  
F7 S31 C4 
284.3 
 
F4 S1 C8 310.2 
266.3 187.2 99.1 - 150.2 162.0 - 
✓  N/A    N/A ✓ 
F6 S33 C4 
266.3 
 
F1 S6 C6 421.3 
342.2 160.2 86.1 - 223.3 200.1 - 
  N/A    N/A ✓ 
F5 S3 C4 
321.3 
 
F5 S7 C1 
325.3 
182.2 185.0 - 182.2 224.1 - 
  N/A    N/A  
F1 S2 C3 356.4 
400.2  
F5 S22 C1 
285.3 
223.3 179.0 - 182.2 105.1 - 
  N/A    N/A  
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Fragment Substrate Catalyst Product  Fragment Substrate Catalyst Product 
F5 S18 C1 
318.3 
 
F3 S7 C3 
311.3 
182.2 138.2 - 168.2 224.1 - 
  N/A    N/A  
F8 S18 C2 
325.4 
 
F4 S9 C4 433.3 
307.4 189.2 138.2 - 150.2 285.1 - 
✓  N/A   ✓ N/A  
F7 S22 C3 
290.3 
 
F5 S8 C5 333.7 
425.2 187.2 105.1 - 182.2 279.5 - 
  N/A    N/A  
F9 S16 C4 
356.4 
 
F9 S15 C3 
329.4 
197.2 161.2 - 197.2 134.2 - 
✓ ✓ N/A ✓ ✓  N/A  
F9 S20 C5 
368.4 
 
F4 S28 C2 
204.2 
197.2 173.2 - 150.2 56.1 - 
✓ ✓ N/A    N/A  
F1 S18 C6 
359.4 
 
F6 S29 C5 
293.3 
223.3 136.2 - 160.2 135.2 - 
✓  N/A   ✓ N/A  
F4 S22 C7 
253.3 
 
F10 S14 C4 370.8 
336.4 150.2 105.1 - 220.3 152.6 - 
  N/A    N/A  
F8 S25 C4 387.3 
352.8  
F2 S6 C1 
338.5 
189.2 200.1 - 219.3 200.1 - 
✓  N/A  ✓  N/A  
F4 S23 C8 
219.3 
 
F1 S27 C8 
327.3 
150.2 71.1 - 223.3 151.1 - 
  N/A ✓ ✓  N/A  
F3 S27 C8 
317.2 
 
F6 S29 C3 
293.3 
168.2 151.1 - 160.2 135.2 - 
  N/A    N/A  
F1 S30 C6 
384.4 
 
F6 S33 C3 
244.3 
223.3 163.2 - 160.2 86.1 - 
✓  N/A ✓   N/A  
F8 S21 C2 
386.5 
 
F1 S31 C1 
320.4 
189.2 199.1 - 223.3 99.13 - 
✓  N/A  ✓  N/A  
F9 S30 C5 
358.4 
 
F10 S26 C2 
391.5 
197.2 163.2 - 220.3 173.2 - 
✓  N/A    N/A  
F3 S7 C1 
390.2 
 
F5 S32 C6 
321.4 
168.2 224.1 - 182.2 141.21 - 
 ✓ N/A    N/A  
F10 S30 C2 
381.4 
 
F4 S26 C5 
321.4 
220.3 163.2 - 150.2 171.2 - 
  N/A    N/A  
F7 S8 C3 338.8 
430.2  
F7 S23 C2 
256.3 
187.2 279.5 - 187.2 71.1 - 
  N/A    N/A  
F1 S5 C7 
330.4 
 
F6 S33 C8 
244.3 
223.3 207.0 - 160.2 86.1 - 
  N/A    N/A  
F4 S9 C8 433.3 
307.4  
F4 S26 C3 
321.4 
150.2 285.1 - 150.2 171.2 - 
 ✓ N/A   ✓ N/A  
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C.1.1.2  Heated Reaction Array 1 
Fragment Substrate Catalyst Product  Fragment Substrate Catalyst Product 
F1 S31 C4 
320.4 
 
F1 S8 C2 374.8 
466.3 189.2 99.13 - 189.2 279.5 - 
  N/A    N/A ✓ 
F3 S29 C4 
301.3 
 
F2 S10 C2 491.4 
365.5 168.2 135.2 - 219.3 274.1 - 
 ✓ N/A  ✓  N/A  
F4 S30 C4 
311.3 
 
F4 S5 C2 
276.3 
150.2 163.2 - 150.2 207.0 - 
  N/A    N/A  
F5 S24 C4 
349.4 
 
F5 S6 C2 380.2 
301.3 182.2 169.2 - 182.2 200.1 - 
  N/A    N/A  
F7 S26 C4 
358.4 
 
F9 S1 C2 
313.4 
187.2 171.2 - 197.2 162.0 - 
✓  N/A  ✓  N/A  
F2 S14 C8 369.9 
335.5  
F2 S30 C6 
380.5 
219.3 152.6 - 219.3 163.2 - 
  N/A    N/A  
F3 S15 C8 
300.3 
 
F3 S29 C6 
301.3 
168.2 134.2 - 168.2 135.2 - 
  N/A  ✓ ✓ N/A  
F5 S23 C8 
251.3 
 
F4 S32 C6 
289.4 
182.2 71.1 - 150.2 141.2 - 
  N/A   ✓ N/A  
F7 S19 C8 397.9 
363.4  
F7 S26 C6 
358.4 
187.2 212.7 - 187.2 171.2 - 
✓  N/A  ✓  N/A  
F9 S26 C8 
368.5 
 
F9 S31 C6 
294.4 
197.2 171.2 - 197.2 99.13 - 
✓  N/A  ✓  N/A  
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C.1.1.3 Heated Reaction Array 2 
Fragment Substrate Catalyst Product  Fragment Substrate Catalyst Product 
F11 R1 C4 
288.5 
 
F14 R17 C7 
316.4 
219.3 71.1 - 243.3 75.1 - 
✓  N/A  ✓  N/A  
F12 R2 C4 
274.4 
 
F15 R18 C7 
326.4 
219.3 57.1 - 255.3 73.1 - 
✓  N/A  ✓  N/A  
F13 R3 C4 
425.5 
 
F8 R19 C7 
284.3 
249.3 178.2 - 189.1 91.1 - 
✓  N/A ✓   N/A  
F14 R4 C4 
293.5 
 
F11 R22 C2 455.7 
364.3 243.3 152.2 - 219.3 272.9 - 
✓  N/A  ✓  N/A ✓ 
F15 R5 C4 
387.5 
 
F12 R23 C2 
296.4 
255.3 134.2 - 219.3 158.0 - 
✓  N/A  ✓  N/A  
F8 R6 C4 
287.3 
 
F13 R24 C2 
350.4 
189.1 100.1 - 249.3 182.2 - 
✓  N/A  ✓  N/A  
F11 R1 C6 
288.5 
 
F14 R25 C2 
358.5 
219.3 71.1 - 243.3 196.1 - 
✓  N/A ✓ ✓  N/A  
F12 R9 C6 
380.4 
 
F15 R26 C2 
361.5 
219.3 163.2 - 255.3 187.0 - 
✓  N/A  ✓  N/A  
F13 R10 C6 
333.4 
 
F8 R27 C2 
308.3 
249.3 86.1 - 189.1 200.0 - 
✓  N/A  ✓  N/A  
F14 R7 C6 
380.5 
 
F11 R30 C8 
335.4 
243.3 139.2 - 219.3 161.1 - 
✓  N/A  ✓  N/A  
F15 R11 C6 
341.5 
 
F12 R31 C8 
351.5 
255.3 128.2 - 219.3 118.1 - 
✓  N/A  ✓  N/A  
F8 R12 C6 
273.3 
 
F13 R32 C8 
370.5 
189.1 86.1 - 249.3 118.1 - 
✓  N/A  ✓  N/A  
F11 R15 C7 
373.5 
 
F14 R33 C8 
338.4 
219.3 156.3 - 243.3 123.2 - 
✓  N/A ✓ ✓  N/A  
F12 R2 C7 
274.4 
 
F15 R34 C8 415.3 
380.9 219.3 57.1 - 255.3 162.0 - 
✓  N/A  ✓  N/A  
F13 R16 C7 
352.4 
 
F8 R35 C8 
337.4 
249.3 105.1 - 189.1 150.2 - 
✓  N/A  ✓  N/A  
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C.2  Fragment and -Diazoamide Reaction Array Product 
Analysis 
Fragment Substrate Catalyst Product  Fragment Substrate Catalyst Product 
F17 D1 C9 
459.0 
 
F17 D6 C10 
362.5 
235.3 251.7 - 235.3 155.2 - 
✓  N/A ✓ ✓  N/A  
F5 D2 C9 
369.4 
 
F5 D7 C10 
323.4 
182.2 215.3 - 182.2 169.2 - 
✓  N/A    N/A  
F10 D3 C9 
375.5 
 
F10 D8 C10 
353.4 
220.3 183.2 - 220.3 161.2 - 
  N/A    N/A  
F8 D4 C9 
341.4 
 
F8 D9 C10 
390.4 
189.2 180.2 - 189.2 220.6 - 
✓  N/A    N/A  
F17 D5 C9 
422.6 
 
F17 D10 C10 
436.5 
235.3 215.3 - 235.3 229.2 - 
✓  N/A ✓ ✓  N/A  
 
C.3  Hsp90 -Diazoamide Fragment and Co-Substrate 
Reaction Array Product Analysis 
Fragment Substrate Catalyst Product  Fragment Substrate Catalyst Product 
DF1* CS1 C9 
343.5 
 
DF2* CS1 C9 
357.5 
219.2 152.1 - 233.3 152.1 - 
✓  N/A    N/A  
DF1* CS10 C9 
364.5 
 
DF2* CS10 C9 
378.5 
219.2 173.1 - 233.3 173.1 - 
✓  N/A    N/A  
DF1* CS19 C9 
364.5 
 
DF2* CS19 C9 
378.5 
219.2 173.1 - 233.3 173.1 - 
✓ ✓ N/A   ✓ N/A  
DF1* CS4 C10 
382.5 
 
DF2* CS4 C10 
396.5 
219.2 191.1 - 233.3 191.1 - 
 ✓ N/A ✓  ✓ N/A  
DF1* CS13 C10 
355.4 
 
DF2* CS13 C10 
369.5 
219.2 164.1 - 233.3 164.1 - 
 ✓ N/A ✓   N/A  
 * Mass of diazo with TBS deprotected 
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Appendix D 
Anisotropy Calculations 
D.1  Calculations for Determination of Tracer Dissociation 
Constant 
D.1.1  P channel 
 
 
D.1.2  S channel 
 
 
D.1.3  Anisotropy 
Calculate anisotropy for each set of corrected p and s values at each protein 
concentration 
𝑟 = 1000 × 
𝑠 − 𝑔𝑝
𝑠 + 𝑔2𝑝
    𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏 
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Calculate average and standard deviation for each protein concentration 
 
 
D.1.4  Ligand Bound 
Convert anisotropy to ligand bound for each protein concentration (see 
experimental equations) and calculate average and standard deviation. 
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D.2  Calculations for array data for Figure 4.5 
Plate layout for screening reaction arrays in triplicate: 
 
 
 
P Values: 
 
 
S Values: 
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Anisotropy Calculations: 
 
Red = Negative controls, Green = Positive controls 
